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Dum vivimus, vivamus 
Laten we van het leven genieten, zolang als we leven
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The clotting process is a dynamic, highly interwoven array of multiple processes and 
can be viewed as occurring in several consecutive overlapping stages (1). An interplay 
between components of the vessel wall, platelets, and coagulation factors give rise 
to the formation of a haemostatic plug. Several control mechanisms are responsible 
for modulation and termination of the clotting cascade. Once vessel wall patency 
has been restored, the mechanism of fibrinolysis is responsible for organizing and 
removing the formed clot. Classically, laboratory-based coagulation tests (e.g., 
prothrombin time, activated partial thromboplastin time, fibrinogen) and platelet 
numbers are being used in evaluating bleeding disorders. However, these tests have 
several limitations as they are performed in plasma under conditioned circumstances 
and give fragmented information on mainly the initiation of the coagulation cascade. 
Moreover, they do not take into account the interaction of clotting cascade and 
platelets as well as other cellular elements in whole blood (2). Also the influence 
of hypothermia is not measured, as standard coagulation tests are performed at 
a standardised temperature of 37�C. Consequently, complex and multifactorial 
haemostatic disturbances, as seen in trauma and massive blood loss, are difficult 
to analyze with these tests. Point-of-care coagulation monitoring devices assessing 
the viscoelastic properties of whole blood, i.e. thromboelastography may overcome 
several limitations of routine coagulation tests.
Thromboelastography (TEG) was first described by Hartert in 1948 as a global test 
of blood coagulation (3). TEG visualizes the viscoelastic changes that occur during 
coagulation in vitro and provides a graphic representation of clot formation and lysis. 
Clinically, two devices are being used: the TEG® system (Haemoscope Corporation, 
Niles, Illinois, USA) and the ROTEM (Pentapharm GmbH, Munich, Germany). 
Although TEG® and ROTEM® traces look similar, the nomenclature and reference 
ranges are different, and outcomes of both techniques are not interchangeable (4-
6). TEG was initially used as a research tool with only limited clinical application. 





































General introduction and outline of the thesis
standardization and better reproducibility of the assay. Renewed interest in TEG is 
also related to the current cell-based model of haemostasis (7). As a global assay 
of haemostasis performed on whole blood, TEG has the bedside capability to asses 
within 30 min a representation of the sum of platelet function, coagulation proteases 
and inhibitors together with the fibrinolytic system, and is therefore considered a 
helpful coagulation tool in various areas of haemostasis testing by a growing number 
of physicians. 
The main use of TEG has been to monitor blood component therapy during surgery. 
Its use was first documented in the field of liver transplantation, followed by the 
field of cardiac- and trauma-surgery (8-11). The use of citrated samples allows TEG 
to be also performed in the laboratory setting, where it is applied to areas where 
conventional coagulation testing is considered insufficient (12). These areas include 
hypercoagulability screening and the assessment of thrombotic risk as well as the 
guidance of recombinant FVIIa and activated prothrombin complex treatment 
in patients with haemophilia (13-16). More recently application of a TEG guided 
transfusion strategy in patients with massive transfusion is advocated in order to 
reduce the amount of bleeding (17,18).
Principles of TeG® methodology
The basic principle of TEG® involves incubation of 360 μl whole blood at 37˚C in a 
heated cylindrical cup. The cup oscillates for 10 s through an angle of 4˚ 45’ with 
a pin freely suspended in the cup by a torsion wire (Figure 1). The torque of the 
rotating cup is transmitted to the immersed pin only after fibrin-platelet bonding has 
linked the cup and pin together. The strength of these fibrin-platelet bonds affects 
the magnitude of the pin motion, such that strong clots move the pin directly in 
phase with the cup motion. Thus, the magnitude of the output is directly related to 
the strength of the formed clot. As the clot retracts or lyses, these bonds are broken 
and the transfer of cup motion is diminished. The rotation movement of the pin is 
converted by a mechanical-electrical transducer to an electrical signal which can be 
monitored by a computer program. The resulting haemostasis profile is a measure of 




































the strength of the clot and dissolution of the clot. The clot’s physical properties are 
dependent of the interaction of fibrinogen, platelets and plasma proteins, and this 
process produces a characteristic trace, reflecting the different phases of the clotting 
process and enables qualitative evaluation (19) (Figure 2).
 
figure 1.
Thromboelastograph® 5000 coagulation analyzer and basic principles
Five major steps involved in haemostasis are routinely measured by TEG®: The R-time 
(reaction time) is the latency time from placing blood in the cup until the clot starts to 
form (taken as reaching a TEG tracing amplitude of 2 mm). The K-time (clotting time) 
is arbitrary assigned to the time between the TEG trace reaching 2 mm and going 
up to 20 mm; thus indicating clot kinetics. The alpha angle (α) is a slope drawn from 
the slope of the TEG tracing from the R to the K value. The alpha angle is visualizing 
the acceleration and the kinetics of fibrin formation and cross-linking. The maximum 
amplitude (MA) is the greatest vertical amplitude of the TEG trace and represents clot 
strength. Clot lyisis at 30 minutes (LY30) measures the rate of amplitude reduction 
30 min after MA and provides information on the fibrinolytic activity (Table 1). A fast 
way to obtain an early impression of the TEG curve is to look at the initial part of the 
TEG trace represented by the time it takes to reach the maximum amplitude (TMA). 






































reaches the base line at the moment clot lysis is completed. An additional parameter 
that can be calculated is the shear elastic modulus strength or clot elasticity (SEMS or 
G, dynes cm-2), which is a parametric measure of clot firmness, expressed in metric 
units, calculated from MA as follows: G = (5000 x MA) / (100 - MA). R-time, K-time 
and α are prolonged by anticoagulants and coagulation factor deficiencies, MA is 
especially influenced by platelet count and platelet function as well as fibrinogen 
level.
figure 2.
Thromboelastograph® trace and parameters
Variations on the TeG® 
Coagulation in vitro is usually initiated by the addition of calcium to citrated plasma. 
However, for TEG analysis, use of native whole blood is more reliable and considered 
the gold standard (20). If rapid information is required, the blood sample can be 
activated by the addition of celite or tissue factor, both causing shortening of the 
R-time. The effect of heparin can be evaluated by placing the blood samples into 
cups that have been coated with the enzyme heparinase (21). With the Reopro-
modified TEG assay the contribution of fibrinogen to clot strength (TEG parameter 
MA) can be evaluated (22). The effects of glycoprotein IIb/IIIa inhibitors, acetylic acid 
or ADP agonists can be visualized by comparing standard and modified (“platelet 
mapping”) TEG curves (23). Finally, the TEG® haemostasis system is able to produce 




































a thrombus generation velocity curve, which can be calculated from the initial part 
of the TEG trace by differentiating the entire initial time-course, providing three new 
parameters of thrombus generation (24).
Table 1. Thromboelastograph® parameters and corresponding measurements
TeG parameter measured: Influenced by / reflecting:
R
R-time is the period of time of latency 
from the time that the blood was 
placed in the TEG until the initial fibrin 
formation.
prolonged: - anticoagulants
shortened: - hypercoagulable conditions
K
K-time is a measure of the speed to 
reach a certain level of clot strength.
prolonged: - anticoagulants
shortened: - increased fibrinogen
                   (- increased platelet function)
α
Alpha angle measures the rapidity of 
fibrin build-up and cross-linking (clot 
strengthening).
decreased: - anticoagulants
increased : - increased fibrinogen
                   (- increased platelet function)
MA
MA, or Maximum Amplitude, is a direct 
function of the maximum dynamic 
properties of fibrin and platelet 
bonding via GPIIb/IIIa and represents 
the ultimate strength of the fibrin clot.
reflecting : - platelet count & function
                    - fibrinogen level
Ly30
LY 30 measures the rate of amplitude 
reduction 30 minutes after MA.
reflecting : - fibrinolytic activity
outline of the thesis.
As stated in the introduction, TEG is gaining popularity as a rapid near site global test 
of haemostasis in different clinical areas. In contrast to standard coagulation tests 
(performed in the central laboratory), the technique is considered easy to perform, 
with results that are easy interpretable and have direct consequences for clinical 
practice. However, although TEG poses many (theoretical) advantages over classical 
coagulation tests, clinicians should be aware of pitfalls in both test methodology 
as well as its interpretation. Importantly, studies comparing TEG parameters with 
standard coagulation tests demonstrate poor correlation and there are no clinical 
trials that link TEG variables to clinical outcome. The overall aim of this thesis is to 
improve the understanding of TEG technology for clinicians working in the field of 
haemostasis, making them aware of the possibilities but also of the limitations of 






































In Chapter 2 we describe, based on literature study, the role TEG and other Point 
of Care tests of haemostasis can play in both the prediction and treatment of 
unexpected massive surgical bleeding. For this purpose we will outline the actual 
cell-based model of haemostasis, with special focus on the haemostatic effects of 
both massive blood loss and massive transfusion. Secondly we will concentrate on 
what part of the coagulation cascade exactly can be monitored with which specific 
coagulation test. Finally we discuss the possibilities and limitations of these Point 
of Care tests of haemostasis in the analysis of the massively bleeding patient, with 
the purpose of improving the use of these tests in the clinical analysis and decision 
making in this patient category. 
As the interpretation of TEG data is hampered by the lack of a validated large series 
of reference ranges, with special attention for the effects of age, gender and the 
use of oral contraceptives, we assessed our own reference ranges, for both native 
whole blood and recalcified citrated whole blood, which are presented in Chapter 
3. Importantly, we used these reference ranges for comparison in the other studies 
that we performed.
Different components of the TEG test tracing are considered to reflect various parts 
of the haemostatic system and to distinguish low platelet count and/or platelet 
dysfunction from lack of plasmatic coagulation factors. In Chapter 4 we describe the 
effects of (isolated) thrombocytopenia on TEG parameters and discuss the sensitivity 
of TEG in the detection of (clinical relevant) thrombocytopenia. For this purpose we 
performed TEG measurements serially in patients with well documented transient 
thrombocytopenia in the context of consolidation courses of chemotherapy because 
of hematological malignancy. 
As we hypothesized that TEG might be a useful tool to monitor the haemostatic quality 
and efficacy of platelet transfusions we describe in Chapter 5 the results of our study 
in which the haemostatic effects of transfused stored platelets were compared to 
native circulating platelets, as measured by TEG. In this study we also assess whether 
storage time of platelets has additional influence on their haemostatic capacity. 




































In Chapter 6 we used TEG to study the role of red blood cells in haemostasis. For 
this purpose we studied haemostasis in patients with different degrees of anaemia. 
Moreover, we studied the effects of red blood cell transfusion on the haemostatic 
profile, with again attention for effects of storage time of the red blood cell product. 
In line with chapter 6 is the study described in Chapter 7, in which we address the 
coagulation profile in patients with sickle cell disease, as we hypothesized that TEG 
might be a useful tool to analyze the pro-coagulant profile observed in this patient 
category. Further we examined the differences in coagulation status between steady 
state and painful vaso-occlusive crises in these patients. Moreover, we also focused 
on the effect of red and white blood cells as well as treatment with Hydroxyurea on 
this status. 
In Chapter 8 we will present a summary and future perspectives on the role TEG can 
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General introdution and outline of the thesis
application of Point-of-Care testing 
of haemostasis in massive blood loss; 
possibilities and limitations








































The management of massive blood loss remains a major challenge for clinicians as 
the underlying coagulopathy is often complex, multifactorial and rapidly evolving. 
The use of classical coagulation tests, although standardized and well validated, 
has limitations as these tests are time consuming and provide only information on 
isolated coagulation factors. To overcome several of these limitations, point-of-care 
(POC) tests of haemostasis have been introduced in various areas of coagulation 
monitoring. POC tests that asses global haemostasis, e.g. thromboelastography, 
have potential for allowing a new look at the process of haemostasis and might add 
to the management of massive blood loss, when incorporated into a transfusion 
algorithm. As these POC tests become increasingly used outside of the specialised 
laboratory, attention should be paid to validation, reliability and quality control 
testing as several techniques are not validated and have never been standardized. 
The present review gives an overview on the current cell-based model of haemostasis 
and the pathophysiology of massive blood loss. Further we describe the different 
POC analysers and methods available and give insight into which parameters of 
the coagulation cascade can be monitored best by these techniques and for which 
clinical indications. Moreover, we will focus on the clinical relevance of the POC test 





































POC testing of haemostasis in massive blood loss
InTRoDUCTIon 
The detection, analysis and correction of haemostatic defects in the patient with 
massive blood loss in the operating theatre remains a major challenge for clinicians. 
Defects in haemostasis may complicate a wide range of surgical conditions and 
much attention has been paid to the management of massive blood loss in patients 
undergoing cardiac, hepatic and trauma surgery, all associated with complex and 
multifactorial coagulopathies (1-3). Although still the standard in haemostasis 
testing, laboratory-based coagulation tests are considered to have several limitations 
in haemorrhagic emergencies. First of all, classical coagulation tests are considered 
time consuming as they are performed in a central laboratory, leading to a delay 
in diagnosis and management of the coagulopathy (4). Further, these classical tests 
provide only a snapshot of the coagulation status on the moment the sample was 
taken, as these tests are based on isolated static end points (5). Also the influence 
of hypothermia is not measured as classical coagulation tests are performed in 
plasma at a normal and standardised temperature of 37�C. Moreover, although the 
classical view of the clotting cascade has been useful in the interpretation of clotting 
times (e.g., PT and aPTT), it may not be physiologically accurate (6). Finally, the 
correlation of laboratory-based coagulation tests with clinical bleeding is currently 
imprecise and requires a more rapid evaluation of haemostasis and fibrinolysis (7). 
As a consequence, “bedside” performed point-of-care (POC) testing of haemostasis 
is increasingly being incorporated in the management of massive blood loss in the 
operating theatre (8,9). Arguments given in favour of POC tests of haemostasis are 
the rapid, real-time information these tests provide on the coagulation process (10). 
Moreover, visco-elastic POC testing i.e. tromboealastography, is considered more 
physiological than classical coagulation testing as it is performed on whole blood, 
taking into account the interaction of the coagulation system with all other cellular 
elements (11).
Since POC testing of haemostasis has gained popularity, it may be tempting for 
clinicians to replace classical coagulation tests by these rapid and ”easy interpretable” 






































theatre. However, before such a change in paradigm can take place, there are several 
aspects of POC testing that need to be ascertained. The most important question to 
be answered is whether POC tests are really suited to monitor massive blood loss in 
general surgery. Secondly, is there sufficient evidence to fully support its use in the 
management of massive unexpected blood loss? To answer the former questions, 
we can speculate on what the “ideal” POC test of haemostasis looks like and what 
the requirements of such a test are (12). Ideally a POC test should deliver a timely 
result that is precise with adequate quality and has the potential to improve patient 
outcome from earlier treatment. As a consequence the test should be performed 
by skilled and trained personal, aware of the tests’ critical analytical steps and its 
potential errors and limitations (13). Further, the technique should be standardized 
according to international guidelines and be subjected to strict internal- and external- 
quality control procedures (14,15). Moreover, the POC test should be validated, not 
only for detection and analysis of the different coagulation disorders, but also for 
monitoring the effects of both anticoagulants and haemostatic agents. Also reference 
ranges should be established in different age- and gender- groups. Importantly, the 
test should be subjected to randomized controlled trials demonstrating positive 
effect on patient care. Finally, the POC data should be stored and transmitted to a 
POC data manager or hospital information system. The most important aspects and 
requirements of the “ideal” POC test of haemostasis are summarized in Table 1. 
Table 1. The “Ideal” POC test of Haemostasis
Important aspects and Requirements of the “Ideal” PoC test.
• Generation of rapid and real-time results and so earlier treatment
• Knowledge of critical analytical steps and potential errors
• Trained and skilled operators
• Standardization of the technique according to international guidelines
• Internal and external quality control and assurance
• Validation of technique for different coagulopathies and monitoring of anticoagulants and 
haemostatic agents
• Reference ranges for different clinical conditions, age and gender
• Data storage and transmittance to hospital information system




































scope of this review
Advanced coagulation monitoring in massive blood loss might employ a combination 
of routine laboratory tests using individual factor measurements as well as POC 
coagulation testing. Therefore, we consider it valuable for clinicians using these tests 
and techniques, to have knowledge of the possibilities and limitations of the different 
POC tests of haemostasis. For this purpose we will first (briefly) overview the current 
(cell-based) model of haemostasis, with special focus on the coagulopathy that arises 
in massive bleeding. Subsequently we will update and review the POC analysers and 
methods available and give insight into which parameters of the coagulation cascade 
exactly can be monitored by these techniques and in which clinical condition. 
Moreover, we will focus on the clinical benefit the POC test has in the prediction 
of surgical bleeding as well as the analysis of massive blood loss in the operating 
theatre. The final goal is that clinicians, overseeing all the possibilities and limitations 
of POC testing of haemostasis, can make a well balanced decision on the appropriate 
POC test of haemostasis to be implemented in their operating theatre.
Principles of haemostasis
Although the clotting process is a dynamic, highly interwoven array of multiple 
processes, it can be viewed as occurring in several consecutive overlapping stages 
(16). An interplay between components of the vessel wall, platelets, and coagulation 
factors give rise to the formation of a haemostatic plug. Several control mechanisms 
are responsible for modulation and termination of the clotting cascade. Once vessel 
wall patency has been restored the mechanism of fibrinolysis is responsible for 
organizing and removing the formed clot.
• Primary haemostasis; platelet adhesion and aggregation
Platelets play an important role in localizing clotting reactions because they adhere 
and aggregate at the sites of injury where tissue factor (TF) is also exposed. They 
provide the primary surface for generation of the burst of thrombin needed 
for effective haemostasis during the propagation phase of coagulation. Platelet 
localisation and activation are mediated by Von Willebrand Factor (VWF), thrombin, 
platelet receptors, and vessel wall components, such as collagen (17). Circulating 
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platelets get in close contact to the injured vessel wall by attachment of the platelet 
surface Glycoprotein Ib (GP-Ib) to VWF in the wound (Fig. 1). VWF is a large molecule, 
synthesized by endothelial cells, and also found in granules of platelets, that circulates 
in complex with coagulation factor VIII (FVIII). After binding to the exposed collagen 
in the wound, VWF is structurally changed and able to bind GP-1b on the platelet 
surface.


















(Reproduced with permission from: Hoffman J. et al. Hematologie. 2rd ed. Arnhem: Syntax 
Media 2007)
During high shear, platelets “role” along the wound surface and, initially, detach, until 
they lose their speed and bind irreversibly to the wound surface. The binding is further 
increased by attachment of both GP-Ia-IIa complex and GP-VI to collagen; which 
results into platelet activation. Moreover, when fibrinogen and fibrin are attached 
to the wound surface, platelets bind via their GP-IIb-IIIa receptor. Platelet adhesion 
is followed by platelet activation mediating platelet spreading and clot retraction. 
Also upon activation, platelets release a variety of substances from their granules like 




































Parallel to adhesion, aggregation and secretion of activated platelets, haemostasis is 
further enhanced by formation of thrombin which further activates platelets. Several 
platelet-blocking agents can interfere with primary haemostasis. Aspirin and other 
non-steroidal anti-inflammatory agents inhibit cyclo-oxygenase (COX), the enzyme 
responsible for the formation of tromboxane A2 out of arachidonic acid (AA) from 
membrane phospholipids. The thienopyridine derivates (ticlopidin, clopidogrel) 
inhibit ADP-induced platelet activation by binding covalently to the P2Y12 receptor. 
Finally, GP-IIb-IIla antagonists (abciximab, tirofiban, eptifibatide) block GP-IIb-IIla 
receptors. 
• Secondary haemostasis; initiation, amplification and propagation of the clotting 
cascade
The generation or exposure of TF at the wound site, and its interaction with FVII, is 
the primary physiologic event in initiating clotting (18). The initiation process takes 
place on the surface of TF-bearing cells such as fibroblasts and platelets where FVII 
binds to TF and is activated. This FVII/TF complex activates Factor X (FX) which in turn 
generates a small amount of thrombin that plays a role in the amplification stage 
(Fig. 2). Thrombin is generated by a complex network of amplification and negative 
feedback loops to ensure a localized and limited production. 
The generation of thrombin is dependent on three enzyme complexes, each 
consisting of a protease, a cofactor and catalyzed by phospholipids (PL) and calcium 
(Ca2+). These three enzyme complexes are extrinsic Xase (FVIIa, TF, PL, Ca2+), 
intrinsic Xase or tenase complex (FIXa, FVIIIa, PL, Ca2+) both generating FXa, and 
prothrombinase complex (FXa, FVa, PL, Ca2+) generating thrombin. With sufficient 
stimulus, components of the intrinsic pathway (i.e., factors VIII, IX, XI) are responsible 
for amplification of this process only after a small initial amount of thrombin has 
been generated through the extrinsic pathway (19). Moreover, once platelets are 
activated, the cofactors Va and VIIIa are rapidly localized on the platelet surface 
(20). The propagation phase catalysts (FVIIIa-FIXa and FVa-FXa) continue to drive 
the reaction as blood is resupplied to the wound site by flow. The generation of 
thrombin via the coagulation cascade results in deposition and cross-linking of fibrin. 
Ultimately, the net result of platelet aggregation, fibrin deposition, and fibrin cross-
linking, is the formation of a stable clot. 
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PT; prothrombin time, aPTT; activated partial thromboplastin time, TT; thrombin time, 
TF: tissue factor, PL; platelets, Ca2+; Calcium
• Terminating of clotting by antithrombotic control mechanism
The control of the haemostatic reaction is governed by the pro- and anticoagulant 
dynamics and the supply of blood reactants to the site of a vessel injury (21). 
Termination of coagulation is regulated by the plasma proteins tissue factor pathway 
inhibitor (TFPI), antithrombin (AT), protein C and protein S. The initiation phase 
(extrinsic Xase) is rapidly inactivated by TFPI, released form platelets and endothelial 
cells as it forms a quaternary complex with FVIIa, TF and FXa, such that only a limited 
amount of thrombin is generated. Thrombin forms a complex with the endothelial cell 
surface receptor thrombomodulin. An endothelial protein C receptor (EPCR) localizes 




































thrombomodulin complex. Protein C (and its cofactor Protein S) are inhibitors of 
coagulation factors Va and VIIIa, preventing further thrombin generation. Finally, the 
thrombin-thrombomodulin complex is also the activator of the fibrinolysis inhibitor 
TAFI (Fig. 3). One of the major natural inhibitors of thrombin is AT, which is only 
active when coagulation is activated as it only binds thrombin, and not prothrombin. 
Moreover, AT binds to all activated coagulation factors with serine proteases (FIXa, 
FXa, FXIa and the FVIIa-TF complex) to form high molecular weight stable complexes. 
Importantly, the reaction between thrombin and AT can be accelerated by heparin.



































TFPI; tissue factor pathway inhibitor, ATIII; antithrombin, TAFI; thrombin-activatable fibrinolysis 
inhibitor; EPCR; endothelial protein C receptor
• Removal of the clot by fibrinolysis
Fibrinolysis is a normal haemostatic response to vascular injury. The final effector 
of fibrinolysis is plasmin, produced from the inactive precursor plasminogen by 
activators either from the vessel wall (intrinsic activation) or from the tissues 
(extrinsic activation) (Fig. 4). The most important route follows the release of tissue 
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plasminogen activator (tPA) from endothelial cells. tPA and plasminogen both bind 
to the evolving fibrin polymer. Once plasminogen is activated to plasmin it cleaves 
fibrin into soluble fibrin degradation products (FDPs) resulting in dissolution of the 
fibrin clot. One of the major FDPs is D-dimer, which consists of two D domains from 
























tPA; tissue Plasminogen Activator, uPA; urokinase like Plasminogen Activator, PAI-1&-2; 
Plasminogen Activator Inhibitor 1 & 2, TAFI; Thrombin-Activated Fibrinolysis Inhibitor
Coagulation stabilization counteracts fibrinolysis through several mechanisms. FXIIIa 
converts fibrin into a tight-knit aggregate. tPA is inactivated by plasminogen activator 
inhibitors (PAI); PAI-1 is a rapid and irreversible inhibitor of tPA and uPA (urokinase 
like plasminogen activator). Further, circulating plasmin is inactivated by the potent 
inhibitors alpha-2 antiplasmin and alpha-2-macroglobin (22). Thrombin inhibits 
fibrinolysis by activating TAFI that removes lysine residues from fibrin, thereby 
impairing fibrin’s capacity to bind plasminogen and tPA.
Coagulopathy in massive bleeding
Haemostasis is the process of quick, localized and carefully regulated clot formation at 
the site of vessel injury. An optimal pH value and body temperature as well as adequate 




































Abnormal bleeding may occur when specific elements of the process are missing 
or dysfunctional, for example in case of Haemophilia or severe thrombocytopenia. 
Also the use of anticoagulants can be the cause of abnormal bleeding. During 
massive bleeding (-and transfusion), with loss of coagulation factors, the evolving 
coagulopathy is often complex and multifactorial and aggravated by hypoperfusion, 
dilution- and consumption- of clotting factors and platelets. This coagulopathy, 
together with hypothermia and acidosis, forms a “lethal” triad (23). 
Dilutional coagulopathy is observed in patients who have lost blood and had the blood 
volume replaced with components without plasma procoagulants and anticoagulants, 
i.e. if volume replacement is mainly performed with red cells, crystalloid and plasma 
expanders (24). Mild dilution mainly results in reduction of clot firmness, this being 
significantly more reduced with colloids than with crystalloids. With dilution >50% a 
delay in the initiation of coagulation is observed (25). Synthetic colloid resuscitation 
fluids (i.e. hydroxyethyl starch; HES) induce a coagulopathy that is characterised 
by acquired hypofibrinogenaemia and abnormal fibrin polymerization (26). Fibrin 
polymerization is also disturbed following extensive administration of blood products 
(platelets and plasma) as these fractionated blood products are stored in preservative 
solutions containing citrate causing hypocalcaemia (27). Fibrinogen may become 
critically low in massive bleeding with a fall below 1 g/l after a loss of 150% of the 
calculated blood volume (28). Coagulation factors II, V and VII as well as platelet 
levels become critical after a blood volume loss of more than 200% (29). Some 
patients with massive bleeding are also at risk of consumptive coagulopathy and are 
liable to develop haemostatic failure without significant dilution. Consumption of 
coagulation factors is seen in obstetric haemorrhage, in patients on cardiopulmonary 
bypass (CPB), following massive trauma and in the context of sepsis (30). In addition, 
massive trauma and shock are associated with activation of anticoagulant pathways, 
especially the thrombomodulin-protein C pathway, resulting in increased fibrinolysis 
(31).
On top of dilution and consumption of coagulation factors, hypothermia and acidosis 
may worsen the developing coagulopathy. Hypothermia-induced coagulopathy 
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attributes to platelet dysfunction, reduced coagulation factor activity (significant 
below 33�C) and induction of fibrinolysis (32). For each 1˚C decline in body 
temperature, there is a 10% reduction in the coagulation factor activity (33). In clinical 
practice, the effect of hypothermia on coagulation is likely to be underestimated as 
most coagulation tests are performed at 37˚C thereby correcting ex vivo any in vivo 
abnormality (34). Acidosis is induced by hypoperfusion and excess administration of 
ionic chloride, i.e. NaCl, impairing almost all essential parts of the coagulation process 
(2). Acidosis not only impairs platelet function as well as the activity of coagulation 
factor complexes and the generation of thrombin, but also leads to an increased 
degradation of fibrinogen, especially at a PH <7.1 (35,36). Although correction of 
hypothermia reverses its detrimental effects on coagulation, correction of acidosis 
by administration of buffer solutions has no such effect (37).
laboratory-based coagulation tests
• Tests of primary haemostasis; platelet count and function
As platelets play an essential role in (primary) haemostasis, the accurate measurement 
of their number and function is important. Laboratories quantify platelet counts by 
automated cell analyzers that mostly are reliable at even very low platelet levels (38). 
However, this method is not perfect as in vitro micro-aggregation and EDTA-induced 
aggregation may lead to underestimation of the absolute platelet count. This EDTA-
dependent pseudo thrombocytopenia can be ruled out by recounting platelets in 
citrated blood. A platelet count <50x109/l in a patient with massive blood loss is 
associated with haemostatic compromise and microvascular bleeding. A minimum 
target platelet count of 75x109/L is appropriate in this situation.
Platelet function is traditionally tested for by performing a bleeding time. However, 
for bleeding time there is a lack of standardisation, the test is invasive, subjective and 
has low sensitivity and specificity in the detection of mild bleeding disorders (39,40). 
Moreover, the most common cause of bleeding time prolongation is improper 
performance of the test and only experienced laboratory personnel should perform 
it. Importantly, no studies have been performed to evaluate the role of bleeding 




































of bleeding and no recent intake of non-steroidal anti-inflammatory drugs, higher 
values for bleeding time and bleeding time-related parameters were not associated 
with higher indices of perioperative and postoperative bleeding at coronary bypass 
surgery (41).
Traditional assays, such as light transmittance aggregometry, are still considered as 
the gold standard for platelet function testing. In this assay, platelet agonists are 
added to platelet rich plasma and the increase of light transmittance is recorded 
as platelets start to aggregate. Only one study, performed in patients undergoing 
off-pump coronary bypass grafting demonstrated that intraoperative bleeding was 
significantly correlated with the decrease in the pre- vs. postoperative platelet count 
and function according to the area under the impedance curve using whole blood 
aggregometry. However, no effects on the use of blood products was observed (42). 
Aggregation will remain an important clinical test within the specialised laboratory. 
Many platelet disorders are easily diagnosed, but the technique has several 
limitations, as the preparation of specimens is difficult, time consuming, operator 
dependent and it cannot be performed at the bedside (43). As a consequence, the 
test is considered too complex and impractical to use in the management of patient 
with massive blood loss.
• Tests of the coagulation cascade; aPTT, PT and TT
The in vitro tests activated partial thromboplastin time (aPTT), prothrombin time (PT), 
and thrombin time (TT) measure the time elapsed from activation of the coagulation 
cascade at different points to the generation of fibrin (Fig. 2). Citrated plasma, an 
activator (tissue factor for PT and phosholipids for aPTT) are added together and 
incubated at 37˚C. Calcium is added and the time necessary for clot formation is 
measured. The aPTT is used to assess the contact activation and the integrity of the 
intrinsic coagulation pathway (factors XII, XI, IX, VIII) and final common pathway 
(factors II (=prothrombin), V, X, and fibrinogen). Prolonged aPTT can be found due 
to isolated deficiencies (or inhibitors) of intrinsic- and common- pathway factors, 
and after heparin administration. Artificially prolonged aPTT occurs in case of 
underfilling the test tube, improper blood collection, and with elevated haematocrit. 
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High concentrations of heparin (>1.0 U/ml), as employed in coronary surgery, can 
be monitored by the activated whole blood clotting time (ACT), since aPTT often 
becomes infinitely prolonged at these higher concentrations (44). The aPTT is often 
used to guide blood product replacement with a target aPTT below 1.5 times normal 
(<60 s). However, the latter may not always be an appropriate target in the situation 
of massive blood loss as haemostatic failure may already be significant at this level 
(9).
The PT is used to assess the integrity of the extrinsic pathway of clotting, which 
consists of TF and FVII and coagulation factors in the common pathway. The function 
of PT has been standardized (for warfarin control) through the use of the international 
normalized ratio (INR). Causes of isolated prolonged PT are inherited or acquired FVII 
deficiency, VKA administration, vitamin K deficiency, liver disease and an inhibitor of 
FVII. PT is not always a sensitive test for the actual coagulation status as a normal PT 
does not rule out haemostatic abnormalities. In massive blood loss a correction to 
within 1.5 of normal is advocated, although this may not be an appropriate target in 
this clinical situation (45). 
When both PT and aPTT are prolonged inherited deficiency of prothrombin, fibrinogen 
or factors V or X can be the cause. More often there is an acquired cause of these 
prolongations, i.e. liver failure, disseminated intravascular coagulation, overdosing 
with heparin or VKA or the combination of both. Finally an inhibitor of prothrombin, 
fibrinogen or factors V or X of the common pathway can be the cause of combined 
prolongation of PT and aPTT.
Both pathways (intrinsic and extrinsic) converge on the activation of Factor X, which 
converts prothrombin to thrombin, the final enzyme of the clotting cascade, which 
in turn converts fibrinogen into fibrin. The Thrombin Time (TT) measures this final 
step of the coagulation cascade (46). Prolongation of the TT can be explained in three 
ways: deficient fibrinogen (<100 mg/dl), abnormal fibrinogen (dysfibrinogenemia), 
or an inhibitor to its activation. Acquired deficiency of fibrinogen is usually due to 




































deficiency of fibrinogen and dysfibrinogenemia. The most common acquired 
inhibitors of the final reaction are heparin and fibrin degradation products (FDP). The 
effect of heparin can be eliminated by catalyzing the reaction with reptilase, which, 
unlike thrombin, is insensitive to heparin. FDP are commonly seen in consumptive 
coagulopathies and primary fibrinolytic states.
• Fibrinogen concentration. 
In the conventional Clauss method, diluted plasma is mixed with a supraphysiologic 
amount of thrombin; the fibrinogen concentration is proportional to the coagulation 
time measured. The formation of fibrin is a key step in blood coagulation, and 
hypofibrinogenemia is a usual component of complex coagulopathies associated 
with massive bleeding. Fibrinogen plays a major role in routine coagulation tests like 
PT and aPTT. Moreover, the fibrinogen level is more sensitive than the PT and aPTT 
to a developing dilutional or consumptive coagulopathy. Excessive bleeding has been 
reported at fibrinogen levels below 0.5-1.0 g/L; levels above 1.5 g/L are probably 
required for sufficient fibrin clot polymerisation (47). 
PoC based coagulation tests
A number of coagulation tests can be performed at the point-of-care, rather than in 
a central laboratory, with the rationale that this will result in the rapid generation of 
results and will improve patient care. POC testing may measure platelet function, 
PT, aPTT, INR, ACT, D-dimer as well as overall coagulation (48). POC tests are also 
being used to diagnose acquired or inherited coagulopathy, to monitor anticoagulant 
therapy and to guide transfusion of blood and blood products (49,50). A summary of 
POC tests and devices available for haemostasis monitoring and their clinical use is 
presented in Table 2.
In the following section we will discuss several important aspects of these POC tests 
and techniques. First we will briefly outline the principle of each test and address 
its clinical use and limitations, especially in the context of the patient suffering from 
massive blood loss. As d-dimer assays are mainly used in the analysis of venous 
thromboembolism, we will consider this out of the scope of this review.
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Table 2. Overview on POC tests of haemostasis
PoC Test














detection of platelet dysfunction & 
inhibition, 
guidance on therapeutic 
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high dose heparin monitoring
Thrombin Time 
(fibrinogen→ fibrin)
Hemochron HiTT high dose heparin monitoring
Fibrinogen Hemochron Signature Elite fibrinogen level
Thrombelastography
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• POC tests on Platelet Function.
The assessment of bedside platelet function has gained attention in two areas of 
coagulation monitoring. First of all, platelet function testing devices have been 
developed to monitor anti-platelet therapy in cardiovascular patients, especially 
during cardiopulmonary bypass surgery (51). Second, visco-elastic POC coagulation 
devices can be used to facilitate the management of bleeding patients by rationalizing 
platelet transfusion (52). A variety of devices are available that offer POC testing of 
platelet function (see for overview Table 3).
Platelet Function Analyser (PFA-100). The PFA-100 measures the closure time i.e. the 
time to cessation of flow of citrated blood, flowing at high shear rate through an 
aperture within a capillary membrane impregnated with the agonists collagen and 
either epinephrine or adenosine diphosphate (53,54). The test is simple and rapid, 
does not require specialist training and may serve as a screening tool for platelet 
dysfunction, in particular as seen in Von Willebrand disease (55,56). However, test 
outcome is not specific for any other thrombocytopathy (57). In the assessment of 
the response to anti-platelet therapy the PFA-100 was found to be sensitive to the 
effects of aspirin, but relatively insensitive to the effects of clopidogrel (58,59). 
Although a normal ADP stimulated closure time was found to be a negative 
predictor of bleeding (60), it was also demonstrated that is was less accurate than 
classical ADP-mediated platelet aggregometry in risk stratification of perioperative 
bleeding and transfusion (61). A major limitation for the use of the PFA-100 as a 
POC test of primary haemostasis in the (massive) bleeding patient is it’s sensitivity 
to thrombocytopenia (<100x109/l) and anaemia (haematocrit <30%) both resulting 
in prolongation of the closure time (62). Moreover, there is only limited literature 
on whether an exact threshold closure time exists above which bleeding tendency is 
increased and below which invasive interventions can be performed safely.
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Table 3. POC tests of platelet function
PoC test Principle Clinical Use limitations
PFA-100® high shear adhesion & 
aggregation of platelets, 
after agonist, forming a 
plug, expressed as Closure 
Time (CT)
• rapid diagnosis of:
- von Willebrand 
disease 
- generalized platelet 
dysfunction
• thrombocytopenia
(<100x10E9/L) & anaemia 
(haematocrit <35%): ↑ 
of CT
• not specific for any 
disorder; just screening
• wide normal range
• low sensitivity detecting 






of platelets over time in 
response to agonists that 









• not performed under 
shear stress
• high costs of cartridges
• inconsistency over 
time in identification of 
aspirin-resistance
PlateletWorks® comparing platelet 
counts before and after 
aggregation with agonist
• platelet count with 
an evaluation of 
platelet function
• detection of 
resistance to 
antiplatelet drugs
• collagen cartridge 
not recommended for 
assessment of aspirin
Multiplate® impedance aggregometry • detection 
of clodipogrel 
resistance
• assesment of need 
for transfusion in 
cardiac surgery
• Reference ranges vary 
widely
• ADP aggregation: 
30 min. pre-analytical 
equilibration
• not validated for low 
platelet counts
Because of the inconsistencies in literature, the Platelet Physiology Subcommittee 
of the Scientific and Standardization Committee of The International Society on 
Thrombosis and Haemostasis (ISTH-SSC) states that the PFA-100 closure time should 
be considered optional in the evaluation of platelet disorders and function, and that 
its use in therapeutic monitoring of platelet function is currently best restricted to 
research studies and prospective clinical trials (63).
The Rapid Platelet Function Assay (RPFA; VerifyNow® systems). The VerifyNow® 




































blood as platelets aggregate over time in response to agonists that are specific to 
various anti-platelet medications such as GPIIb/IIIa inhibitors (abciximab), aspirin 
and P2Y12 antagonists (64). The VerifyNow assay is simple to handle, gives rapid 
results and can be used at the patients point-of-care. The assay is mainly applied 
in cardiovascular patients to monitor the effects of (-or resistance against) platelet 
antagonists. The VerifyNow results correlated with clinical outcome in patients 
treated with respectively GPIIb/IIIa inhibitors, aspirin and P2Y12 antagonists (65-67). 
A limitation is that the test is not performed under shear stress. Further, a lack of 
consistency over time in the identification of aspirin resistance was found by others 
(68). Therefore, until so far, the VerifyNow assays are still considered research tools, 
not yet suitable for guiding clinical decision making, until prospective trials prove 
otherwise (69,70). As a consequence, this test of platelet function has no role in 
analyzing and treating coaugulopathy in patients with (massive) bleeding.
Plateletworks®. Plateleworks (PW) is a simple and easy to use whole blood assay 
that compares platelet counts in a control tube with platelet counts in a citrate tube 
after aggregation with either ADP or collagen (71). The PW ADP cartridge appears 
useful for the assessment of both P2Y12 inhibitors and GPIIb/IIIa antagonists (72). 
In patients undergoing cardiopulmonary bypass surgery a correlation was found 
between PW collagen reagent tubes preoperatively and chest tube drainage and 
was considered a useful predictor of blood product use (73). In another study, no 
correlation was found between pre-operative platelet dysfunction and postoperative 
bleeding using PW (74). Thus far, no studies have been performed evaluating the 
performance of PW as a POC test in the (massive) bleeding patient.
Multiplate®. Multiple electrode platelet aggregometry, performed on whole blood 
after addition of agonists, produces a trace with results expressed as the area under 
the curve parameter in aggregation units. The essay is relatively simple to perform 
and will produce a result in under 10 min after sampling, except when ADP is used as 
an agonist, as this requires a pre-analytical 30-min equilibration period. As reference 
ranges may vary widely it is advised to obtain own reference ranges. Multiplate can 
be used to detect the effects of both medication and (cardiac) surgery on platelet 
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function (75,76). Platelet aggregation was found to be reduced during and after 
cardiopulmonary bypass, especially in patients who were transfused, suggesting 
that Multiplate might have a role in guiding platelet transfusion (77). However, the 
Multiplate assay has not been validated for low platelets count, making this device 
unsuitable in clinical decision making in the patient with massive blood loss.
• Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT)
Several POC tests measuring PT, INR and aPTT have been developed. They are mainly 
used because of their rapidity to obtain results in the ambulant setting and less in the 
setting of major surgery or to guide blood product replacement. Table 4 summarizes 
the devices that provide a rapid portable way to check PT, INR and aPTT. Although a 
variety of devices have been developed, the use of POC for measuring the PT (other 
than for monitoring the INR) is not widespread. Further, POC testing of INR is limited in 
situations of altered blood composition as extremes of haematocrit (<25% or >55%), 
haemolysis and increased viscosity all affect test outcome (48). Also, the combined 
use of warfarin and (low molecular weight-) heparin may impair the accuracy of POC 
testing for INR (78,79). Finally, only very few studies have been published on the 
use of POC PT/INR in a clinical setting (80). Despite adequate test validity, the wide 
variation in outcomes of POC testing for aPTT makes it less accurate compared to 
measurement of aPTT in the central laboratory (81). Furthermore, only few devices 
developed to monitor aPTT, are available for purchase. In the next section we will 
focus on the commercial available devices on PT and aPTT that have been evaluated 
in the bleeding patient.
CoaguChek systems. The Coaguchek XS (plus) is a POC test of INR, mainly used to 
monitor treatment with oral anticoagulants. Although the test looses its sensitivity 
with INR above 3.5, it is rapid and highly accurate compared with the reference test 
both in patients undergoing major surgery and in the intensive care setting (82-84). 
Moreover, in patients undergoing major surgery it could reduce the transfusion 
of fresh froze plasma, suggesting that the use of POC testing of PT could lead to 
a more rational use of blood products (85). However, INR is not an appropriate 




































vitamin K antagonists. As a consequence, results may be misleading in the context of 
coagulopathy due to dilution, consumption or liver disease.
Table 4. POC tests of secondary haemostasis: INR, PT, aPTT, ACT














of changes in 
electrochemical 
impedance
• monitoring treatment 
with oral VKA
• assessment extrinsic 
pathway of coagulation
• extremes of haematocrit 
(<25% or >55%), 
haemolysis and increased 
viscosity affect test 
outcome
• poor correlation with 




warfarin is combined with 
LMWH
• only limited data on PT/
INR measurements in 
clinical setting.
• baseline PT/INR in 







of changes in 
electrochemical 
impedance
• mainly used to 
monitor activated 
clotting time, but also 
PT, aPTT and ACT
• assessment intrinsic 
pathway of coagulation
• outcome affected 
by type of activator, 
temperature and 
haematocrit.
• unclear correlation with 
laboratory measured PT 
and aPTT, especially:
- INR in VKA users














• monitoring ACT and 
high dose heparin
• monitoring of heparin
• during CPB the ACT is 
variable for Hemochron
• Hepcon:overestimation 
of heparin dose in CPB 
surgery & sensitive to 
haemodilution and 
hypothermia
• poor correlation 
between HiTT and ACT
PT; prothrombin time, aPTT; activated partial thromboplastin time, INR; international 
normalized ratio; ACT; activated clotting time, VKA; vitamin K antagonist, LWMH; low molecular 
weight heparin, CPB; cardiopulmonary bypass
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INRatio Monitoring System. This POC test of INR is mainly used as a self testing device 
for oral anticoagulation. It measures the change in impedance of the blood-reagent-
mixture during the process of coagulation and determines PT which correlated well 
with the standard laboratory measured PT (86). No data exists on device performance 
in the analysis of coagulation in the bleeding patient.
Hemochron devices. The Hemochron is a POC electromechanical device, mainly 
used to monitor activated clotting time, but it is also marketed to monitor PT and 
aPTT. There are conflicting reports, concerning the correlation between Hemochron 
POC measured- and standard laboratory measured- PT and aPTT. During orthotopic 
liver transplantation, determination of PT and aPTT using the Hemochron device 
showed good correlation with laboratory coagulation assays (87). In contrast, a 
poor correlation was found between standard laboratory measurements for INR in 
patients using vitamin K antagonists and for aPTT in patients on intravenous heparin 
and in patients post CBP surgery (88), 89). The Hemochron technique has not been 
validated for its potential role in both the prediction and the treatment of massive 
blood loss.
• Activated Clotting Time (ACT)
The principle of this screening test of the intrinsic coagulation pathway is based on 
mechanical detection of coagulation, which is optically measured, after activation 
(with celite, kaolin or Cilicia parts) in a cartridge. ACT is mainly used to monitor 
high concentrations (>1 IU/ml) of unfractionated heparin in patients undergoing 
cardiopulmonary bypass (CPB). Although the ACT is considered the gold standard, 
the test correlates poor with heparin plasma levels. Further, no formal external 
quality assessment programme exists for the ACT; lyophilized quality control plasma 
samples, commercially available, should be used on a regular base to ensure that test 
results are within reference ranges (89). The type of activator used, hypothermia and 
haematocrit all can affect test outcome (90). Several systems for the estimation of 
free heparin have been developed; all are fundamentally based on the test principle 




































In contrast to control conditions, where a linear relationship was found between ACT 
and heparin, ACT was highly variable during CPB using the Hemchron device (91,92). 
In patients undergoing vascular surgery, both a poor and a good correlation were 
found between the Hemochron low range heparin ACT with respectively aPTT and 
anti-Xa activity (93,94). Using a heparin-protamin titration system, the Hemochron 
RxDx, led to a significant reduction in postoperative blood loss, as well as the amount 
of heparin and initial doses of protamin used during CPB (95). During CPB procedure 
and haemodialysis, i-STAT provided measurements of clotting time quite similar to 
Hemochron ACT, which were significantly correlated with heparin levels (96).
Given the conflicting reports, further studies are needed to determine whether 
maintaining heparin levels during CPB using a protocol based on ACT is more effective 
in preventing consumptive activation of the haemostatic system, reducing bleeding, 
and minimizing the use of blood products, when compared with conventional 
monitoring of heparin concentration. As ACT is only a global test of haemostasis and 
cannot, without modification, distinguish between the causes of coagulopathy, the 
technique has no role in both the prediction and the treatment of massive blood loss.
• Thrombin Time (TT)
The TT measures the conversion of fibrinogen to fibrin following the addition of 
exogenous thrombin and was historically used to monitor patients on unfractionated 
heparin. Because the classical TT becomes immeasurably prolonged at high 
concentrations of unfractionated heparin, both the High Dose Thrombin Time (HiTT, 
Hemchron) and the Hepcon HMS have been employed to overcome this problem. 
HiTT was found a useful assay for monitoring heparin effects during cardiac surgery, 
even during hypothermia and hemodilution, although HiTT correlated poor with 
ACT during CPB (97). The heparin concentrations determined with the Hepcon/HMS 
instrument did not agree with laboratory determination of heparin concentration 
during CPB (98). The TT, and its modifications, have no role in neither the prediction 
of bleeding nor in the analysis of the patient with massive bleeding.
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• Tests of overall coagulation; Thromboelastography.
Thromboelastography measures the visco-elastic properties of a developing clot and 
provides real time information about the quality of the clot and aspects of formation 
and lysis. Moreover, the coagulation status is assessed at the patients temperature 
and in whole blood, taking into account the interaction with all other cellular 
elements. The two instruments currently available are: TEG® Haemostasis Analyzer 
and the ROTEM® (Table 5). The basic principle of thromboelastography involves 
incubation of whole blood in a heated sample cup into which a pin is suspended. 
The pin and the cup or the cup alone oscillates as the clot forms. The resulting 
thromboelastogram is a continuous graphic record of the physical shape of the clot 
during fibrin formation and subsequent lysis. There are minor mechanical differences 
between the two instruments, and the activators used differ with respect to potency. 
In the TEG® a pin is connected to a torsion wire, and clot formation generates a 
physical connection between the cup and pin that is converted to an electrical signal 
which is recorded via transducer and monitored via chart recorder. In the ROTEM® 
the pin is fixed on the tip of a rotating shaft, whereas the sample cup is stationary and 
the position of the axis is detected by reflection of light on a smaller mirror on the 
axis. Therefore, the results differ from each other and are not comparable between 
instruments (99-101). 
Table 5. POC tests of global haemostasis; thromboelastography







- native or citrated 
samples
- use of activators
- use of heparinase
• detection of 
coagulopathy
• guide to blood product 
and drug administration 
during cardiac- and 
hepatic surgery




• outcome affected 
by type of activator, 
temperature and 
haematocrit.





• no quantitative 
analysis of clotting or 
anticoagulant factors
• correlation to classical 
coagulation tests is poor






































Thromboelastography was initially used to guide transfusion in the setting of 
trauma-, cardiovascular-, and hepatic- surgery as the technique offers (the 
theoretical) advantage to provide insight into the underlying pathophysiology 
driving the complex and multifactorial haemostatic disturbances and to tailor 
haemostatic treatment (49,50,102-105). Since then, its use has been expanded 
to all other areas of haemostasis- and thrombosis- testing (106-110). Moreover, 
various guidelines recommend its possible role in both analyzing and managing 
haemostatic defects in patients with massive bleeding (9,111). However, studies 
evaluating the role of thromboelastography as a predictor of excessive bleeding after 
CPB show conflicting reports, with only minimal support in favor of its usefulness 
(112-114). Three prospective randomized trials (one blinded) demonstrated reduced 
transfusion requirements using an thromboelastography-guided transfusion 
algorithm, compared to a laboratory guided algorithm, in patients during complex 
cardiac surgery, whereas another study demonstrated no benefit (104,105,115,116). 
In hepatic surgery no prospective studies were performed on the preoperative 
thromboelstographic haemostatic profile and subsequent transfusion requirements. 
However, hyperfibrinolysis, complicating orthotopic liver transplantation, can 
preoperatively be predicted by thromboelastography (117). Also the treatment of 
fibrinolysis by aprotinin can readily be monitored by TEG (118). Although Kang et 
al advocated TEG-guided transfusion in hepatic surgery some 25 years ago, since 
then one randomized clinical trial has been performed demonstrating decreased 
transfusion of fresh frozen plasma, without effect on red blood cell transfusion or 
3-year survival (50,119). However, the absence of guidelines and clear evidence as to 
the most appropriate threshold has left questions with regard to the clinical use of 
algorithm based replacement therapy in hepatic surgery (120). A recently published 
Cochrane review concluded that application of a TEG or ROTEM guided transfusion 
strategy seems to reduce the amount of bleeding but whether this has implications 
for the clinical condition of patients is still uncertain (121). They further concluded 
that there is an absence of evidence that TEG or ROTEM improves morbidity or 
mortality in patients with severe bleeding.





































Even though there are several publications using thromboelastography it remains 
a research tool as the methodology is still not standardized which result into 
significant intra-and inter-laboratory variability as was recently demonstrated by 
the TEG-ROTEM Working Group (122). Moreover, it is important to realize that the 
technique does not provide any quantitative analysis of clotting or anticoagulant 
factors. Also the correlation to classical coagulation tests is poor. We demonstrated 
that the TEG variable “Maximum Amplitude“ (corresponding to clot strength and 
related to platelet count) was insensitive in detecting the haemostatic effects of 
severe thrombocytopenia (< 50 x 109/L). Even more importantly, we found that 
platelet count not only affects the TEG parameter corresponding to clot strength, but 
also all other phases of plasmatic coagulation (123). As a consequence, the results 
of thromboelastography must be carefully interpreted correlating them to clinical 
conditions.
ConClUsIon
The classical coagulation tests for evaluation of bleeding disorders are especially 
useful in analyzing isolated defects in the coagulation cascade, whereas complex 
and multifactorial haemostatic disturbances, as seen in trauma and massive blood 
loss, are difficult to analyze. Despite it’s shortcomings, it is important to realize that 
classical coagulation tests are well standardized, and that blood collection, sample 
handling and test running is performed by trained laboratory personal minimizing 
pre-analytical errors. Moreover, these tests are subject to strict internal- and external- 
quality control procedures making them reproducible and reliable. The investigation 
of haemostasis at the central laboratory versus POC testing have distinct objectives. 
The utility of the former for diagnosis and adjustment of therapeutics have been 
well demonstrated. In contrast, the experience with POC testing is relatively recent, 
and its utility for patient management remains to be demonstrated in prospective 





































However, as several of the discussed POC test of haemostasis continue to evolve 
and have potential clinical benefit, it seems likely that these tests will be used 
on a larger scale in clinical practice. Therefore it is of importance that workers in 
the field of haemostasis remain aware of new developments and applications of 
these evolving techniques and assays. Furthermore, as these POC tests become 
increasingly used outside of the specialised laboratory, attention should be paid to 
validation, reliability and quality control. As far as POC platelet function is concerned, 
at this time no single POC test of platelet function has conclusively been shown to 
deliver reliable and reproducible results. POC tests that assess global haemostasis, 
e.g. thromboelastography, have potential for allowing a new look at the process 
of haemostasis. Many transfusion medicine specialists feel that POC assays and 
transfusion algorithms may provide an effective concurrent method in clinical 
decision-making and in the use of blood products in the surgical setting. Gradually, a 
shift of paradigm is seen in the management of massive blood loss, as two guidelines 
now propose near-patient testing, e.g. thromboelastography, if available, next to the 
assessment of classical coagulation tests, in characterising coagulopathy and guiding 
haemostatic therapy (9,111). However, there is no evidence that these assays give an 
advantage over conventional coagulations tests where there is access to rapid result 
reporting from the laboratory and in situations where the surgery is relatively low 
risk. (48,63). It is important to realize that the validity of POC tests of haemostasis has 
to be based on the achievement of accurate and reliable results leading to improved 
patient care. Still work needs to be done to standardise the methodology and its 
applications as well as to correlate clinical outcome with the measured parameters. 
Importantly, randomised studies evaluating thromboelastography-guided transfusion 
therapy versus fixed ratios of blood components on overall mortality in patients with 
massive blood loss are highly warranted. 
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Chapter 2
In normal Controls, both age and 
Gender affect Coagulability, as measured 
by Thrombelastography®
Wilfried W.H. Roeloffzen, MD, Hanneke C. Kluin-Nelemans, PhD, Andre B. Mulder, 








































baCKGRoUnD: Our objective was to analyze the effects of age, gender and the use of 
oral contraceptives (OCs) on coagulation using Thrombelastography® (TEG), a single 
test to analyze both plasma coagulation factors and cellular elements in whole blood. 
meTHoDs: TEG variables were measured in native whole blood and in recalcified 
citrated blood from 120 healthy adults (60 men and 60 women) with various ages 
and in an additional 29 healthy women using OCs. 
ResUlTs: We observed hypercoagulability in females compared to males and in 
women using OCs compared with age-matched nonusers. Moreover, we found 
hypercoagulability with aging. Using the method of Bland Altman (Lancet 1986;1:307-
10), we demonstrated no correlation between TEG measurements in native and 
recalcified citrated blood.
ConClUsIons: Aging, female gender, use of OCs and low-normal hematocrit levels 
have significant procoagulant effects. TEG measurements in native and recalcified 
citrated blood are not interchangeable, as indicated by differences between the 2 
measurements ranging from 20% in maximum amplitude to 246% in clotting time. 





































Effects of age and gender on haemostasis
InTRoDUCTIon
Thrombelastography® (TEG) is classically used in situations where point-of-
care testing of haemostasis is desired. There is also increasing clinical interest in 
assessment of the prothrombotic tendency by TEG, for example in thrombophilia 
screening, but also in prediction of arterial or venous thrombosis in the general 
population (1). An advantage of TEG over conventional tests of haemostasis is that 
it is performed on whole blood, taking into account the role of interacting blood 
elements such as phospholipid-bearing cells and platelets (2,3). The technique 
offers a rapid overview of the cumulative effect of all the individual components of 
haemostasis, without having to analyze each of these components separately. Further, 
TEG provides information about the quality of the clot as well as the dynamics of its 
formation and its lysis. The different parts of the TEG tracing correspond to specific 
deficiencies in coagulation factors or inhibitors of coagulation, use of anticoagulants, 
platelet count as well as platelet function and fibrinogen level. Depending on the 
shape of the TEG tracing, the haemostatic condition of a patient can be defined as 
normal, hypocoagulable or hypercoagulable. TEG is considered more sensitive than 
routine assays in detecting hypercoagulability (4-7). The interpretation of TEG data 
is, however, hampered by the lack of a validated large series of reference values, 
especially from elderly persons and from subjects with a physiologic hypercoagulable 
state like users of oral contraceptives (OCs) and pregnant women (8,9). The purpose 
of the present study was both to establish reference ranges and to asses whether 
age, gender and use of OCs influence haemostasis as measured by TEG in fresh 
native whole blood in healthy persons. Although TEG was originally designed as 
a bedside monitor for native whole blood, recalcified citrated blood is used as an 
alternative to perform tests within the laboratory. Therefore we also performed TEG 
in recalcified citrated native whole blood to explore whether both TEG techniques 






































The institutional review board approved the study, and informed consent was obtained 
from all study participants. Sixty healthy male and 60 healthy female subjects, age 
distributed equally between 19 and 87 years, participated in the study. The following 
exclusion criteria were used: coagulation disorders, use of anticoagulants, use of oral 
contraceptives (except for the substudy, see below), use of acetylsalicylic acid within 
the past 10 days, use of nonsteroidal anti-inflammatory drugs within the last 24 
hours, renal diseases or plasma concentration of creatinine more than 120 μmol/L, 
and liver disease or increased plasma concentration of aspartate aminotransferase 
(>50 U/L) or alanine aminotransferase (>50 U/L). A history of thromboembolism 
was permitted. The effects of OCs on coagulation were examined by comparing TEG 
variables of 29 healthy young female OC users with age-matched controls.
blood sampling and assays
Blood samples were obtained simultaneously for TEG analysis and standard laboratory 
and coagulation tests (i.e. complete blood count, white blood cell differentiation, 
creatinine, aspartate aminotransferase, alanine aminotransferase, prothrombin 
time [PT], activated partial thromboplastin time [aPTT], fibrinogen concentration 
and antithrombin [AT]). Venous blood samples were collected by vein puncture at 
the antecubital fossa, using a 19 gauge butterfly needle. One single experienced 
examiner obtained all blood samples. To minimize the effects of venous endothelial 
damage by using a tourniquet, the first aspirate of 10 mL blood was discarded. Blood 
was collected into a 20-mL polypropylene syringe to prevent contact activation of 
clotting by glass. Some of the collected blood, 3.5 mL, was filled into two Vacutainers 
(Greiner Bio-One, Kremsmünster, Austria), containing 0.5 mL coagulation sodium 
citrate 3.2% for subsequent standard coagulation tests and TEG analysis (recalcified 
citrated native whole blood; C). All standard coagulation tests were performed on 
the STA-R coagulation analyzer (Roche, Diagnostica Stago, Asnières, France): PT with 
Thromborel S reagents and aPTT with Actin FS reagents (Dade Behring, Marburg, 
Germany), fibrinogen with excess thrombin (BioPool, Umea, Sweden) according to 





































Normal values for these variables in our laboratory are PT 11 to 16 sec, aPTT 26 to 36 
sec, fibrinogen 1.7 to 3.5 g/L, AT 75% to125%.
Thrombelastographic assays were carried out using a computerized TEG coagulation 
analyzer (Model 5000; Haemoscope Corp., Niles, IL). All analyses were performed 
with TEG disposable cups and pins as devised by the manufacturer. Polypropylene 
and polyethylene pipettes were used to handle reagents and blood. TEG analyses 
were performed in native whole blood and recalcified citrated native whole blood. 
For TEG analysis in native blood, 360 ml whole blood was pipetted into the prewarmed 
TEG cup and measurements were performed within 6 minutes of sampling (10). 
Recalcification and TEG measurements in citrated blood were performed after 
storage at room temperature for 1 hour, as described previously11. Twenty microliters 
of 200-mM calcium chloride was pipetted into the prewarmed TEG cup. The citrated 
blood was gently inverted to ensure mixing of the sample. Next, 340 ml citrated blood 
was added to the TEG cup. 
The following TEG variables were recorded: the reaction time (R-time, min), 
representing the rate of initial fibrin formation, the clotting time (K-time, min), 
representing the time until a fixed level of clot firmness is reached, the angle (α, 
degrees), which is closely related to K-time and represents the rate of clot growth, the 
maximum amplitude (MA, mm), is a measurement of maximum strength or stiffness 
of the developed clot, the shear elastic modulus strength (SEMS or G, dynes/cm2) is 
a parametric measure of clot firmness expressed in metric units calculated from MA 
as follows: 
 G = (5000 x MA) / (100 - MA). 
Furthermore we calculated the coagulation index (CI), which is an overall 
measurement of coagulation, using the following equation: 
 CI= (-0.1227R + 0.0092K) + (0.1655MA – 0.0241α) – 5.022. 
R-time, K-time and α are prolonged by anticoagulants and factor deficiencies, but they 
can also be affected to a degree by platelet dysfunction or thrombocytopenia. MA 
is especially influenced by platelet count and platelet function as well as fibrinogen 
level. 
3




































In addition to “classical” TEG variables, we made velocity calculations, describing 
thrombus generation (TG) during blood clotting, from the signature graph produced 
by thrombelastography. These variables give additional information on the kinetics 
of the coagulation cascade as these variables represent the more parametric 
measurements of clot propagation (12). The following TG parameters were recorded: 
the Maximum TG (MTG, dynes/cm2/s); this variable presents the first derivate of the 
velocity of the increase in clot strength, beginning as G begins to increase and ending 
after clot strength stabilizes. The information from this parameter is equivalent to 
the information from the alpha angle, however MTG provides a more parametric 
evaluation than the determination of α. The second variable is Time to Maximum rate 
of TG (TMG, seconds), which is the time it takes to reach MTG. Finally we determined 
Total TG (TTG, dynes/cm2), which is the total positive area under the velocity curve, 
representing the total change in elastic resistance until clot strength stabilization 
occurs. MTG and TTG are expressed using metric units of elastic resistance that 
accurately describe changes in clot strength. 
statistical analysis
TEG values were presented as mean and standard deviation (SD). All normal values 
of TEG variables were calculated by the mean value ± 2 x SD. Group comparisons 
were made by the Student’s t test if normally distributed or Mann-Whitney U test if 
the distribution was skewed. Where appropriate, age was treated as a dichotomous 
variable, with a cutoff value of 50 years. Linear regression was used to quantify 
the associations of TEG parameters with age, sex and relevant blood test. In these 
analyses, Pearson correlation coefficients (r2) were calculated, as well as the level of 
significance (with a null-hypothesis r = 0). Multivariable regression analyses were 
performed to obtain adjusted correlation coefficients of TEG variables with age, 
sex and blood tests. All variables univariately associated with the TEG variable of 
interest at a p level of <0.10 were included in the multivariable regression analysis. 
Co-linearity between independent variables was assessed prior to the multivariable 
analyses. To evaluate the level of agreement of TEG values in noncitrated whole blood 
versus citrated whole blood, the method of Bland Altman was used (13). The Bland-





































The range in limits of agreements determines how much the new method (citrated 
native whole blood) differs from the old one (native whole blood). All individually 
reported p values must be interpreted within the concept of an explorative testing, 
rather than formal hypothesis testing. Therefore, a correction for multiple testing 
was not applied. Analyses were performed using commercially available computer 
software (Statistical Analysis System, version 8.0, SAS Institute, Cary, NC, and SPSS 
17.0 software for Windows, SPSS, Chicago, IL).
ResUlTs
We studied 120 healthy adults, 10 per age decade, mean age 50 ± 17 years, 60 women 
and 60 men. Another 29 healthy female controls using OC, of which more than 60% 
used a second generation OC, were analyzed. In Table 1 the demographics of all 
subgroups are shown, with a comparison of male with female (non-OC users) and 
a comparison of OC users with age-matched non-OC users. Apart from hemoglobin 
and creatinine levels, there were no statistically significant differences between the 
male and female control group.
Table 1. Healthy control demographics.
Variable male p female p female oC+
(n=60) (n=60) (n=29)
Age (yr) 50 ± 18 ns 49 ± 18 <0.001 26 ± 6
Leukocytes, x 109/L 7.1 ± 1.2 ns 7.3 ± 1.5 ns 7.4 ± 1.4
Hemoglobin, mmol/L 9.0 ± 0.5 <0.001 8.1 ± 0.6 ns 7.8 ± 0.6
Platelets, x 109/L 243 ± 54 ns 257 ± 49 0.01 275 ± 54
Creatinine, µmol/L 98 ± 18 <0.001 85 ± 16 ns 80 ± 7
Values are mean ± SD. OC+, using oral contraceptives; ns, not significant.
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effect of gender on TeG parameters
Mean values ± SD of TEG variables, measured in native and citrated whole blood, 
and classical coagulation tests in the 3 subgroups are presented in Table 2. There 
were statistically significant differences in coagulability between male and female 
subjects. Except for R-time measured in citrated blood (p=0.06), all other TEG 
variables in the female group were statistically significant in hypercoagulability 
when compared with the male group, whereas no statistically significant differences 
were found between the classical coagulation tests in both sexes. In females we 
observed a significantly faster and higher initial rate of fibrin formation as illustrated 
by a shorter R- and K-time. The female group also had a significantly higher rate 
of clot growth, represented by a wider α angle. Moreover, MA, SEMS, and CI were 
significantly higher in the female group. The latter suggests that both maximum clot 
strength as well as the viscoelastic property of the formed clot were higher in women 
compared with men. Also, the novel TG variables were different in men compared 
with women. According to these variables, thrombin was generated significantly 
quicker (TMG) and with greater velocity (MTG) in women. Finally, the value for TTG 
was also significantly higher in women.
effect of oCs on TeG Variables
We compared TEG variables of the group using OCs with an age-matched subgroup of 
women who did not take OCs (n = 22). In our study women using OCs had significant 
higher values respectively for MA, SEMS, and TTG generated. Apart form a higher 
fibrinogen level in women using OCs, no other statistically significant differences 
were found in classical coagulation tests between groups (Table 2).
effect of age on TeG Variables
Weak to moderate correlations between age and most TEG variables were observed 
in both sexes. The strongest correlations emerged between age and MA (r = 0.47), 
SEMS (r = 0.47) and TTG (r = 0.47). The scatter diagrams and regression equations 
of these 3 TEG variables versus age are presented in Figure 1, a-c. Observing the 
different TEG variables per decade, a gradual change toward hypercoagulability with 





































both sexes when subjects younger than 50 years were compared with subjects older 
than 50 years (Table 3). In the classical coagulation tests, the older male group also 
had statistically significant shorter aPTT (p=0.03), higher fibrinogen levels (p=0.003) 
and lower AT percentages (p<0.001) compared to the younger male group. Females 
above 50 years had significant higher fibrinogen levels (p<0.001) and demonstrated 






figure 1a - d.
Correlation and linear regression of age with maximal clot strength (maximum amplitude), 
maximal clot elasticity (shear elastic modulus strength), and the total amount of thrombus 
that is generated (total thrombus generation) and of hemoglobin with the time to reach a fixed 
level of clot firmness (clotting time); R Sq linear = correlation coefficient.
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Table 2. Thrombelastography variables and classical coagulation tests in male and female 
















































































































































PT 12 ± 0.6 ns 13 ± 0.6 13 ± 0.6 ns 13 ± 0.6
aPTT 31 ± 3 ns 31 ± 3 30 ± 3 ns 32 ± 3
Fibrin. 3.0 ± 0.5 ns 3.0 ± 0.5 3.3 ± 0.6 <0.005 2.7 ± 0.5
AT 100 ± 13 ns 103 ± 10 104 ± 10 ns 104 ± 10
Values are mean ± SD. ns; not significant; OC+, using oral contraceptives; OC-, not using 
oral contraceptives; R-time (min), reaction time; K-time (min), clotting time; A, alpha angle 
(degree); MA (mm), maximum amplitude; SEMS (dynes/cm2), shear elastic modulus strength; 
CI, coagulation index; MTG (dynes/cm2/sec), maximum thrombus generation; TMG (sec), time 
to maximum thrombus generation; TTG (dynes/cm2), total thrombus generation; N; native 
whole blood, C: citrated whole blood. PT (sec), prothrombin time; aPTT (sec), activated partial 





































Table 3. Thrombelastography variables and classical coagulation tests for both sexes, 
comparing subjects younger than 50 years with age older than 50 years.
Variable male < 50
(n=30)













































































































































PT 12.3 ± 0.7 ns 12.5 ± 0.5 12.7 ± 0.6 ns 12.3 ± 0.5
aPTT 31.8 ± 3.0 0.03 30.3 ± 2.3 31.5 ± 2.7 ns 29.8 ± 3.8
Fibrin. 2.8 ± 0.5 0.003 3.2 ± 0.5 2.8 ± 0.4 <0.001 3.2 ± 0.5
AT 106.7 ± 10.8 <0.001 93.3 ± 12.5 104.4 ± 9.1 ns 102.2 ± 11
Values are mean ± SD. R-time (min), reaction time; K-time (min), clotting time; A (degrees), 
alpha angle; MA (mm), maximum amplitude; SEMS (dynes/cm2), shear elastic modulus 
strength; CI, coagulation index; MTG (dynes/cm2/sec), maximum thrombus generation; TMG 
(sec), time to maximum thrombus generation; TTG (dynes/cm2), total thrombus generation; 
PT (sec), prothrombin time; aPTT (sec), activated partial thromboplastin time; Fibrin. (g/L), 
fibrinogen; AT (%), antithrombin.
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association of other variables with TeG Variables
In addition to the relationship of TEG variables with age and gender, we also studied 
the association among TEG variables, PT, aPTT, and blood cell counts. In a univariate 
analysis TEG variables were associated with gender, age, hemoglobin level, platelet 
count, aPTT and fibrinogen level (data not shown). Remarkably, no correlation was 
found between the PT and any of the TEG variables. In multivariable analysis, age 
remained statistically correlated with the MA and with the derived variables SEMS 
and TTG (Table 4). Furthermore, gender was associated with all TEG variables except 
TMG. Regarding classical coagulation tests, the lack of correlation between platelet 
count and TEG variables is surprising but in the context of a platelet count in the 
normal range. However, aPTT showed a correlation with the initial fibrin formation 
as demonstrated by a positive correlation with R-time, K-time and the time to MTG 
and a negative correlation with the α angle. Fibrinogen was associated with all TEG 
variables, except the R-time. 
Finally, a positive correlation between hemoglobin level and the clotting time 
(K-time; r = 0.24) was present. With increasing hemoglobin level, a prolongation of 
the time to reach a fixed degree of viscoelasticity, as a result of fibrin buildup and 
cross-linking, was observed (Figure 1d). Hemoglobin level had comparable effects on 
TEG variables in both sexes.
TeG Variables in fresh whole blood versus recalcified citrated whole blood
We determined limits of agreement for the differences in native and recalcified 
citrated whole blood for each of the TEG variables (Table 5 and Figure 2). Our data 
show a lack of correlation between the TEG measurements in both types of blood 
samples, due to the very large limits of agreement. As is shown in Figure 2, for the R- 
time and K-time the lack of agreement increased with an increase of the R-time and 
K time. For MA, this was less pronounced. The mean difference between the K-time 















































Scatter plots for the time until initial fibrin formation occurs (R-time), the time until a fixed level 
of clot firmness is reached (clotting time), the rate of clot growth (alpha), and the maximal clot 
strength (maximum amplitude) of mean versus difference of the fresh and recalcified citrated 
whole blood thromboelastography values.
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Table 4. Significant correlation coefficients by multivariate analysis among variables age, 
gender, classical coagulation tests and TEG variables in Native whole blood.
R-time K-time Α ma sems CI mTG TmG TTG
Age ns ns ns 0.32 0.32 0.19 ns ns 0.30
Gender -0.26 -0.22 0.27 0.24 0.22 0.3 0.23 ns 0.24
Hb ns 0.24 ns ns ns ns ns ns ns
Platelet ns ns ns ns ns ns ns ns ns
aPTT 0.36 0.24 -0.22 ns ns -0.21 ns 0.21 ns
Fibrinogen ns -0.27 0.28 0.37 0.37 0.25 0.27 ns 0.40
ns, not significant; R-time, reaction time; K-time, clotting time; α, alpha angle; MA, maximum 
amplitude; SEMS, shear elastic modulus strength; CI, coagulation index; MTG, maximum 
thrombus generation; TMG, time to maximum thrombus generation; TTG, total thrombus 
generation; Hb, hemoglobin; aPTT, activated partial thromboplastin time
Table 5. Limits of agreement for differences in Native and Citrated whole blood.
mean
difference
mean diff in % 
change in native 
compared to Cn
95% CI of mean 
difference
limits of agreement
R time (min) 10.6 101% 9.8 to 11.5 1.2 to 20.1
K time (min) 6.3 246% 5.8 to 6.7 1.7 to 10.8
A (degree) -30.6 -55% -31.7 to -29.4 -43.0 to -18.2
MA (mm) -11.6 -20% -12.5 to -10.6 -21.6 to -1.5
SEMS (dynes/cm2) -2576 -36% -2788 to -2364 -4873 to -280
CI -3.7 -243% -3.9 to -3.4 -6.4 to -0.9
MTG (dynes/cm2/sec) -6.7 -61% -7.2 to -6.2 -11.3 to -2.1
TMG (sec) 983 132% 862 to 1105 -330 to 2297
TTG (dynes/cm2) -192 -20% -206 to -177 -365 to -18
R-time, reaction time; K-time, clotting time; A, alpha angle; MA, maximum amplitude; SEMS, 
shear elastic modulus strength; CI, coagulation index; MTG, maximum thrombus generation; 







































In the present study we assessed reference values for TEG variables in a large 
population of healthy volunteers. Our report is unique because we are the first who 
study a population with a well-balanced age and gender distribution. Moreover, 
we describe both classical and dynamic (TG) TEG variables and compare these with 
classical coagulation tests. Finally, we performed TEG measurements in both native 
and recalcified citrated whole blood in order to see whether both techniques produce 
the same results and are thus interchangeable. 
In our study population we demonstrated significant gender differences in 
coagulation, with a more procoagulant TEG profile in women compared to men. In 
women, not only a faster rate of fibrin formation was observed (clotting time 7.7 ± 
2.5 min [women] vs. 10.0 ± 2.7 min [men]; p<0.001), but also a greater ultimate clot 
strength with better viscoelastic properties (MA 48.7 ± 6.9 mm [women] vs. 44.0 ± 6.6 
mm [men]. In contrast, there were no gender differences using classical coagulation 
tests in these same subjects. The observed gender-related differences in coagulation 
remained with aging and, as a consequence, could not solely be explained by the 
effects of female sex hormones. Neither could pregnancy nor the use of OCs be held 
responsible for this difference, because both conditions were excluded from this sub-
analysis. Lang and colleagues found a trend towards enhanced coagulation in women 
compared with men (14). However, in their female reference population, use of OCs 
was not an exclusion criteria which may have affected the outcome.
Although the exact mechanism is unknown, OC use increases the risk of venous 
thrombosis (8). From this study, we conclude that women using OC have higher 
ultimate clot strength with better viscoelastic properties compared to age-matched 
controls not using OC. In contrast, Zahn and co-workers, using celite as activator, 
found no significant TEG changes in women using low estrogen dose OCs (15). Adding 
coagulation activators such as celite results into shortening of the initial part of the 
TEG line, making rapid interpretation of the coagulation process possible. However, 
this same activation may be at the cost of subtle information from this initial part 
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of the TEG line. Therefore, we would like to emphasize on the use of nonactivated 
whole blood in TEG when studying circumstances in which coagulation differences 
are considered to be small. 
Gorton et al. have reported significant gender-related differences in TEG variables, 
with a significant procoagulant trend from men through nonpregnant women to 
pregnant women (16). However, these results may have been biased, since half of 
the non-pregnant women were taking third generation OC and only patients with an 
average age of 30 years were included. In our study we could demonstrate that the 
effect of gender is not limited to the younger age group but is a phenomenon that 
persists with aging.
Aging is associated with hypercoagulability and considered as an important risk factor 
for venous thrombosis (17). We demonstrated a tendency towards hypercoagulability 
in both sexes with advancing age. Although there was no statistically significant 
difference per decade, there was a trend that may have been relevant with greater 
numbers of healthy study subjects. Moreover, statistically significant differences in 
most TEG variables were found comparing the age group younger than 50 years with 
the group older than 50 years, as shown in Table 3. TEG variables mostly influenced 
by age were MA, SEMS, and TTG, all linked with the building up and cross-linking of 
fibrin, leading to a stronger thrombus with better viscoelastic properties. For the 
classical coagulation tests, aging was accompanied by a shortening in aPTT in the male 
subgroup and a rise in fibrinogen level in both genders. Others demonstrated that 
in patients undergoing orthopedic surgery, aging was associated with procoagulable 
TEG variables (18). However, in contrast to our study, age was not equally distributed 
in that study because patients older than 80 years were overrepresented. More 
recently no age-related differences in kaolin-activated TEG variables in healthy 
children could be identified and no significant differences between children and 
adults were observed (19). A possible explanation, given by the investigators, is that 






































TEG with recalcified citrated blood is used as an alternative to noncitrated blood 
in situations in which immediate TEG determination is not practically feasible. The 
use of a citrated blood sample, however, generates different results to that seen 
when a native sample is used (11,20). Others demonstrated that coagulation 
analyses using blood that has been exposed to citrate and recalcified afterwards, 
do not yield reliable depictions of the natural dynamics of the blood coagulation 
process (21). We studied TEG variables in noncitrated as well as in recalcified blood 
and demonstrated an important lack of agreement between the 2 techniques. As 
a consequence we consider both techniques not exchangeable. Both gender- and 
age-related differences in TEG variables were more prominent when measured in 
noncitrated than in citrated whole blood. The latter suggests that preparation of the 
blood sample (native versus recalcified citrated native) is important for the detection 
of subtle age- and gender-related hypercoagulable states. 
We demonstrated by multivariate analysis a strong reversed correlation between 
hemoglobin level (still within the normal range) and the speed to reach a certain 
level of clot strength (= K or clotting time). In other words, a more rapid fibrin buildup 
was observed in control persons with lower hematocrit levels. The importance of 
erythrocytes in haemostasis has been described before. In the absence of platelets, 
erythrocytes can contribute to thrombin generation through exposure of pro-
coagulant phospholipids at their outer cell membrane (22). Iselin and co-workers 
demonstrated that a progressive isolated reduction in hematocrit from 40% to 
10% resulted in an accelerated blood coagulation profile resulting in increased clot 
strength as measured in celite-activated citrated blood (23). Others found a state 
of relative hypercoagulability (shortened R-time) immediately after a rapid 10% loss 
in circulating blood volume (24). Because we examined healthy persons with their 
hematocrit within the normal range, we can only speculate on an optimal hematocrit 
favoring haemostasis. 
There were a number of limitations to this study. First, we did not correct for multiple 
testing. Although such an adjustment of p-values, e.g., by Bonferroni or Hochberg 
step-up Bonferroni, can be applied to our data, we a priori decided not to apply such 
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an adjustment because the purpose of all hypothesis testing was not to identify a 
single significant result, but rather to evaluate differences between groups on all 
the TEG variables as a whole. Second, although operation procedures were strictly 
followed in accordance with the Thrombelastograph Operation Manual, the (native) 
TEG values in general were hypocoagulable compared to what has been historically 
reported by several laboratories worldwide. As TEG outcome is influenced by 
many variables (blood collection site, sample stability, repeat sampling, and also 
modifications of the technique like citration or adding activators) we think that 
for correct interpretation of TEG results each center should perform analyses in 
a standardized way, with assessment of outcomes against (own) normal ranges 
derived from samples handled in the same manner. Finally, in clinical practice, where 
TEG is used as a rapid point of care test of haemostasis, coagulation activators are 
often added to the blood samples. As we used only whole blood samples without 
activators, the study observations may not be applicable to other methods of TEG 
measurement. 
In summary, we present reference values in a large random population, equally 
distributed for age and gender. We observed significant procoagulant effects of aging, 
female gender, use of OC and low-normal hematocrit levels on TEG variables. We also 
demonstrated an important lack of agreement between TEG measurements in native 
and recalcified citrated blood and considered both techniques not exchangeable. Our 
study underlines the sensitivity of TEG over classical coagulation tests in detecting 
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Chapter 3
Thrombocytopenia affects Plasmatic 
Coagulation as measured by 
Thrombelastography®
Wilfried W.H. Roeloffzen, Hanneke C. Kluin-Nelemans, André B. Mulder,
Joost Th.M. de Wolf







































baCKGRoUnD: Thrombelastography® (TEG) is used as a point-of-care test of 
haemostasis. Different components of the test tracing are considered to reflect 
various parts of the haemostatic system and to distinguish low platelet count, 
platelet dysfunction or both from lack of plasmatic coagulation factors. To analyze the 
influence of one single element of the coagulation system, namely the platelet count, 
we used TEG serially in patients with well documented transient thrombocytopenia.
sTUDy DesIGn anD meTHoDs: A total of 189 TEG analyses were performed from 
16 patients with a hematological malignancy in remission, receiving consolidation 
courses of chemotherapy. TEG outcome using unmanipulated and citrated blood 
samples at a median of 11 times (range 1-17) in the same patients during the decrease 
of platelet count in response to chemotherapy were compared with outcomes in 120 
healthy adults from various age categories. 
ResUlTs: We found a correlation (r = 0.7; p<0.001) between TEG clot strength 
(maximum amplitude) and platelet count. Moreover, platelet count was correlated 
with respectively the initial rate of clot formation (reaction time and clotting time), 
the rate of clot growth (alpha angle), and also with maximum thrombus generation, 
time to maximum thrombus generation and total thrombus generation. 
ConClUsIon: We conclude that platelet count not only affects the strength of clot 
formation, as was expected, but also all other phases of plasmatic coagulation. 
Citration of the blood sample, aiming at easy storage of the material, masked some 






































To determine the relative contribution of the different components of haemostasis, 
conventional coagulation tests like prothrombin time (PT), activated partial 
thromboplastin time (aPTT), fibrinogen concentration and platelet count are 
measured. The limitation of these classical coagulation assays is that only information 
on the plasma coagulation factor levels is provided. Moreover, as most of these 
tests are performed in a central laboratory it often takes time to obtain results, 
making the test less suitable as a perioperative test of haemostasis. In recent years 
the Thrombelastograph® (TEG; Haemoscope Corporation, Niles, Illinois, USA) has 
gained popularity as a useful point-of-care coagulation monitor in the perioperative 
setting (1-4). TEG is a whole blood test that gives information not only on plasma 
coagulation factors but also on the influence of platelets, leukocytes and erythrocytes 
on haemostasis, defining TEG as a more physiological instrument (5). The different 
components of the TEG profile reflect different parts of the coagulation process and 
are used to assess the need for blood component therapy (6). 
The purpose of the present study was to examine the influence of one single 
component of the coagulation system, the platelet count, on all available TEG 
parameters as measured in both native and citrated native whole blood. Although 
often used in clinical practice, we decided not to add activators of the coagulation 
process, in order to improve interpretation of the initial part of the TEG line. We 
investigated patients with a hematological malignancy receiving chemotherapy, 
and assessed TEG multiple times during the chemotherapy-induced decrease of 
platelet count. Thus, in a single patient all variables remained constant except for the 
changing platelet counts. The analyses were performed in a standardized way and 
results were compared to ranges obtained from healthy controls. We hypothesized 
that the platelet count correlates with the strength of clot formation, and, that this 







































The institutional review board approved the study and informed consent was 
obtained from all patients (n=16) and control persons (n=120). Patients were treated 
for hematological malignancies and admitted for their second or third course of 
chemotherapy. For all patients the underlying disease was in complete remission 
after the preceding chemotherapy, precluding any effect of the underlying disease on 
the coagulation process. Also the bone marrow function had to be restored to normal 
with concomitant normal peripheral blood counts. In these 16 patients we studied 
the TEG performance multiple times (median 11, range 1-17) during the decrease 
and subsequent recovery of platelet count. The 120 controls were healthy adults 
from all age categories. For both study patients and controls, the following exclusion 
criteria were used: coagulation disorders, use of anticoagulants, use of acetylsalicylic 
acid within the preceding 10 days, use of non steroidal anti-inflammatory drugs 
within the last 24 hour, renal diseases or plasma concentration of creatinin more 
than 120 μmol/L and liver disease or increased plasma concentration of aspartate 
aminotransferase (ASAT) (> 50 U/L) or alanine aminotransferase (ALAT) (> 50 U/L). 
Patients with septicemia, diffuse intravascular coagulation or thrombosis during the 
study period were also excluded. Finally patients with a recent history (<1 week) of 
platelet or red blood cell (RBC) transfusion were also not eligible.
blood sampling and assays
Blood samples were obtained simultaneously for TEG analysis and standard 
laboratory and coagulation tests [i.e. complete blood count, white blood cell 
differentiation, creatinine, ASAT, ALAT, PT, aPTT, fibrinogen and anti-thrombin (AT)]. 
Platelet aggregation assays with ADP, adrenalin, ristocetin and arachidonic acid 
were performed once at study entrance to exclude an underlying thrombopathic 
disorder. Venous blood samples were drawn from an indwelling central venous 
catheter (patients) or collected by vein puncture at the antecubital fossa using a 
21-gauge butterfly needle (controls). Two examiners obtained all blood samples, 





































polypropylene syringe to prevent contact activation by glass. To minimize the effects 
of using a tourniquet and to exclude effects of heparin in the central venous catheter, 
the first aspirate of 10 mL blood was discarded. In addition to the native whole blood 
(native) test, some of the collected blood, 3.5 mL, was filled into two Vacutainers 
(Greiner Bio-One, Kremsmünster, Austria), containing 0.5 mL Coagulation Sodium 
Citrate 3.2% for subsequent standard coagulation tests and TEG analysis (recalcified 
citrated native whole blood; citrated native). All standard coagulation tests were 
performed on the STA-R coagulation analyzer (Roche, Basel, Switzerland); PTT with 
Thromborel S reagents and aPTT with Actin FS reagents (DadeBehring, Marburg, 
GmbH, Marburg, Germany), fibrinogen with excess thrombin (BioPool US Inc., 
Ventura, California, USA) according to the Clauss method and AT with thrombin as 
enzyme (STAchrome ATIII, Roche kit). Normal values for these parameters are PT 11-
16 s, aPTT 26-36 s, fibrinogen 1.7-3.5 g/L and AT 75-125%.
Thromboelastographic assays were carried out using a computerized TEG coagulation 
analyzer (Model 5000; Haemoscope Corp). All analyses were performed with 
TEG disposable cups and pins as devised by the manufacturer. Polypropylene and 
polyethylene pipettes were used to handle reagents and blood. 
TEG measurements (and standard blood laboratory evaluation) took place at study 
entrance, before starting chemotherapy, and 3 times a week afterwards until the 
platelet count dropped below 100 x 109/L. From that point on, TEG analyses and blood 
tests were performed daily until a patient needed a RBC transfusion (hemoglobin < 8 
g/dl) or a platelet transfusion (platelet count < 10 x 109/L). 
For TEG analysis in native blood, 360 mL whole blood was pipetted into the 
prewarmed TEG cup and measurements were performed within 6 minutes from 
sampling (7). Recalcification and TEG measurements in citrated native blood were 
performed after storage at room temperature (RT) for 1 hour, as described previously 
(8). Twenty mL 0.2 mol/L calcium chloride was pipetted into the prewarmed TEG 
cup. The citrated native blood was gently inverted to ensure mixing of the sample. 
Then 340 mL citrated native blood (RT) was added to the prewarmed TEG cup. The 






































the rate of initial fibrin formation; the clotting time (K, min), representing the time 
until a fixed level of clot firmness is reached; the angle (α, degrees), which is closely 
related to K-time and represents the rate of clot growth; the maximum amplitude 
(MA, mm), is a measurement of maximum strength or stiffness of the developed clot; 
the shear elastic modulus strength (SEMS or G, dynes/cm2) is a parametric measure 
of clot firmness expressed in metric units calculated from MA as follows: 
 G = (5000 x MA) / (100 - MA). 
R time, K time and α are prolonged by anticoagulants and coagulation factor 
deficiencies, maximum amplitude is especially influenced by platelet count and 
platelet function as well as fibrinogen level. 
In addition to the former “classical” TEG parameters we made velocity calculations, 
describing thrombus generation during blood clotting, from the signature graph 
produced by TEG. These dynamic parameters are considered to give better insight 
into the initial part of the TEG trace by differentiating the entire initial time course (9). 
The following Thrombus generation parameters were recorded: Maximum Thrombus 
Generation (MTG), Time to Maximum rate of thrombus Generation (TMG) and Total 
Thrombus Generation (TTG). First, MTG (dynes/cm2/s), representing the velocity by 
which clot strength increases, beginning as SEMS starts to increase and ending after 
clot strength has been stabilized. The information from this parameter is equivalent 
to the information from the alpha angle, however MTG provides a more parametric 
evaluation than the determination of α. The second variable is TMG (s), which is the 
time it takes to reach MTG. Finally we determined TTG (dynes/cm2), which is the area 
under the velocity curve, representing the total change in elastic resistance until clot 
strength stabilization occurs. MTG and TTG are expressed using metric units of elastic 
resistance that accurately describe changes in clot strength. A characteristic velocity 
profile of whole blood clot formation is shown in Figure 1.
statistical analysis
For statistical analysis SPSS 14.0 software for Windows (SPSS Inc., Chicago, Illinois, 
USA) was used. Variables are expressed as mean ± SD. Mean values of the TEG 





































with different levels of thrombocytopenia. Significance levels were set at 0.05 (two-
tailed). The correlations of changes in platelet level and individual TEG variables were 
calculated using Spearman rank correlations. 
 



























Characteristic velocity profile of whole blood clot formation with maximum thrombus 
generation, which represents the velocity by which clot strength increases, beginning as 
SEMS starts to increase and ending after clot strength has been stabilized. TTG is the area 
under the velocity curve, representing the total change in elastic resistance until clot strength 
stabilization occurs. MTG, maximum thrombus generation; TTG, total thrombus generation.
ResUlTs
To obtain our own reference values, 120 controls, age 50 ± 18 years, range 20-80 
years, 10 women and 10 men per decade, were studied. In Table 1 the values of 
the TEG parameters for native blood and citrated native blood are presented. The 
study group consisted of 16 patients (seven women and nine men), median age 
45 years, range 18-62 years. Ten patients were treated for acute leukemia, five for 
multiple myeloma and one for Hodgkin’s lymphoma. In these patients a total of 189 
TEG analyses were performed. In 16 patients, 121 TEG analyses in native blood were 
performed (median 7, range 1-15). In 10 patients 68 TEG analyses in citrated native 
blood were performed (median 7, range 2-17). At study entrance each patient had 







































Table 1. TEG parameters in controls and in patients at different platelet counts, in Native (N) 
and Citrated Native (CN) whole blood.
Patients
Platelet count x109/l
TeG parameter Controls >100 100-50 50-25 <25
N (n=120) (n=46) (n=21) (n=13) (n=9)
CN (n=120) (n=36) (n=12) (n=10) (n=9)
R-time (min) N 22 ± 5 26 ± 13* 46 ± 32* 52 ± 27* 68 ± 25*
CN 11 ± 2 13 ± 6 10 ± 3 17 ± 12* 15 ± 3*
K-time (min) N 9 ± 1 9 ± 4 19 ± 11* 30 ± 13* 46 ± 11*
CN 3 ± 1 3 ± 2 3 ± 1 7 ± 3* 9 ± 3*
α (°) N 26 ± 8 30 ± 10 17 ± 9* 10 ± 6* 5 ± 1*
CN 56 ± 7 54 ± 12 51 ± 7* 34 ± 10* 28 ± 7*
MA (mm) N 46 ± 7 58 ± 9 54 ± 10 45 ± 10 30 ± 5*
CN 58 ± 6 61 ± 17 55 ± 10 49 ± 9* 37 ± 6*
SEMS (dyne/cm2) N 4506 ± 1392 7288 ± 3371 6323 ± 2471 4333 ±1654 2182 ± 489*
CN 7082 ± 1545 8504 ± 3103 6608 ± 2464 5046 ±1543* 3049 ± 727*
MTG N 4,1 ±1,3 3,2 ± 1,3* 2 ± 1,1* 1,6 ± 0,9* 1,4 ± 0,6*
(dynes/cm2/sec) CN 10,6 ± 2,8 6,6 ± 3,2* 5,6 ± 2,7* 2,6 ± 1,4* 2,8 ± 1,5*
TMG (sec) N 1747 ± 693 981 ± 809* 771 ± 242 1747 ± 1956* 1184 ± 653*
CN 764 ±147 2340 ± 1404* 3639 ± 2621* 4359 ± 2572* 5088 ± 4254*
TTG (dynes/cm2) N 769 ± 114 559 ± 117* 524 ± 83* 426 ± 167* 400 ± 63*
CN 959 ± 88 552 ± 91* 511 ± 83* 449 ± 85* 347 ± 44*
TMA (min) N 49 ± 10 56 ± 18* 99 ± 45* 117 ± 40* 140 ± 30*
CN 31 ± 4 34 ± 10 34 ± 5 51 ± 16* 55 ± 14*
R+K (min) N 30 ± 8 35 ± 13 66 ± 32* 82 ± 27* 107 ± 25*
CN 13 ± 3 16 ± 6 14 ± 4 24 ± 12* 24 ± 3*
*p<0.05 different between control and study group. R-time, reaction time; K-time, clotting 
time; α, alpha angle; MA, maximum amplitude; SEMS, shear elastic modulus strength; MTG, 
maximum thrombus generation; TMG, time to maximum thrombus generation; TTG, total 






































Thrombocytopenia strongly influenced the TEG performance. Of the 121 TEG 
analyses, 30 (25%) could not be evaluated because no fibrin formation was detected. 
This phenomenon was related to decreasing platelet counts. No coagulation at all 
could be detected in 18 out of 29 (62%) patients with platelet counts less than 25 
x 109/L, in five out of 18 (28%) patients with platelet counts between 25-50 x 109/L 
and in seven out of 74 (9%) patients with platelet counts more than 50 x 109/L. In 
all of these cases, however, classical coagulation tests showed normal plasmatic 
coagulation as measured by PT, aPTT, AT and fibrinogen (data not shown). 
Relation between platelet count and TeG parameters
Fibrin formation could be measured in 91 patient samples by TEG. Figures 2 and 3 
illustrate the effect of decreasing platelet count on TEG tracings, respectively velocity 
profiles, as measured in one patient. Identical TEG patterns were found in all other 
study patients with increasing thrombocytopenia. Table 1 shows the results of TEG 
parameters from controls and patients with decreasing platelet counts. Bar charts 
presenting TEG parameters found at different platelet counts are shown in Figure 
4 and 5. At a platelet count below 100 x 109/L, we found an increase in time to clot 
initiation (R-time and K-time were significantly prolonged) as well as a decrease in 
clot propagation (α-angle) compared to controls. Remarkably, only at platelet levels 
below 25 x 109/L, clot strength (maximum amplitude) became significantly inferior 
compared to the control group. Clot propagation (MTG) and total change in elastic 
resistance (TTG) declined significantly compared to controls even at platelet count 
more than 100 x 109/L (in this group one-third of the patients had a platelet count 
below 150 x 109/L). Statistically significant correlations were found between platelet 
count and respectively maximum amplitude (r = 0.7; p<0.0001), R-time (r = -0.5; 
p<0.0001) K-time (r = -0.7; p<0.0001), a-angle (r = 0.8; p<0.0001), MTG (r = 0.6; 
p<0.0001), TMG (r = -0.3; p<0.008) and TTG (r = 0.6; p<0.0001) (Figure 6a-g). In other 
words, both the time until clot initiation and propagation increased, and the ultimate 
clot strength and (change in) viscoelastic properties decreased significantly at lower 
platelet counts. In contrast, no significant correlations were found between platelet 
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Classical thrombelastography tracings in the same patient at decreasing platelet counts.
 



























Novel thrombelastography velocity profiles in the same patient at normal platelet counts (light 
grey area) and at low platelet count (dark grey panel). MTG, maximum thrombus generation; 
TTG, total thrombus generation.
Predictive value of TeG parameters regarding low platelet count 
As TEG maximum amplitude is considered the parameter most reflecting functional 
thrombocytopenia, we calculated the sensitivity of maximum amplitude in detecting 
clinically significant thrombocytopenia (< 50 x 109/L). We found a sensitivity of 79%, 
with a specificity of 93% and a positive and negative predictive value of respectively 
79% and 94% of TEG maximum amplitude in detecting important thrombocytopenia. 





































Table 2. Predictive value of TEG parameters regarding low platelet count (<50x109/L), in Native 
(N) and Citrated Native (CN) whole blood.
TeG parameter
Test characteristic







































































PPV = positive predictive value, NPV = negative predictive value.
R-time, reaction time; K-time, clotting time; A, alpha angle; MA, maximum amplitude; SEMS, 
shear elastic modulus strength; MTG, maximum thrombus generation; TMG, time to maximum 
thrombus generation; TTG, total thrombus generation.
Thrombelastography and bedside monitoring
TEG is considered a “near-patient” bedside test allowing rapid assessment of 
haemostasis. A fast way to obtain an early impression of the TEG curve is to look at 
the initial part of the TEG trace represented by time to maximum amplitude (TMA) 
and the sum of R- and K- time. The results of TMA and R+K time at different platelet 
counts, compared to controls are shown at the bottom of Table 1. This demonstrates 
that with platelet counts less than 100 x 109/L it took about 1 - 1.5 hours to get this 
“early” impression, whereas with platelet counts of less than 25 x 109/L it took 1.5 - 


























































Bar charts representing reaction time (R-time), clotting time (K-time) and α-angle in patients 








TMG, min. x 0.1
TTG, dynes/cm2 x 0.01
















Bar charts representing maximum thrombus generation, time to maximum thrombus 
generation and total thrombus generation in patients at different platelet counts in native 
whole blood. Parameters are presented as mean ± SD. MTG, maximum thrombus generation; 





































Recalcified citrated native whole (citrated native) blood.
All of the 68 analyses in citrated native blood could be evaluated because fibrin 
formation was detected (R-time, K-time or both were detectable).
Relation between platelet count and TeG parameters
Table 1 shows the effect of decreasing platelet count on TEG parameters. We found 
a correlation between platelet count and clot strength (maximum amplitude; r = 
0.75; p=<0.001). At platelet counts below 50 x 109/L, maximum amplitude became 
significantly smaller than the maximum amplitude in healthy controls. No significant 
correlation was found between platelet count and clot initiation (R-time; r = 0.2; 
p=0.07). Significant correlations were found between platelet count and respectively 
K-time (r = -0.3; p=0.03), a-angle (r =;0.6; p<0.0001), maximum amplitude (r = 0.7; 
p<0.0001), SEMS (r = 0.7; p<0.0001), MTG (r = 0.4; p=0.003), and TTG (r = 0.6; 
p<0.0001). In other words, in citrated native blood, platelet count influenced both 
(the velocity of) clot propagation as well as the ultimate strength and elasticity of the 
formed clot.
Predictive value of TeG parameters regarding low platelet count
With citrated native blood, the sensitivity of a maximum amplitude in detecting 
clinically significant thrombocytopenia (< 50 x 109/L) was 85%, with a specificity of 
the test of 82% and a positive and negative predictive value of respectively 65% and 
95%. The test characteristics for all TEG parameters are shown in Table 2.
Thromboelastography and bedside monitoring
The results of TMA and R+K time at different platelet counts, compared to controls, 
are shown at the bottom of Table 1. After storage for 1 hour (equilibration time), it 
took another 0.5-1 hour to obtain an early impression of the coagulation profile at 
































































































































































Correlation of platelet count and, respectively, clotting time (K-time), activated partial 
thromboplastin time, α-angle, maximum amplitude, maximum thrombus generation, total 
thrombus generation and time to maximum thrombus generation in patients in native whole 
blood. aPTT, activated partial thromboplastin time; MTG, maximum thrombus generation; 








































By studying the effect of different levels of thrombocytopenia on TEG parameters, 
we found that platelet count not only influenced the strength of clot formation 
(maximum amplitude) - an expected result - but also all other elements of the 
system. The finding of a correlation between platelet count (at levels < 100 x 109/L) 
and R- respectively K-time as well as α-angle and MTG, suggests an important role of 
platelets in initiating and propagating the coagulation cascade. A possible explanation 
for this observation is that platelets, but also platelet-derived micro particles, have 
a major role in providing membrane surface for the assembly of the reactants of the 
blood coagulation cascade (10). Moreover, platelets are a storage compartment for 
many proteins involved in blood coagulation and its regulation (11). 
Low platelet counts (< 50 x 109/L) are considered a major risk factor for bleeding 
complications (12). TEG maximum amplitude is considered as the parameter best 
reflecting the effect of platelet count. However, in our study a significant decrease 
in maximum amplitude was noticed only after the platelet count dropped below 
25 x 109/L. On the other hand, in native whole blood, both K-time and α-angle had a 
high sensitivity as well as high negative predictive values in detecting platelet counts 
below 50 x 109/L. This emphasizes again the importance of platelets in initiating the 
coagulation process. Also the novel thrombus generation parameters MTG and TTG 
were very sensitive and had high negative predictive values for low platelet counts, 
as measured in both native and citrated native whole blood. TEG is considered a 
bedside test, capable to deliver an impression of platelet count and function, 
coagulation proteins and fibrinolytic system within 30 minutes. We demonstrated 
that with decreasing platelet count both TMA and R+K time substantially prolong 
to more than 60 minutes, making rapid assessment of the coagulation process 
impossible. In order to circumvent this problem, perioperative TEG is performed with 
coagulation activator (e.g. kaolin, celite and diluted tissue factor). The coagulation 
activator makes blood clotting less dependent on platelets with R and K times more 
reproducible compared to R and K times obtained with non-activated samples. 





































we wanted to minimize, in order to eliminate artificial influences and to get more 
realistic data. The present study suggests an important role for platelets in the entire 
coagulation process; compressing the initial part of the TEG trace may result in the 
loss of information on the initial phase of this cascade.
Another advantage of TEG over classical coagulation tests is that the assay provides 
information on the kinetics of the coagulation cascade as well as the quality and 
firmness of the resultant clot. The latter is calculated from the maximum amplitude 
and is defined as SEMS (dyne/cm2). As with maximum amplitude, a significant 
reduction in SEMS was noticed compared to controls in native blood, only if the 
platelet count dropped below 25 x 109/L. In citrated native blood SEMS decreased 
earlier at platelet counts between 50 and 25 x 109/L.
TEG analysis was performed with both native and recalcified citrated native 
blood to determine which test technique gives best insight into the effects of 
thrombocytopenia on haemostasis. From a scientific point of view, TEG analysis 
with native blood is superior to TEG with citrated native blood and is for a long time 
considered the gold standard (13). However, in clinical practice TEG with citrated 
native blood seems more feasible because this can take place in the coagulation 
laboratory after one-hour equilibration time, compared to TEG with native blood, 
which has to take place within 6 minutes after sampling (14). The correlations found 
between TEG variables and platelet counts with both techniques are comparable. 
However, in case of severe thrombocytopenia (platelets <50 x 109/L), TEG performed 
with native blood showed a flat line in over more than 40% of the analyses, which 
makes it insensitive to detect these low platelet counts. Moreover, at these low 
platelet counts it often took more than two hours until TMA was reached, making the 
test with (nonactivated) native whole blood unsuitable as a rapid test of haemostasis. 
In contrast, TEG performed with citrated native blood at low platelet counts showed 
clot formation in all cases and TMA was reached within one hour in most of these 
cases. The latter suggests that citration could not completely prevent the activation 
of coagulation and platelets. This is in accordance with the findings of Camenzind 






































to 60 min citrate storage, with a decrease in reaction time, coagulation time and 
alpha angle (8). Others demonstrated that coagulation analyses using blood exposed 
to citrate followed by recalcification do not yield reliably depictions of the natural 
dynamics of blood coagulation processes (15).
Although TEG performances with different platelet counts were studied before 
(1,16,17), we consider our study unique at several points. First, multiple serial TEG 
measurements were performed in patients in whom only one component of the 
haemostatic system was altered, namely the platelet count. The latter is in contrast 
to studies in which the examined patients suffered from multiple haemostatic 
derangements, making analysis of the different underlying coagulopathies much more 
complex. Second, the fact that all measurements were performed ex vivo instead 
of using an in vitro model, makes our results more robust (18,19). More recently 
Larsen and co-workers, using ROTEM technology, found that the coagulopathy 
associated with thrombocytopenia in recalcified citrated blood, was characterized by 
a reduced MTG and maximum amplitude (20). Similar to our results they found that 
the minimum amount of platelets required to obtain a healthy MTG of whole blood 
clot formation was estimated to be 65 x 109/L. In their model, however, platelet 
preactivation cannot be excluded as they used a model of mixing platelet- poor 
plasma with platelet-rich plasma to obtain different levels of thrombocytopenia. 
Third, we compared TEG outcomes in study patients with our own normal values 
obtained from a large series of healthy controls from all age categories. In all these 
controls TEG was performed in a uniform way by the same examiners, thereby 
reducing interobserver bias.
A limitation of our study is that we cannot preclude any direct or late effect of 
chemotherapy on the coagulation system. Also the underlying hematological 
condition, although in remission, may have affected study results. On the other hand, 
no significant changes were seen in the classical coagulation tests during the entire 
study period in these subjects.
Analysis of haemostasis by TEG cannot replace conventional coagulation tests, but 
can be seen as a valuable tool, giving extra insight into the kinetics of haemostasis, 





































We conclude that platelet count not only affects the strength of clot formation, 
but also all other phases of plasmatic coagulation. Remarkably, TEG variable 
maximum amplitude was insensitive in detecting the haemostatic effects of severe 
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Transfused stored platelets have the 
same haemostatic function as circulating 
native platelets 
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baCKGRoUnD anD obJeCTIVes: As thrombelastography® (TEG) measures 
haemostasis in whole blood, we used this instrument to study whether transfused 
platelets (PLTs) have the same haemostatic function compared to native circulating 
platelets. Further we studied the effect of storage time on the haemostatic potential 
of platelet concentrates (PCs). 
maTeRIals anD meTHoDs: During the decrease in PLT count after chemotherapy, 
TEG parameters were measured serially until the transfusion trigger was reached in 
92 patients. TEG parameters for different ranges of native circulating PLT could be 
assessed, which were compared to ranges obtained in the thrombocytopenic period 
in which the patient received PLT transfusions. Finally we compared the haemostatic 
potential of fresh PCs (1-3 days) with PCs with longer storage time (4-5 days).
ResUlTs: No differences could be found in haemostatic potential between native 
PLTs and transfused stored PLTs (all p values ≥0.1). The transfusion of fresh PLTs 
demonstrated better haemostatic effects then longer stored PLTs, measured 1h after 
transfusion. Both the time until a fixed level of clot firmness was reached (K-time) as 
well as the rate of clot growth (alpha angle) were superior for fresh PCs. 
ConClUsIon: TEG is able to monitor the haemostatic effects of PLT transfusion, 
with comparable haemostatic properties of native circulating and transfused stored 
PLTs. Further, our data suggest that limited storage time is associated with a better 
haemostatic capacity. However, before TEG can be applied as a qualitative test in PLT 





































Platelet transfusion and TEG
InTRoDUCTIon
Low platelet (PLT) counts (<50 x 109/L) are considered a major risk factor for 
bleeding complications (1). PLT transfusion is used therapeutically in patients with 
quantitative or qualitative PLT disorders who are actively bleeding, or as prophylaxis 
in patients who are at serious risk of bleeding (2). The main use of PLT transfusion is 
in the prevention of bleeding in patients with hematological malignancies who have 
bone marrow failure (3). Optimally, transfused PLTs should have the same functional 
properties as native circulating PLTs. The therapeutic effect of transfused PLTs 
however, cannot be predicted with certainty as efficacy is influenced by variables like 
storage and recipient’s condition. The storage time of Platelet concentrates (PCs) is 
normally restricted to 5-7 days due to an increased risk of bacterial contamination. 
(4,5). Evaluation of the function of stored PLTs is only possible by the use of laborious 
and complicated in vitro tests and markers (6). Moreover, these in vitro tests do not 
provide information on the in vivo haemostatic potential of PLTs. In clinical practice PLT 
recovery is measured 1 and 24 hour after transfusion and corrected count increments 
(CCIs) are calculated in order to evaluate transfusion efficacy. In addition, the bleeding 
time used to be the most frequently used test of PLT function. However, the results 
of this test are considered poorly reproducible with poor sensitivity and specificity 
(7). Given the limitation of the bleeding time, several other tests in diagnosing and 
managing disorders of primary haemostasis and PLT function were developed (8). 
Thrombelastography® (TEG) is a whole blood test that gives information not only 
on plasma coagulation factors but also on the influence of PLTs, leukocytes and 
erythrocytes on haemostasis, defining it as a more physiological instrument to study 
haemostasis (9,10). The technique is classically used as a point-of-care test providing 
a global assessment of haemostasis in a graphic format. Different components of 
the test tracing are considered to reflect various parts of the haemostatic system 
and to distinguish low PLT count and/or PLT dysfunction from lack of plasmatic 
coagulation factors (11). The specificity of TEG was greater than that of bleeding time 
and PLT count in discriminating patients likely to benefit from transfusion of blood 
components during cardiac surgery (12). The Maximum Amplitude (MA), of the TEG 
curve, representing clot firmness, is seen as the parameter best reflecting the effect 





































We hypothesized that TEG might be a useful tool to improve the understanding and 
monitoring of the haemostatic quality and efficacy of PLT transfusion. The aim of the 
current study was to evaluate whether transfused PLTs have the same haemostatic 
function compared to native circulating PLTs, as measured by TEG. Moreover, we 
studied the effects of storage time on the haemostatic potential of PLTs. 
maTeRIals anD meTHoDs
study patients
The institutional review board approved the study and informed consent was 
obtained from all patients. Patients were treated for hematological malignancies 
and admitted for their second or third course of chemotherapy. For all patients the 
underlying disease was in complete remission after the preceding chemotherapy, 
precluding any effect of the underlying disease on the coagulation process. Also 
the bone marrow function had to be restored to normal with concomitant normal 
peripheral blood counts. For study patients the following exclusion criteria were 
used: coagulation disorders, use of anticoagulants, use of acetylsalicylic acid within 
the preceding 10 days, use of non steroidal anti-inflammatory drugs within the last 
24 hours, renal diseases or plasma concentration of creatinine more than 120 μmol/L 
and liver disease or increased plasma concentration of aspartate aminotransferase 
(ASAT) (>50 U/L) or alanine aminotransferase (ALAT) (>50 U/L). Study patients who 
became febrile or demonstrated signs of soluble immune response suppressor 
or even sepsis, according to the ACCP criteria, were excluded from the study. 
Moreover, included patients had to have normal values for antithrombin (AT) and 
fibrinogen, making low grade disseminated intravascular coagulation (DIC, defined 
as systemic activation of pathways leading to and regulating coagulation, which 
result in the generation of fibrin clots that may cause organ failure with concomitant 
consumption of platelets and coagulation factors that may result in clinical bleeding) 
or consumptive coagulopathy very unlikely. Finally, patients who developed 
thrombosis, as demonstrated by ultrasonography, were also excluded from the 
study. In order to obtain our own normal (reference) values, we performed TEG and 





































decade, age distributed equally between 19 and 87 years, mean age 50 ± 17 years. 
We used exactly the same exclusion criteria as used for our study population.
study protocol
During the subsequent decrease in PLT count after chemotherapy, TEG parameters 
were measured serially until the transfusion trigger was reached (PLT count <10 x 
109/L). Consequently, TEG parameters for different ranges of native circulating PLTs 
could be assed. We compared TEG parameters obtained before the start of the first 
PLT transfusion with those obtained in the thrombocytopenic period in which the 
patient was transfused with PCs (Figure 1). We assumed that in this aplastic period 
only transfused PLTs were circulating. Further we studied the effects on haemostasis 
comparing PCs with limited storage time (storage time 1-3 days) with PCs with longer 
storage time (4-5 days).
figure 1.
Graphical presentation of study protocol
blood sampling and assays
Blood samples were obtained simultaneously for TEG analysis and standard laboratory 
and coagulation tests [i.e. complete blood count, white blood cell differentiation, 
creatinine, ASAT, ALAT, prothrombin time (PT), activated partial thromboplastin time 
(aPTT), fibrinogen and antithrombin (AT)]. Venous blood samples were drawn from 
an indwelling central venous catheter (patients) or collected by vein puncture at the 
antecubital fossa using a 21-gauge butterfly needle. Two examiners obtained all blood 
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samples, both experienced in performing phlebotomy. Blood was collected into a 20-
mL polypropylene syringe to prevent contact activation by glass. To minimize the 
effects of using a tourniquet and to exclude effects of heparin in the central venous 
catheter, the first aspirate of 10 mL blood was discarded. All standard coagulation 
tests were performed on the STA-R coagulation analyzer (Roche, Basel, Switzerland); 
PT with Thromborel S reagents and aPTT with Actin FS reagents (Dade Behring, 
Marburg GmbH, Marburg, Germany), fibrinogen with excess thrombin (BioPool US 
inc, Ventura, CA, USA) according to the Clauss method and AT with thrombin as 
enzyme (STAchrome ATIII, Roche kit). Normal values for these parameters are PT 11-
16 s, aPTT 26-36 s, fibrinogen 1.7-3.5 g/L and AT 75-125%.
Thrombelastographic assays were carried out using a computerized TEG coagulation 
analyzer (Model 5000; Haemoscope Corp., Niles, IL, USA). All analyses were performed 
with TEG disposable cups and pins as devised by the manufacturer. Polypropylene 
and polyethylene pipettes were used to handle reagents and blood. 
TEG measurements (and standard blood laboratory evaluation) took place at study 
entrance, before starting chemotherapy, and 3 times a week afterwards until the 
PLT count dropped below 100 x 109/L. From that point on, TEG analyses and blood 
tests were performed daily until a patient needed a PLT transfusion (trigger was a PLT 
count <10 x 109/L). 
For TEG analysis 360 mL whole blood was pipetted into the prewarmed TEG cup and 
measurements were performed within 6 minutes from sampling (16). No activators 
of coagulation were added to the samples. The following TEG parameters were 
recorded (between parenthesis normal values expressed as mean ± SD obtained in 
our laboratory in 120 normal persons): the reaction time (R, 22 ± 5 min), representing 
the rate of initial fibrin formation; the clotting time (K, 9 ± 3 min), representing the 
time until a fixed level of clot firmness is reached; the angle (α, 26 ± 8 degrees), 
representing clot growth and correlated to thrombin generation which results into 
interaction between platelets and fibrin; the maximum amplitude (MA, 46 ± 7 mm), 





































shear elastic modulus strength (SEMS or G, 4506 ± 1392 dynes/cm2) is a parametric 
measure of clot firmness expressed in metric units calculated from MA as follows: 
 G = (5000 x MA) / (100 - MA). 
R-time, K-time and α are prolonged by anticoagulants and coagulation factor 
deficiencies, MA is especially influenced by PLT count and PLT function as well as 
fibrinogen level. 
Platelet transfusion
PCs were prepared from five buffy coats and one unit of plasma as described 
elsewhere (17). The platelet pooling system used was Optipure PLT Baxter (Utrecht, 
The Netherlands). At the time of issue of the PCs, the swirling effect had to be present 
and the bacterial screening test (BacT/Alert; Biomerieux, Marcy L’Etoile, France) had 
to be negative. Patients received PCs that had been stored between 1 and 5 days 
after blood collection according to standard Dutch guidelines (18). The corrected 
count increment (CCI) was calculated by subtracting the pre transfusion PLT (x 109/L) 
from the post transfusion PLT count (x 109/L), dividing this by the number of PLTs 
transfused (x 1011) and multiplying this with body surface of the patient (m2).
statistical analysis
For statistical analysis SPSS 17.0 software for Windows was used. Variables are 
expressed as mean ± SD. Mean values for TEG parameters before and after transfusion 
with PCs were tested by a paired t-test. Comparisons between mean TEG values of 
native circulating PLTs with transfused allogeneic PLTs and between mean TEG values 
of “fresh” and “old” PCs, were made using an unpaired t-test. Significance levels were 
set at 0.05 (two-tailed). 
ResUlTs
effect of PlT transfusion on haemostasis
In 92 patients (mean age 46 ± 15 yr, 42 women, 50 men) we studied the effect of PLT 
transfusion on haemostasis, as measured by both TEG and classical coagulation tests 
(Table 1). Overall we observed a good PLT recovery, as calculated by a 1 h CCI of 18 ± 
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7 and a 24 h CCI of 12 ± 8. No significant effects on classical coagulation tests could 
be observed after PLT transfusion. 
Table 1. Classical coagulation tests and TEG parameters, measured before PLT transfusion,









Platelet 11 ± 5 <0.001 37 ± 13 <0.001 27 ± 14
CCI - - 18 ± 7 - 12 ± 8
PT 14.4 ± 4.6 ns 14.2 ± 2.8 ns 14.2 ± 2.9
aPTT 30.3 ± 7.3 ns 29.6 ± 5.4 ns 30.2 ± 6.0
AT 95 ± 16 ns 95 ± 15 ns 97 ± 14
Fibr. 5.5 ± 1.9 ns 5.4 ± 1.8 ns 5.7 ± 1.9
R 156 ± 131 (n=51) <0.001 73 ± 60 (n=76) ns 103 ± 86 (n=51)
K 43 ± 17 (n=13) 0.04 32 ± 20 (n=63) 0.03 39 ± 22 (n=36)
Alpha 2.2 ± 2.8 (n=51) <0.001 10.0 ± 9.2 (n=75) 0.020 7.3 ± 8.9 (n=51)
MA 14 ± 17 (n=51) <0.001 41 ± 18 (n=75) 0.003 30 ± 19 (n=51)
G
2370 ± 11113 
(n=51)
ns
4198 ± 2539 
(n=75)
ns
2804 ± 2524 
(n=51)
Values are expressed as means ± SD.
P, significance (set at <0.05); ns, not significant; TEG, thrombelastograpy; Platelet, thrombocytes 
(x109/l); CCI, Corrected Count Increment; PT, prothrombin time (sec.); aPTT, activated partial 
thromboplastin time (sec.); AT, Antithrombin (%); Fibr., Fibrinogen (g/l); R, reaction time (min); 
K, clotting time (min); alpha, alpha angle (°); MA, maximum amplitude (mm); G, shear elastic 
modulus (dyne·cm-2).
By TEG however, we observed a significant acceleration in the initiation phase of the 
plasmatic coagulation (decrease in R- & K-time) with also a higher rate of fibrin built 
up (higher alpha angle), and ultimately a clot with superior strength (higher MA), 
measured 1h after PLT transfusion. These pro-haemostatic effects could be measured 
until 24 hour after PLT transfusion, with only a trend in improvement for Reaction 
time. Further, we observed that it might take some time for stored PLTs to regain 
optimal function in circulation. In 21% of the transfusions Alpha, MA and G were 





































this was not influenced by the storage time of the concentrates. Alpha 16 ± 15 versus 
7 ± 6 degrees (p=0.01) versus 3 ± 2 before transfusion, MA 47 ± 17 versus 27 ± 22 
mm (p=0.003) versus 17 ± 11 before transfusion and G 5251 ± 3105 versus 2519 ± 
2376 dyne/cm2 (p=0.005) versus 1090 ± 760 before transfusion; whereas platelet 
count decreased from 40 ± 12 x 109/L 1 hour after transfusion to 29 ± 14 x 109/L 24 
hours after transfusion (p=0.0005). Noticeably, in 41 out of 92 study patients with 
severe thrombocytopenia, the initial TEG curve (before transfusion) showed a flat 
line, meaning that no initiation of coagulation could be measured at all. 
Comparison of the haemostatic potential of native- and transfused-PlTs
The comparison of coagulation tests (classical and TEG) as measured in patients 
with different degrees of thrombocytopenia without any PLT transfusion (with 
only circulating patient’s own, native PLTs) and during PLT transfusions (with most 
of the circulating PLTs being allogeneic), is shown in Table 2. With the exception of 
fibrinogen level, no statistically significant differences could be found in haemostatic 
potential between native PLTs and transfused blood bank stored PLTs (all p-values 
≥0.1). Although clot initiation (R and K) and clot strength (MA) were similar for native- 
and transfused PLTs, there is a non-significant trend towards higher clot strength 
(MA) after PLT transfusion, compared to the effect on MA caused by native PLTs. 
The p-values for the difference in MA between both groups for the various platelet 
ranges are; PLT<25 x 109/L: p=0.4; PLT 25-50 x 109/L: p=0.12 and PLT 50-100 x 109/L: 
p=0.07.
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Table 2. Classical coagulation tests and TEG parameters before and during PLT transfusions, for 
different ranges of PLTs.
PlT count <25 x109/l 25-50 x109/l 50-100 x109/l
Transfusion before during before during before during
N 10 15 16 51 8 21
PT 14 ± 2 14 ± 1 13 ± 1 14 ± 3 14 ± 1 12 ± 1
aPTT 30 ± 3 31 ± 3 30 ± 5 29 ± 5 27 ± 3 27 ± 3
AT 78 ± 29 94 ± 14 95 ± 20 96 ± 14 97 ± 11 100 ± 11
Fibr. 4 ± 2 5 ± 2 4 ± 1* 6 ± 2 6 ± 3* 4 ± 1
R 89 ± 48 90 ± 36 67 ± 40 63 ± 34 62 ± 67 46 ± 32
K 42 ± 8 55 ± 24 30 ± 13 30 ± 16 21 ± 13 19 ± 11
Alpha 4 ± 2 4 ± 4 8 ± 6 10 ± 8 16 ± 12 17 ± 9
MA 21 ± 14 26 ± 14 38 ± 17 45 ± 15 44 ± 19 54 ± 10
Values are expressed as means ± SD.
 * p, significance (set at <0.05); PLT, platelet; TEG, thrombelastography; N, number included; PT, 
prothrombin time (sec.); aPTT, activated partial thromboplastin time (sec.); AT, Antithrombin 
(%); fibr., Fibrinogen (g/l); R, reaction time (min); K, clotting time (min); alpha, alpha angle (°); 
MA, maximum amplitude (mm).
effect of storage time of PCs on haemostatic potential of PlTs
A comparison between the haemostatic effects of PCs with limited storage time to 
PCs with longer storage time on both classical coagulation tests and TEG parameters, 
measured before PLT transfusion, 1 hour after PLT transfusion and 24 hours after PLT 
transfusion, is shown in Table 3. Also in this table, native values for identical ranges 
of thrombocytopenia are presented between parenthesis. The transfusion of PLTs 
stored for 1-3 days (n=35, age 45±17 yr, 16 women, 19 men) demonstrated better 
pro-haemostatic effects then PLTs stored for 4-5 days (n=35, age 47±14 yr, 17 women, 
18 men), measured 1 hour after transfusion. Both the time until a fixed level of clot 
firmness was reached (K-time; p=0.03) as well as the rate of clot growth (alpha angle; 
p=0.02) were superior for PCs with limited storage time (Figure 2). Although not 
significant, the same trend was observed 24 hour after transfusion, when the effects 
of fresh PLTs (n=23, age 45 ± 17 yr, 9 females, 14 males) were compared to the effects 
of older PLTs (n=21, age 47 ± 14 yr, 8 females, 13 males).
Importantly, although storage time might influence the haemostatic competence of 
PLT, both fresh and stored PLT demonstrated adequate haemostatic activity when 





































Table 3. Effect of fresh (vs. native) compared to stored (vs. native) platelets on classical 
coagulation tests and TEG parameters, measured 1 hour after PLT transfusion and 24 hours 
after PLT transfusion.
effect after 1 hour effect after 24 hour










CCI 19 ± 7 17 ± 6 12 ± 8 11 ± 6
PT 14 ± 1 (13 ± 1) 14 ± 1 (13 ± 1) 14 ± 1 (14 ± 1) 14 ± 1 (13 ± 1)
aPTT 28 ± 3 (31 ± 9) 29 ± 4 (32 ± 15) 28 ± 3 (33 ± 13) 29 ± 4 (31 ± 9)
AT 95 ± 13 (94 ± 20) 96 ± 14 (90 ± 21) 99 ± 13 (91 ± 33) 97 ± 15 (93 ± 20)
Fibr. 5 ± 2 (4 ± 1) 5 ± 2 (4 ± 1) 5 ± 2 (4 ± 1) 5 ± 1 (4 ± 1)
R 62 ± 42 (64 ± 36) 73 ± 40 (70 ± 35) 78 ± 49 (72 ± 35) 83 ± 55 (68 ± 36)
K 27 ± 16* (28 ± 13) 37 ± 22 (34 ± 13) 34 ± 21 (36 ± 14) 40 ± 24 (36 ± 15)
Alpha 13 ± 10* (10 ± 8) 8 ± 8 (7 ± 6) 9 ± 10 (6 ± 5) 8 ± 11(6 ± 5)
MA 46 ± 14 (39 ± 18) 40 ± 18 (33 ± 17) 35 ± 19 (28 ± 18) 31 ± 17 (28 ± 18)
G
4862 ± 2239 
(3800 ± 2383) 
4017 ± 2566





Fresh =storage time of 1-3 days, Stored = storage time of 4-5 days. Native = autologous PLTs
Values are expressed as means ± SD.
* p < 0.05 for fresh vs stored PLT, by unpaired t-test; TEG, thrombelastography; PLT, platelets 
(x109/l); CCI, corrected count increment; PT, prothrombin time (sec); aPTT, activated partial 
thromboplastin time (sec) AT, antithrombin (%); fibr., fibrinogen (g/l); R, reaction time (min); 



































Effect storage time of platelet concentrates on clotting time and alpha angle, 1 hour after 
transfusion, expressed as percentage (Mean ± SEM) from pretransfusion level.
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In this study, we did not observe differences in haemostatic function between 
transfused (allogeneic) blood bank-stored PLTs and patient’s own circulating native 
PLTs as measured by TEG. Moreover, we observed by TEG that transfusion of PCs 
with limited storage time (1-3 days) had superior haemostatic potential compared to 
transfusion of PCs with longer storage time (4-5 days). 
The purpose of PLT transfusion is to supply a sufficient number of donor PLTs with 
haemostatic properties similar to those of the patient’s own PLTs. Further, donor PLTs 
are supposed to remain their haemostatic capacity in the circulation for a substantial 
period of time, without clinical significant effects of prior storage time. The therapeutic 
effect of transfused PLTs cannot be predicted with certainty as storage, age and the 
recipient’s condition alter the efficacy of PLT transfusion. In clinical practice the 
corrected count increment is used to quantify transfusion efficacy. Very few tests of 
PLT function performed on PCs in vitro correlate with PLT viability after transfusion 
and none has been adequately validated after transfusion (19). Classically, quality 
control analyses of PCs focus on PLT metabolism and energy state (20). In recent 
years, the testing of PLT function has shifted to the assessment of signaling processes 
and activation properties relevant to haemostasis. Although newer technologies like 
the use of flow chamber systems, thrombin generation assays and proteomics are 
promising, these techniques are time consuming to carry out and require specialized 
technical expertise (21-23). Thrombocytopenia primarily affects clot firmness (MA), 
but also the initiation phase of plasmatic coagulation (R- & K-time) as well as the 
speed of thrombin formation and fibrin built up (alpha angle), as monitored by TEG 
(13,15,24). In agreement with these studies, we observed a significant improvement 
of the initiation phase of plasmatic coagulation (decrease in R-&K-time) with also 
a higher rate of fibrin built up (higher alpha angle) and ultimately an improved in 
clot strength (higher MA) after PLT transfusion. These pro-haemostatic effects could 
be measured until 24 hour after PLT transfusion. Apart from the absolute PLT count 
and the derived corrected count increment, none of the other classical coagulation 
tests performed could detect any pro-haemostatic effect of the transfused PLTs. 





































study patients with severe thrombocytopenia. The latter is in accordance to the 
findings of Johansson et al, who observed diminished or absence of clot formation 
in thrombocytopenic patients (PLT counts 10-20 x 109/L) who were 7 days post-stem 
cell transplantation (25). Although study populations are comparable, in the study 
of Johansson et al activated, recalcified citrated whole blood samples were used. 
However, despite the activation by tissue factor, clot formation was observed in only 
three out of 11 patients. This is in accordance to the concept that (functional) PLTs 
are essential to initiate and support thrombin generation. In clinical practice, where 
TEG is classically used as a rapid point of care test, activators of coagulation are often 
added to the TEG sample, which results into shortening of the initial part of the TEG 
line, making rapid interpretation of the coagulation process possible. However, as 
we demonstrated, this same activation may be at the cost of (subtle) information 
that can be obtained from the initial part of the TEG line (26). In this study on the 
haemostatic function of PLTs, we used TEG not because of its rapidity, but because we 
consider it an unique research tool as it offers an overview of the cumulative effects 
of all the individual components of haemostasis, providing information about the 
quality of the clot as well as the dynamics of its formation. By using this technique, 
we were able to demonstrate in a novel and unique way, comparable haemostatic 
function of circulating native PLTs and transfused, allogeneic PLTs. Further, by using 
TEG we were able to detect differences in haemostatic capacity between fresh and 
stored PCs in favor of fresh PCs. Noticeably this inferior haemostatic capacity for 
stored PCs was only significant for parameters related to the initiation phase of the 
coagulation process. Results from other studies on transfusion of fresh versus stored 
PCs showed that storage resulted in impairment of PLT viability in vivo, demonstrated 
by decreased PLT recovery and survival (27) and also in decreased PLT activation 
sensitivity (28). Moreover, in our study the observed haemostatic differences were no 
longer statistical significant 24 hours after the transfusion. The latter is in accordance 
to the findings of Owens and colleagues who found that stored PLTs may regain 
function in vivo, requiring at least 24 hours (29), as was also demonstrated in some 
of our study patients. The in vivo restoration of PLT function seems only beneficial in 
situations where PCs are prescribed for prophylaxis. In thrombocytopenic patients 
who show signs of active bleeding PCs with limited storage time might be more 
effective.
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There were a number of limitations to this study. First, our study population was not 
healthy as patients in study group I had been treated for hematological malignancy 
with chemotherapy. As we did not include patients with active disease treated for 
with “induction” courses of chemotherapy, we tried to exclude any effect of the 
earlier disease on the coagulation process. Although we cannot exclude any (subtle) 
confounding effect of the (response on) treatment on study outcome, we assume 
that, due to our strict inclusion criteria, our study results and conclusions may be 
applicable to “normal” patients with thrombocytopenia who receive PLT transfusions. 
A second limitation is that whole blood samples without activators were used for TEG 
measurements as we wanted to use TEG as a research tool on (unmanipulated) whole 
blood as stated in our discussion section. However, the usage of activators resembles 
normal physiology as it is the TF pathway that provides the major stimulus for clot 
formation in vivo. Moreover, clinical evidence for clinical utility of TEG is mainly 
based on investigations using activators. As a consequence, the study observations 
may not apply to other methods of TEG measurement. Finally, as we measured only 
parameters of coagulation, but not the (clinical) effects of platelet transfusion on 
bleeding episodes (between study groups), we can only speculate on the clinical 
relevance of our findings. 
In summary, we demonstrated that TEG was able to monitor the haemostatic effects 
of PLT transfusion with comparable haemostatic properties of transfused stored PLTs 
compared to native circulating PLTs. Further, our data suggest that limited storage 
time of PLTs is associated with better haemostatic capacity. However, before TEG can 
be applied as a clinically relevant qualitative test in PLT transfusion, further research 
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effects of Red blood Cells on Haemostasis
Wilfried W.H. Roeloffzen, Hanneke C. Kluin-Nelemans,








































baCKGRoUnD: Currently there is no sensitive laboratory test to establish the 
influence of red blood cells (RBCs) on haemostasis. As thrombelastography® (TEG) 
measures haemostasis in whole blood, taking into account the interactions of 
all cellular elements, we used this instrument to investigate the role RBCs play in 
haemostasis.
sTUDy DesIGn anD meTHoDs: In 29 patients with chemotherapy-induced anaemia 
we studied the effect of progressive anaemia on the coagulation profile. In 24 patients 
with chronic anaemia we studied the effect of transfusion of RBCs on coagulation. 
Finally, in 18 patients we evaluated whether storage time of RBCs has additional 
effects on haemostasis. 
ResUlTs: We observed a significant negative correlation between hemoglobin 
and TEG variables related to both cloth strength and elasticity (p<0.05). Moreover, 
anaemia was associated with a delay in the initiation of the coagulation cascade. 
Correction of anaemia by RBC transfusion resulted in significant shortening of this 
initiation phase with now the opposite effect on clot strength and elasticity. The 
negative effects on clot quality were significantly worse when fresh RBCs were 
transfused compared to longer stored RBCs. Furthermore, in contrast to the longer 
stored RBCs, fresh RBCs did not enhance initial fibrin formation. 
ConClUsIon: In this study we found that anaemia was associated with a delay in the 
initiation of the coagulation cascade with a finally formed clot with superior strength 
and viscoelastic properties. Transfusion of RBCs was associated with impaired clot 





































Effects of Red Blood Cells on Haemostasis
InTRoDUCTIon 
The role of platelets (PLTs) in haemostasis has been well established. This is in contrast 
to the possible role of red blood cells (RBCs) in haemostasis. Erythrocytes are involved 
in haemostasis as they flow in the center of the vessel pushing PLTs towards the site 
of action at the vessel wall and enhance shear forces, which activate PLTs. There is 
increasing evidence that RBCs not only have passive (rheological) effects on blood 
coagulation, but also actively stimulate both thrombin generation and PLT function in 
vitro (1-3) In addition, erythrocytosis is considered a risk factor for the development 
of thrombosis (4). The transfusion of RBC concentrates in anemic patients has been 
associated with a reduction in bleeding time (5,6). Further, a significant decrease in 
the activated partial thromboplastin time (aPTT) after RBC transfusions in patients 
with anaemia has been described (7). 
Whether transfusion of RBCs with differences in storage time has similar effects on 
haemostasis is yet unclear. It is known that storage and blood banking procedures 
of RBCs have negative effects on viability and flow characteristics of the transfused 
erythrocytes (8). Berezina and associates reported that blood clotting progressively 
decreases after 2 weeks of storage, probably due to the exhaustion of some 
procoagulant plasma factor (9). 
Currently there is no sensitive laboratory test to establish the potential impact of RBCs 
on haemostasis. To determine the relative contribution of the different components 
of haemostasis, conventional coagulation tests like bleeding time (BT), prothrombin 
time (PT), aPTT, fibrinogen concentration, and PLT count are measured. The limitation 
of these classical tests is that only information on the plasma coagulation factor levels 
is provided, but not on the potential physiological role of other cellular elements like 
RBCs.
Thrombelastography® (TEG) is a technology which can asses whole blood coagulation 
and offers a rapid overview of the cumulative effect of all the individual components 





































TEG provides information about the quality of the clot as well as the dynamics of its 
formation and its lysis. The different parts of the TEG tracing correspond to specific 
deficiencies in coagulation factors or inhibitors of coagulation, use of anticoagulants, 
PLT count as well as PLT function and fibrinogen level (10-12). TEG is classically 
used in situations where point-of-care testing of haemostasis is desired such as 
the perioperative setting. In trauma patients with penetrating injury as well as in 
patients after cardiac surgery, a reduction in TEG variable maximum amplitude (MA 
[clot strength]) has been more indicative of bleeding and transfusion requirements 
than “classical” tests of coagulation (13,14). Moreover, modifications of TEG allows 
the measurement of thrombin generation at different time points during the clot 
formation which is a clinical relevant approach to assess the global integrity of the 
thrombin complex (15,16). 
As TEG measures haemostasis in whole blood, taking into account the interactions 
of all cellular elements, we decided to study the role of RBCs on haemostasis as 
measured by TEG in patients with different degrees of anaemia. In addition, we 
studied the effect of transfusion and of storage time of RBCs on haemostasis.
maTeRIals anD meTHoDs
study patients
The institutional review board approved the study and informed consent was obtained 
from all patients and control persons. A total of 71 patients, divided over three groups 
were included in the study. In Group 1 we studied the effect of progressive anaemia on 
the coagulation profile. A total of 29 measurements were performed in 12 patients. 
All included patients were treated for hematological malignancies and admitted for 
their second or third course of chemotherapy. For all patients the underlying disease 
was in complete remission after the preceding chemotherapy, eliminating any effect 
of the disease on the coagulation process. Moreover, the bone marrow function had 
to be restored to normal levels with concomitant normal peripheral white blood cell 





































Patients included in Study Groups 2 and 3 suffered from chronic anaemia and needed 
RBC transfusion on a regular basis. The transfusion trigger was set at a Hb level 
of 7 to 8 g/L and patients were transfused with 2 to 3 units of RBC. We decided 
to study patients who were transfused with 3 units of RBC because we expected 
that the effect of RBC transfusion on haemostasis would be best measurable in 
this group. All transfusions were administered consecutively in a time interval of 6 
hours. Group 2 consisted of 24 patients with chronic anaemia in whom we studied 
the effect of transfusion of three stored units of RBCs on coagulation. Finally, in 
Group 3 (18 patients), we evaluated whether storage time of RBCs has additional 
effects on haemostasis. All included patients in Group 3 were transfused with units 
of RBCs with a storage time of two days. In both Group 2 and Group 3, TEG and 
classical coagulation tests were performed before, 1 hour after, and 24 hours after 
the transfusion of 3 RBC units. 
For all patients the following exclusion criteria were used: coagulation disorders, 
use of anticoagulants, use of acetylsalicylic acid within the past 10 days, use of non 
steroidal anti-inflammatory drugs within the last 24 hours, renal diseases or plasma 
concentration of creatinine more than 120 μmol/L and liver disease or increased 
plasma concentration of aspartate aminotransferase (ASAT; >50 U/L) or alanine 
aminotransferase (ALAT; >50 U/L). Patients with septicemia, diffuse intravascular 
coagulation, or thrombosis during the study period were also excluded. 
blood sampling and assays
Blood samples were obtained simultaneously for TEG analysis and standard 
laboratory and coagulation tests (i.e. complete blood count, WBC differentiation, 
creatinine, ASAT, ALAT, PT, aPTT, fibrinogen concentration and antithrombin [AT]). 
Venous blood samples were collected by vein puncture at the antecubital fossa using 
a 21-gauge butterfly needle. One single experienced examiner obtained all blood 
samples. To minimize the effects of venous endothelial damage by using a tourniquet, 
the first aspirate of 10 mL of blood was discarded. Blood was collected into a 20-
mL polypropylene syringe to prevent contact activation of clotting by glass. Some 
of the collected blood, 3.5 mL, was filled into a tube (Vacutainer, Greiner Bio-One, 





































Kremsmünster, Austria), containing 0.5 mL of 3.2% Sodium Citrate for subsequent 
standard coagulation tests. All standard coagulation tests were performed on a 
coagulation analyzer (STA-R, Roche, Woerden, the Netherlands); PT and aPTT with 
reagents (Thromborel S and Actin FS, respectively, Dade Behring, Deerfield, IL), 
fibrinogen with excess thrombin (BioPool, Ventura, CA) according to the Clauss 
method and AT with thrombin as enzyme (STAchrome ATIII kit, Roche). Normal values 
for these variables in our laboratory are PT 11 to 16 sec, aPTT 26 to 36 sec, fibrinogen 
1.7 to 3.5 g/L, and AT 75% to 125%.
TEG assays were carried out using a computerized TEG coagulation analyzer (Model 
5000; Haemoscope Corp., Niles, IL). All analyses were performed with TEG disposable 
cups and pins as devised by the manufacturer. Polypropylene and polyethylene 
pipettes were used to handle reagents and blood. TEG analyses were performed in 
native whole blood, without activator. Adding activators to the TEG sample results 
into shortening of the initial part of the TEG line, making rapid interpretation of 
the coagulation process possible. However, this same activation may be at the 
cost of (subtle) information from this initial part of the TEG line (17). To maximize 
the information that can be obtained by TEG, we used nonactivated whole blood. 
For TEG analysis in native whole blood, 360 mL of whole blood was pipetted into 
the prewarmed TEG cup and measurements were performed within 6 minutes of 
sampling (18). The following TEG variables were recorded (in parenthesis normal 
values expressed as mean ± SD obtained in our laboratory in 120 normal persons): 
the reaction time (R-time, 22 ± 5 min), representing the rate of initial fibrin formation; 
the clotting time (K-time, 9 ± 3 min), representing the time until a fixed level of clot 
firmness is reached; the angle (α, 26 ± 8 degrees), which is closely related to K-time 
and represents the rate of clot growth; the maximum amplitude (MA, 46 ± 7 mm), 
is a measurement of maximum strength or stiffness of the developed clot; the shear 
elastic modulus strength (SEMS or G, 4506 ± 1392 dyne cm-2) is a parametric measure 
of clot firmness expressed in metric units calculated from MA as follows: 
 G = (5000 x MA) / (100 - MA). 
R-time, K-time and α are prolonged by anticoagulants and factor deficiencies; MA is 





































In addition to the former “classical” TEG variables we made velocity calculations 
describing thrombus generation during blood clotting that are derived from the 
signature graph produced by TEG. The following Thrombus generation (TG) parameters 
were recorded: the Maximum Thrombus Generation (MTG, 4.1 ± 1.3 dynes/cm2/
sec); this variable presents the first derivate of the velocity of the increase in clot 
strength, beginning as G begins to increase and ending after clot strength stabilizes. 
The information from this variable is equivalent to the information from the α angle, 
however MTG provides a more parametric evaluation than the determination of α. 
The second variable is Time to Maximum rate of thrombus Generation (TMG, 1747 
± 693 sec), which is the time it takes to reach MTG. Finally we determined Total 
Thrombus Generation (TTG, 769 ± 114 dynes/cm2), which is the total positive area 
under the velocity curve, representing the total change in elastic resistance until clot 
strength stabilization occurs. MTG and TTG are expressed using metric units of elastic 
resistance that accurately describe changes in clot strength. 
Statistical analysis
For statistical analysis SPSS computer software (SPSS 16.0 software for Windows, 
SPSS, Inc., Chicago, IL) was used. Variables are expressed as mean ± SD. The 
correlations of changes in Hemoglobin (Hb) level and individual TEG variables were 
calculated using Pearson’s correlations. Mean values of TEG and classical coagulation 
variables were tested by an unpaired t test comparing patients with Hb levels of less 
than 10 g/dL with patients with Hb levels of more than 10 g/dL. To study the effects 
on coagulation variables 1 and 24 hours after blood transfusion, a paired samples t 
test was used. Significance levels were set at 0.05 (two-tailed). 
ResUlTs
effect of anaemia on coagulation
In group 1 we studied the relationship between Hb level and coagulation variables. 
Patient demographics are summarized in Table 1. In this study group a total of 
29 measurements were performed in 12 patients, of which four were treated for 
multiple myeloma, seven for acute leukemia and one for Hodgkin’s lymphoma. Due 





































to more intensive induction chemotherapy in patients with acute leukemia these 
patients entered this part of the study with a lower Hb level. To compare the effects 
of higher Hb levels with lower Hb levels we chose the cutoff Hb of 10 g/dL to obtain 
groups of equal size. Due to the lower age of acute leukemia patients compared to 
patients with multiple myeloma and to the lower Hb level with which acute leukemia 
patients entered this part of the study the age of patients in the group with Hb levels 
of less than 10 g/dL in Table 1 is considerable lower compared to the age in the 
groep with Hb levels of more than 10 g/dL. We found that Hb level was significantly 
negatively correlated with the classical coagulation test PT (r = -0.7; p<0.001) and 
TEG variables related to both cloth strength (MA, MTG) and clot elasticity (SEMS; 
r = -0.4, p<0.05). Moreover, we observed that anaemia was associated with a higher 
rate of fibrin built up (increase in α angle). A decreasing Hb level was associated with 
prolongation of R-time, suggesting a delay in the initiation of the coagulation cascade 
in anemic patients. As expected there was a significant positive correlation between 
the classical coagulation test PT and TEG variable R-time. The most illustrative scatter 
diagrams and regression equations of classical coagulation test PT and TEG variables 
R, MA and MTG versus Hb level are presented in Figures 1a-d. 







 > 2 days’ storage
 Group 3
 RbC transfusion,
 2 days’ storage
Hb <10g/dl Hb >10g/dl 1 hr 24 hr 1 hr 24 hr
Number 15* 14† 24 24 18 18
Age (yr) 24 ± 9 46 ± 17‡ 51 ± 18 53 ± 17 49 ± 14 50 ± 15
male/female 4 / 11 4 / 10 12 / 12 12 / 12 12 / 6 13 / 5
* Fifteen measurements in 5 patients; 4 with acute leukemia and 1 with Hodgkin’s lymphoma.
















































Correlation and linear regression of PT, R-time, Maximum Amplitude and MTG with Hb level.





































We also divided Group 1 into two groups of equal size; one group with a “lower” 
Hb and another group with a “higher” Hb. We chose a cutoff level for Hb of 10 g/
dL because this was both the mean and the median Hb level of the entire cohort. 
Significant differences in PT (p=0.01), clot strength (MA; p=0.02), and viscoelastic 
properties of the formed cloth (SEMS; p=0.02) were found when patients with Hb 
levels less than10 g/dL were compared to patients with Hb levels of more than10 g/
dL. Box plots for these three variables are shown in Figures 2a-c.
Figure 2a 
Box plots of the variable prothrombin time (pt) comparing patients with hemoglobin 









Box plots of the variable PT, Maximum Amplitude and SEMS comparing patients with Hb levels 





































effect of transfusion of stored RbC on coagulation
In study Groups 2 and 3 we studied the effect of transfusion of stored and “fresh” 
RBCs on coagulation. The basic demographics of both study groups are demonstrated 
in Table 1. The percentage change in coagulation parameters 1 and 24 hours after 
transfusion of 3 units of RBCs with a mean storage time of 18 ± 7 days is shown 
in Table 2. It demonstrates that 1 hour after transfusion, the initiation of plasmatic 
coagulation is accelerated, illustrated by a significantly shortened R-time. This results, 
however, in a clot with inferior strength and quality as is demonstrated by a decrease 
in the TEG variables MA, SEMS, MTG and TTG. This negative effect on clot quality 
even persisted 24 hours after the transfusion. From the classical coagulation tests, 
a significant increase in aPTT was observed during the first hour after transfusion.
effect of transfusion of fresh RbCs on coagulation 
Table 3 shows the effects on coagulation parameters 1 and 24 hours after the 
transfusion of 3 units of RBCs with a limited storage time of 2 days. A significant 
decrease in clot strength and clot quality (TEG variables MA, SEMS, and TTG) was 
observed 1 and 24 hours after the transfusion. From the classical coagulation tests, 
a significant increase in aPTT was observed 1 hour after transfusion. Compared to 
the results obtained with the longer-stored RBC’s, MA and SEMS are significantly 
more reduced (MA 1 and 24 hr, respectively, p=0.003 and p=0.002; SEMS 1 and 24 
hr, respectively, p=0.02 and p=0.004), suggesting an even greater decrease in clot 
strength and quality when fresh RBCs are used (Tables 2 and 3, Figure 3).





































Table 2. Exact baseline values and changes (%) in classical and TEG coagulation variables after 






after 24 hour p
Hb 8.2 ± 0.7 135 ± 8 <0.0001 140 ± 7 <0.0001
Platelet 144 ± 98 90 ± 12 0.004 89 ± 14 0.024
PT 13.6 ± 1.5 99 ± 3 0.241 98 ± 3 0.013
aPTT 28.1 ± 3.1 103 ± 5 0.001 111 ± 25 0.116
Fibr 4.0 ± 1.0 103 ± 11 0.244 106 ± 13 0.114
 AT 99.4 ± 17.2 100 ± 8 0.871 102 ± 6 0.218
R 36.7 ± 21.3 83 ± 36 0.004 92 ± 50 0.465
K 13.7 ± 12.0 113 ± 71 0.315 152 ± 155 0.324
α 28.5 ± 17.4 108 ± 38 0.713 108 ± 50 0.452
MA 61.5 ± 12.8 92 ± 7 <0.0001 91 ± 18 0.025
SEMS 9358 ± 4424 80 ± 14 <0.0001 83 ± 35 0.014
MTG 5.7 ± 3.9 97 ± 40 0.004 94 ± 51 0.206
TMG 4372 ± 1647 88 ± 42 0.143 104 ± 67 0.762
TTG 1013 ± 224 92 ± 6 <0.0001 93 ± 14 0.0020
Table 3. Exact baseline values and changes (%) in classical and TEG coagulation variables after 







Hb 8.3 ± 0.7 135 ± 10 <0.001 137 ± 13 <0.001
PLT 181 ± 136 90 ± 11 0.004 82 ± 22 0.001
PT 14.1 ± 1.1 99 ± 2 0.117 98 ± 5 0.165
aPTT 31.2 ± 5.4 105 ± 8 0.019 104 ± 8 0.102
Fibr 5.3 ± 2.0 102 ± 7 0.333 99 ± 7 0.266
AT 107.4 ± 21.1 103 ± 8 0.135 107 ± 22 0.429
R 36.1 ± 15.4 106 ± 52 0.256 107 ± 47 0.301
K 13.1 ± 5.7 113 ± 40 0.241 134 ± 60 0.161
α 20.8 ± 11.9 94 ± 38 0.543 82 ± 43 0.039
MA 61.9 ± 18.8 82 ± 13 <0.001 75 ± 23 <0.001
SEMS 10768 ± 6835 67 ± 19 <0.001 55 ± 18 <0.001
MTG 4.9 ± 2 89 ± 25 0.116 72 ± 28 0.034
TMG 3117 ± 1418 107 ± 73 0.669 100 ± 44 0.781
TTG 1070 ± 224 87 ± 11 <0.001 82 ± 11 0.347
Hb; hemoglobin, PT, partial thromboplastin time; aPTT, activated partial thromboplastin time; 
AT, anti-thrombin, Fibr; fibrinogen, R-time, reaction time; K-time, clotting time; α, alpha angle; 
MA, maximum amplitude; SEMS, shear elastic modulus strength; CI, coagulation index; MTG, 







































Shear Elastic Modulus Strength (SEMS) 1 and 24 hours after transfusion of 3 RBCs, 








Older RBC Fresh RBC
before 1 h 24 h
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SEMS 1 and 24 hours after transfusion of 3 RBC units expressed as percentage of SEMS before 
transfusion. (g) Older RBCs; (c) fresh RBCs.
DIsCUssIon
In this study we observed that RBCs indeed play a role in haemostasis. In case of 
decreasing Hb level, we observed a significant improvement in both clot strength 
and quality, as was demonstrated by the finding of an increase in TEG variables 
MA, SEMS, and TMG. However, this phenomenon was accompanied by a tendency 
towards a delay in the initiation phase of plasmatic coagulation, illustrated by an 
increase in both PT and R-time. 
Further, we found that correction of anaemia by RBC transfusion resulted in 
significant shortening of the initiation phase of plasmatic coagulation (decrease in 
R-time) with now the opposite effect on clot strength and clot elasticity (decrease 
in MA, SEMS, MTG and TTG). These negative effects on clot strength and elasticity 
persisted until 24 hours after RBC transfusion. Transfusion of RBCs with storage 
time of 2 days showed a significantly stronger negative effect on clot strength and 





































quality. Remarkably, with these fresh RBCs no significant (procoagulant) effect on the 
initiation phase of plasmatic coagulation (R-time) was observed. 
Translated into terms of coagulation we found that in case of anaemia the initial 
rate of fibrin formation seems to be delayed, until a certain amount of thrombus 
was generated. From that point on, the coagulation profile was superior in terms 
of a more rapid fibrin build-up with finally a stronger clot with better viscoelastic 
properties. 
Correction of anaemia by RBC transfusion, on the other hand, showed exactly the 
opposite effects on the coagulation profile. After transfusion the initiation phase 
of the plasmatic coagulation was shortened with deterioration of the ultimate clot 
strength and quality. Although haemostatic effects could be seen with both stored 
and fresh RBCs, the detrimental effects on haemostasis were more obvious for fresh 
RBCs compared to stored RBCs.
In group 1, patients with Hb levels below 10 g/dL were significantly younger than 
patients with Hb levels above 10 g/dL (Table 1). Apart from age, no significant 
differences in gender were found, neither was there is a significant difference in PLT 
count between the two groups. It is know that aging affects the coagulation profile 
as measured by TEG (19). If age might have affected our study results, the true 
(prothrombotic) effect of anaemia on TEG variables may have been underestimated 
as aging usually is accompanied by a trend towards hypercoagulability. 
It is known that bleeding time is prolonged in anemic patients, independent of their 
PLT count, and is shortened by elevating the hematocrit (Hct). The initial phase of 
haemostasis consists of PLT adhesion to subendothelial collagen, their activation 
and aggregation and finally the formation of a PLT plug. Lateral migration of RBCs 
in flowing blood contributes to this process, as it induces near-wall excess of PLTs 
(1). Also procoagulant phospholipids exposed on the outer surface of erythrocytes 
can serve as an trigger for the initiation of the coagulation cascade (20). The relation 





































hypercoagulability (decrease in R-time) was found immediately after a rapid 10% 
loss in circulating blood volume, probably related to rapid immediate hemodilution 
(21). Our findings are only partially in accordance with the findings of Iselin and co-
workers (22). In their in vitro study, a decrease of the Hct from 40% to 10% resulted 
in a shortening of R- and K-time, with an increase in α angle, MA, and G, representing 
acceleration of blood coagulation with low Hct values. They concluded that the 
isolated reduction in Hct did not compromise in vitro blood coagulation. The finding 
of a faster initiation of the plasmatic coagulation process might be related to their 
study procedure in which RBCs were diluted with various amounts of 0.9% saline 
and resuspended into PLT- rich plasma in order to obtain samples with different Hct 
values. Another study observed a procoagulant state with mild saline hemodilution 
in vivo (23). They found a shortened R-time and K-time and widened α angle at levels 
of hemodilution of 20% to 30%. A disproportionate reduction in concentrations of 
natural anticoagulants such as AT with hemodilution has previously been suggested 
as a possible explanation (5,21). More recently, an inverse correlation was found in 
vitro between Hct and closure time as measured with the Platelet Function Analyzer 
(PFA-100®, Dade Behring) (24). This observation is in agreement with our finding of an 
inverse correlation between Hct and R-time. In contrast to the TEG technique, which 
gives insight into the total coagulation process, the PFA-100 only gives information 
about primary haemostasis. Therefore, no effects on clot strength and clot firmness 
could be measured. Although TEG variable MA is considered as an equivalent of 
bleeding time, as both give information on PLT count and function, our finding of 
improved clot strength (higher MA) is not in accordance to earlier observations of 
increased bleeding time in anemic patients.
In our study we observed that transfusion of RBC led to an improvement in the initial 
rate of fibrin formation, as was demonstrated by a significant decrease in R-time. 
However, the latter was accompanied by a significant negative effect on clot strength 
and clot elasticity. All these haemostatic effects could be measured immediately 
after the transfusion of RBCs and lasted for at least 24 hours. Although a positive 
relation was found between PT and R-time, no significant effect on PT was observed 
in the first 24 hours after transfusion of RBCs. 





































We also examined the influence of storage time of RBCs on the coagulation profile 
after transfusion. It is known that RBCs undergo lesions upon storage, which affect 
their function and possibly clinical outcome (25). Storage of RBCs also leads to the 
loss of RBC 2,3-diphosphoglycerate with impaired oxygen release during the first 
hours after transfusion. In a study performed in critically ill patients, RBC transfusions 
were independently associated with an increased mortality (25,26). In the CRIT study 
however, mortality was not increased in patients receiving old RBCs (>14 days stored) 
versus fresh RBCs. Others however reported that the transfusion of RBCs older than 
7 days may contribute to hemorheologic disorders in critically ill patients (9). They 
observed a decrease in blood clotting time, measured by Sonoclot coagulation 
analyzer (Sienco, Inc., Färgelanda, Sweden), starting after 2 weeks of storage. It is, 
however, noticeable that, in contrast to our study, the latter study was performed in 
vitro. In our in vivo study, transfusion of both stored and fresh RBC led to a decrease 
in ultimate clot strength and clot quality. Moreover, in contrast to fresh RBCs, the 
transfusion of stored RBCs had beneficial effects on the initiation of plasmatic 
coagulation as R-time was significantly shortened. Further, both clot strength and clot 
quality seemed to be more compromised after transfusion of fresh RBCs compared 
to transfusion of stored RBCs. The inferior haemostatic function of fresh RBC’s 
might be related to the manufacturing process of RBCs. Centrifuge speed may also 
have an impact on blood cell damage (27,28). It is conceivable that high centrifugal 
forces, used to separate whole blood into its components, and leukofiltration induce 
damage, which only slowly recovers due to the small amount of plasma left and the 
use of the additive solution saline-adenine-glucose-mannitol (SAGM). The difference 
in haemostatic effect of old versus fresh RBC could also be related to the effects of 
SAGM. Gulliksson and colleagues (29) observed during storage of RBC in SAGM an 
increased thrombin acitivity measured by fibrinopeptide A determination especially 
at a storage time longer than 3 weeks. However, provided the observed effect of 
RBC transfusion on haemostasis is of clinical relevance, it is important to state that 
the primary goal of RBC transfusion is to improve oxygen delivery. In this context, 






































There were a number of limitations to this study. First of all, our study identifies 
associations between changes in Hb level variables of coagulation as measured by 
TEG and classical coagulation tests. Although the associations observed showed 
significance, no causality was demonstrated. Importantly, as we measured 
only variables of coagulation, but not the (clinical) effects of anaemia and RBC 
transfusion on bleeding episodes, we can only speculate on the clinical relevance 
of our findings. Moreover, our study population was not healthy as patients in 
study Group 1 had been treated for haematological malignancy with chemotherapy, 
As we did not include patients with active disease treated for with “induction” 
courses of chemotherapy, we tried to exclude any effect of the earlier disease on 
the coagulation process. Importantly, all included patients had normal values for 
PLT count and fibrinogen and antithrombin levels, making low-grade disseminated 
intravascular coagulation or consumptive coagulopathy very unlikely. Although we 
cannot exclude any (subtle) confounding effect of the (response on) treatment on 
study outcome, we assume that, due to our strict inclusion criteria, our study results 
and conclusions may be applicable to “normal” patients with different degrees of 
anaemia. Further, hemodilution as well as the effects of anticoagulants in the blood 
products could both have played a role in the first hours after transfusion; although 
only small amounts of plasma (10–20 mL/U) and anticoagulants are present in 
leukoreduced RBCs stored in SAGM. However, we observed identical haemostatic 
effects 1 and 24 hours after blood transfusion, making the effects of hemodilution 
and the effects of anticoagulants less likely. Another limitation is that whole blood 
samples without activators were used for TEG measurements. As a consequence, 
the study observations may not apply to other methods of TEG measurement. Also 
the additional measurement of TEG fibrinolysis variable(s) could have been of great 
interest, especially with regard to the qualitative influence of thrombin generation 
on clot resistance to fibrinolysis (30). 
In summary, in this study we observed that lower Hb levels were associated with 
improvement in TEG variables corresponding to clot strength and elasticity, but also 
with a delay in the initiation of the coagulation cascade. Further, we observed that 
correction of anaemia by transfusion of RBCs seemed to have the opposite effects 





































on the coagulation profile, with shortening of the initiation phase of coagulation, but 
at the cost of inferior cloth strength. Stored and fresh RBCs both showed effects on 
clot quality, with even worse effects on the initial fibrin built up and clot quality by 
fresh RBC. Future studies on outcome (i.e., bleeding episodes) are needed to further 
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Thrombelastography can detect 
hypercoagulability and monitor the 
effects of Hydroxyurea in patients with 
sickle Cell Disease
Wilfried W.H. Roeloffzen, Hanneke C. Kluin-Nelemans, Nic J.G.M. Veeger,








































baCKGRoUnD anD obJeCTIVes: The pro-coagulant profile observed in patients 
with Sickle Cell Disease (SCD) is complex and multifactorial. Thrombelastography 
(TEG) has the advantage of integrating all the aspects of coagulation into one single 
test. We used TEG to analyze hypercoagulability in patients with SCD, both in steady 
state and in painful crisis. Further, we studied the effects of Hydroxyurea (HU) and 
the role of red- and white- blood cells on haemostasis in SCD.
PaTIenTs anD meTHoDs: In 18 patients with SCD (11 on HU), coagulation 
parameters could be measured in steady state and during 34 painful crises. 
Coagulation parameters in SCD patients were compared to controls and steady state 
was compared to crisis, in relation to HU use.
ResUlTs: We observed statistically significant pro-coagulant TEG parameters in 
the SCD population not using HU compared to the control group both in steady 
state and in crisis. Apart from the ultimate clot strength, HU significantly reduced 
hypercoagulability compared to both controls and HU non-users. Further, both 
red and white blood cells were respectively negatively and positively correlated to 
hypercoagulabity. 
ConClUsIon: In patients with SCD, TEG might be a useful tool to both identify- and 




































TEG in sickle cell disease
InTRoDUCTIon
Patients with sickle cell disease (SCD) have chronically activated coagulation (1). The 
pro-coagulant state in SCD is considered multifactorial, involving haemostatic changes, 
activation of the coagulation cascade and endothelial activation (2,3). Although the 
activating effects of SCD on the coagulation system have been studied intensively, 
a unifying mechanism explaining this phenomenon has been elusive (4). Reported 
mechanisms include increased generation of both thrombin and fibrin, increased 
platelet and tissue factor activity, alterations in markers of coagulation activation and 
natural anticoagulant proteins and thrombophilic DNA mutations (5-9). Classically, 
SCD-related complications are thought to be caused by micro vascular occlusions 
and ischemic tissue necrosis following the adhesion of red blood cells (RBCs) and 
other cellular elements to vascular endothelium and the polymerization of sickle 
hemoglobin. More recently, interest has shifted toward the effects of intravascular 
hemolysis, leading to increased plasma concentrations of microparticles and the 
release of both cell-free hemoglobin and RBC arginase resulting into impaired nitric 
oxide (NO) bioavailability resulting into endothelial dysfunction and vasculopathy 
(10,11). 
Thrombelastography (TEG) has gained popularity as a global point of care test of 
haemostasis and has the advantage over conventional tests of haemostasis that it is 
performed on whole blood, taking into account the role of interacting blood elements 
such as phospholipid bearing cells and platelets (12). The technique offers a rapid 
overview of the cumulative effect of all the individual components of haemostasis, 
without having to analyze each of these components separately, defining it as a 
more physiological instrument to study haemostasis (13,14). Moreover, TEG provides 
information about the quality of the clot as well as the dynamics of its formation and 
its lysis. There is also increasing clinical interest in assessment of the prothrombotic 
tendency by TEG, for example in thrombophilia screening, but also in prediction of 
arterial or venous thrombosis in the general population (15). TEG is considered more 





































As a consequence, we hypothesized that TEG might be a useful tool to further 
elucidate the complex derangements in haemostasis in SCD. In the present study we 
used TEG to analyze hypercoagulability in patients with SCD, both in steady state and 
in painful crisis. Further, we studied the role of red and white blood cells as well as 
the effects of Hydroxyurea (HU) on haemostasis as measured by TEG in SCD.
maTeRIals anD meTHoDs
study patients
The institutional review board approved the study and informed consent was obtained 
from all patients. Study patients were recruited from the SCD population visiting the 
outpatient department. 11 of the 18 included patients were on HU therapy. Patients 
were classified as having a painful crisis if symptoms consistent with a vaso-occlusive 
episode were present leading to hospital admittance. 
In order to obtain our own normal (reference) values, we performed TEG and classical 
coagulation tests in 120 healthy adults; 60 women and 60 men, ten per decade, age 
distributed equally between 19 and 87 years, mean age 50 ± 17 years (20). From this 
cohort we selected an age matched control group. 
For study patients and controls, the following exclusion criteria were used: coagulation 
disorders, use of anticoagulants, use of acetylsalicylic acid within the preceding 10 
days or use of non steroidal anti-inflammatory drugs within the last 24 hours.
study protocol
In patients with SCD TEG measurements and blood laboratory tests were performed 
in steady state at a routine visit to the outpatient department. During admittance 
for painful crisis, several serial TEG measurements and blood laboratory tests were 
performed until the crisis resolved. In the age matched control group the same TEG 
measurements and standard coagulation tests were performed. TEG and coagulation 
tests comparisons were made between steady state and crisis in the study group 





































group with SCD, coagulation effects of HU were evaluated by comparing patients 
using HU with HU non-users.
blood sampling and assays
In both the study and control group blood samples were obtained simultaneously 
for TEG analysis and standard laboratory- and coagulation-tests (i.e. the complete 
blood count, prothrombin time (PT), activated partial thromboplastin time (aPTT), 
fibrinogen and antithrombin (AT). Moreover, in the study group reticulocyt count, 
lactate dehydrogenase (LDH), total billirubin, fetal hemoglobin level (HbF), factor 
VIII concentration (FVIII) and haptoglobin level were tested as parameters of SCD 
activity. Venous blood samples were collected by vein puncture at the antecubital 
fossa using a 21-gauge butterfly needle. Two examiners obtained all blood samples, 
both experienced in performing phlebotomy. Blood was collected into a 20-mL 
polypropylene syringe to prevent contact activation by glass. To minimize the effects 
of using a tourniquet, the first aspirate of 10 blood was discarded. All standard 
coagulation tests were performed on the STA-R coagulation analyzer (Roche, 
Diagnostica Stago, Asnières, France): PT with Thromborel S reagents and aPTT 
with Actin FS reagents (Dade Behring, Marburg, Germany), fibrinogen with excess 
thrombin (BioPool, Umea, Sweden) according to the Clauss method, and AT with 
thrombin as enzyme (STAchrome ATIII, Roche kit). Normal values for these variables 
in our laboratory are PT 11 to 16 sec, aPTT 26 to 36 sec, fibrinogen 1.7 to 3.5 g/L, AT 
75% to 125%. 
Thrombelastographic assays were carried out using a computerized TEG coagulation 
analyzer (Model 5000; Haemoscope Corp., Niles, IL). All analyses were performed 
with TEG disposable cups and pins as devised by the manufacturer. Polypropylene 
and polyethylene pipettes were used to handle reagents and blood. For TEG analysis 
360 mL whole blood was pipetted into the prewarmed TEG cup and measurements 
were performed within 6 minutes from sampling (16). No activators of coagulation 
were added to the samples. The following TEG parameters were recorded: the 
reaction time (R), representing the rate of initial fibrin formation; the clotting time 
(K), representing the time until a fixed level of clot firmness is reached; the angle 
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(α), representing clot growth and correlated to thrombin generation which results 
into interaction between platelets and fibrin and, finally, the maximum amplitude 
(MA), which is a measurement of maximum strength or stiffness of the developed 
clot. the R time, K time and α are prolonged by anticoagulants and coagulation factor 
deficiencies, MA is especially influenced by platelet count and platelet function as 
well as fibrinogen level. 
Statistical analysis
For statistical analysis SPSS 17.0 software for Windows was used. TEG and classical 
coagulation variables are presented as mean and SD. Group comparisons were 
made by an unpaired t-test. Significance levels were set at 0.05 (two-tailed). Linear 
regression was used to quantify the associations of TEG variables with relevant blood 
test. In these analyses, Pearson correlation coefficients (r2) were calculated, as well 
as their level of significance (with a null hypothesis r = 0).
ResUlTs 
We studied 18 patients with SCD; the demographics of the study and control 
population are presented in Table 1. Of the 18 included patients, 11 were on HU 
treatment. Coagulation tests could be performed in all included patients during 
steady state of the disease. During admittance because of painful episode (=crisis), a 
total of 34 measurements of coagulation could be performed; 20 in patients on HU 
and 14 in patients without HU treatment.
Coagulation tests in sCD in steady state
Table 2 demonstrates TEG variables and classical coagulation test in patients with 
SCD in steady state compared to the same tests performed in healthy controls. The 
SCD cohort was divided into HU users and HU non users. We observed significant pro-
coagulant parameters in the SCD population not using HU compared to the control 
group. Both the initial fibrin formation (R-time, p=0.02) and the time until a fixed 
level of clot firmness was reached (K-time, p=0.008) as well as the rapidity of clot 





































clot (Maximum Amplitude, p<0.001) were significant pro-coagulant in the HU naïve 
cohort. 
Table 1. Demographics of study- and control- population
sickle Cell Disease
HU - HU +
Control
Group
Number included 7 11 40
Mean age ± SD (yr) 33 ± 18 25 ± 7  29 ± 6
Gender (female: male) 5 : 3 3 : 8 21 : 19
Hb F (%) 3.8 ± 2.6 14.6 ± 7.3 -
Hb (mmol/l) 5.9 ± 1.3 6.3 ± 0.8 8.6 ± 0.8
Leuco (x109/l) 11.4 ± 2.9 6.9 ± 2.4 7.3 ± 1.4
Trombo (x109/l) 332 ± 74 346 ± 142 246 ± 48
HU -; Hydroxyurea non-user, HU +; Hydroxyurea user, Hb F; Fetal Hemoglobin, Hb; hemoglobin, 
Leuco; leucocytes, Trombo; trombocytes
Table 2. Comparison of TEG- and coagulation- parameters between control group and patients 





















































* Displayed values are mean ± standard deviation. # p<0.05 HU- vs. HU+
SCD: Sickle cell disease HU -; Hydroxyurea non-user, HU +; Hydroxyurea user.
R-time; reaction time, K-time; clotting time, Alpha; alpha angle, MA; maximum amplitude.
Trombo; trombocytes, PT; prothrombin time, APTT; activated partial tromboplastin time, 
AT; antithrombin, ns; not significant.
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Interestingly, in HU users we observed that, apart from the ultimate clot strength, TEG 
parameters differed not statistically significant from the TEG parameters observed in 
the control group. Moreover, when HU users were compared to non HU users we 
found that the latter not only had significant higher ultimate clot strength (Maximum 
Amplitude, p=0.003) but also higher fibrinogen levels (p=0.02) with trends for 
hypercoagulabitiy for all other TEG parameters.
Coagulation tests in sCD in crisis
Table 3 demonstrates TEG parameters and classical coagulation tests performed in 
34 painful episodes compared to the same tests performed in controls. A statistically 
significant procoagulant profile for all TEG parameters was observed in the HU naïve 
group compared to controls. Although in the group using HU the pro-coagulant 
patterns was somewhat weaker, patients still demonstrated significant higher initial 
fibrin formation (R-time; p=0.02) as well as a higher ultimate clot strength (Maximum 
Amplitude; p<0.001) compared to controls. 
When HU users were compared to non HU users we found that HU naïve patients 
not only had significant higher initial fibrin formation (R-time; p=0.006) but also 
demonstrated a more rapid clot growth (Alpha angle; p=0.04) with trends for 
hypercoagulabitiy for the other TEG parameters. 
When TEG parameters during crisis were compared to those in steady state, 
although not significant, a further increase towards hypercoagulability was observed 
for all TEG parameters in both HU users and HU naïve patients. From the classical 
coagulation test, platelet count significantly decreased during crisis, possibly caused 
by consumption (data not separately shown). A graphical presentation of our findings 
is demonstrated in Figure 1. Bar charts in this figure represent TEG parameters (+95% 





































Table 3. Comparison of TEG- and Coagulation- parameters between control group and patients 
with SCD, in crisis*
TeG- & Coagulation-

















































* Displayed values are mean ± standard deviation. # p<0.05 HU- vs. HU+
SCD: Sickle cell disease HU -; Hydroxyurea non-user, HU +; Hydroxyurea user.
R-time; reaction time, K-time; clotting time, Alpha; alpha angle, MA; maximum amplitude.
Trombo; trombocytes, PT; prothrombin time, APTT; activated partial tromboplastin time, 
AT; antithrombin, ns; not significant.
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Bar charts (+95%CI) representing TEG parameters in Hydroxyurea users- and non-users, in 
steady state and in crisis
association of TeG variables with parameters of sCD activity
A lowered Hb and increased leucocyte number are considered part of disease activity. 
We observed statistically significant correlations between most TEG parameters 
and both Hb level and leucocyte count, suggesting an enhancement of the clotting 
process in patients with leucocytosis and/or progressive anaemia. The scatter 
diagrams and regression equations of TEG parameters versus Hb level respectively 
leucocyte count are presented in Figures 2 and 3. Decreasing Hb level was associated 
with a shortening of the rate of initial fibrin formation (R-time; r = 0.43) and with 
the time until a fixed level of clot firmness was reached (K-time; r = 0.45). Moreover, 





































r = -0.58) and the maximum strength or stiffness of the developed clot (MA; r = 
-0.72). A higher leucocyte count was also associated with both an increase in the 
rate of fibrin formation (R-time; r = -0.31 and K-time; r = -0.24) and with a faster clot 
growth (alpha angle; r = 0.41) and improved ultimate clot strength (MA; r = 0.41). 
Remarkably, no correlations were found between Platelet count and any of the TEG 
parameters. Further we found that the level of Fetal Hemoglobin (HbF) was positive 
correlated to the rate of initial fibrin formation (R-time; r = 0.43) and negative to the 




















Correlation and linear regression of Hemoglobin values with various TEG parameters. (R Sq 
linear = correlation coefficient)
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Correlation and linear regression of Leucocyte values with various TEG parameters. (R Sq 
linear = correlation coefficient).
DIsCUssIon 
The procoagulant profile observed in patients with SCD is complex and multifactorial. 
Instead of analyzing all the separate underlying haemostatic aspects with different 
tests, the thrombelastography technique has the advantage of integrating all these 
(dynamic) aspects of coagulation into one single test. Apart from a study in pediatric 
patients by Yee and colleagues (21), we are the first to report on TEG variables 





































In the current study in adult patients with SCD, not using HU, we observed 
hypercoagulable TEG parameters, both in steady state and during crisis, when 
compared with healthy age matched controls. This procoagulant TEG profile involved 
both the initiation and propagation of thrombin formation (respectively Reaction-
time, Clotting-time and Alpha angle), but also the ultimate clot strength and clot 
elasticity (Maximum Amplitude). Classical coagulation tests demonstrated higher 
platelet- and fibrinogen- levels as well as shortened APTT in patients with SCD in 
steady state compared to controls. Moderate thrombocytosis is characteristic of 
patients with SCD and has been attributed to functional asplenia and the lack of 
splenic sequestration (22). 
Although TEG parameter Maximum Amplitude is propagated to reflect both 
plateletcount and platelet activity as well as fibrinogen level, we did not observe 
a significant correlation between MA and these two classical coagulation test. A 
possible explanation for this finding is the relatively small distribution wide of both 
platelet counts and fibrinogen levels in our study group. 
Our findings are in accordance with those of Yee and colleagues who observed 
hypercoagulable TEG patterns in pediatric patients with SCD. However, in their study 
recalcified citrated whole blood samples were used, instead of “unmanipulated” 
fresh whole blood as we did. TEG with recalcified citrated blood is used as an 
alternative to non-citrated blood in situations in which immediate TEG determination 
is not practically feasible. However, the use of a citrated sample generates different 
results than those obtained with fresh whole blood making both techniques not 
interchangeable (20,23). 
During crisis, TEG profiles of patients with SCD became even more pro-coagulant 
compared to the profiles observed in steady state. This procoagulant state was 
observed for all measured TEG parameters, but not for the classical coagulation 
tests. The significant lower platelet count is probably caused by decreases in lifespan 
accompanying vaso-occlusive crisis. Demonstration of a procoagulant state during a 
vaso-occlusive crisis is (indirectly) supported by other studies in which during crisis 
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an increase in the levels of markers of thrombin generation as well as an increase in 
the expression of tissue factor was observed (6,24).
To date, the only agent that has been specifically approved for the treatment of SCD 
is HU, a drug known to increase HbF and to reduce white blood cell count. HU has 
been shown to decrease the frequency of painful crises, episodes of acute chest 
syndrome, hospitalizations, and blood transfusions (6,25). Our data clearly illustrate 
the effects HU has on the coagulation profile in patients with SCD as measured by 
TEG. When HU users and HU naïve patients were compared to controls, the HU naïve 
group had significant procoagulant TEG parameters compared to controls, whereas 
HU users only had significant elevated Maximum Amplitude. This suggests that HU 
particularly has (beneficial) influence on the initiation and propagation phase of 
the coagulation profile, but less on clot strength and clot elasticity. Unexpectedly, 
however not statistically significant, we observed higher platelet counts in the HU 
treatment group compared to the HU naïve group.
A high level of HbF in SCD correlates with a decrease in the incidence of vaso-
occlusive crises (26). The latter is in agreement with our observation of significant 
correlations of HbF level with both Reaction Time (r =0.43; p<0.01) and Maximum 
Amplitude (r =-0.41; p<0.05). In terms of coagulation; with the increase in HbF level 
(as a result of HU treatment), both a delay in the initiation phase of coagulation as 
well as a decrease in ultimate clot strength and clot elasticity were observed.
In this study we demonstrated that red and white blood cells do play a role in 
haemostasis in patients with SCD as both were significantly correlated to TEG 
parameters corresponding to different parts of the coagulation cascade. In case of 
increasing Hb level, we observed a significant delay in the initiation phase of plasmatic 
coagulation (as was demonstrated by the finding of an increase in both Reaction-
Time and Clotting-Time (r = 0.43 and r = 0.45; p<0.01) and a decrease in cloth growth 
and ultimate clot strength, corresponding to a decrease in both Alpha Angle and 
Maximum Amplitude (r = -0.58 and r = -0.77; p<0.01). These findings suggest that 





































The latter is (partly) in accordance to observations made in an earlier study performed 
in (healthy) patients with anaemia in which lower Hb levels were associated with an 
increase in ultimate clot strength and elasticity (27). However in that study, increasing 
Hb level was correlated to a faster initiation of plasmatic coagulation. 
Further we observed that leucocytosis in patients with SCD led towards a 
hypercoagulable TEG profile, with both a faster initiation and propagation phase 
of coagulation (K-time; r = -0.31; p<0.05 and alpha angle; r = 0.41; p<0.01) and an 
increase in clot strength and clot elasticity (MA; r = 0.41; p<0.01). We assume that 
lower Hb levels and higher leucocyte counts in patients with SCD are representatives 
of an increased in vivo sickling activity, resulting in a procoagulant haemostatic 
profile. An important limitation of our study is that we did not match our controls for 
ethnicity, which may have implications for the interpretation of the results. Hagger 
et al observed in their study significant differences in parameters of coagulation 
between Black and Caucasian control subjects (28). Moreover, in clinical practice, 
where TEG is used as a rapid point-of-care-test of haemostasis, coagulation activators 
are often added to the blood samples. As we used only whole blood samples without 
activators, the study observations may not be applicable to other modalities of TEG 
measurement. Finally, despite the evidence that the coagulation system is activated 
in patients with SCD, we did not prove that this procoagulant state is etiologically 
linked to the vascular occlusion and end-organ damage that is characteristic of SCD. 
However, we think the coagulation profile as determined by TEG might be of value 
in both predicting clinical behavior and in diagnosing (the severity of) a painful crisis. 
Moreover TEG could be used as a tool to monitor the effects treatment with HU 
has on the coagulation profile. In order to further elucidate the role of TEG in SCD, 
further prospective studies are warranted with focus on clinical course- and outcome, 
in relation to TEG profiles, in individual patients with SCD.
In summary, in patients with SCD we observed a procoagulant TEG profile compared 
to matched healthy controls. Moreover, vaso-occlusive crisis led to a further increase 
of this procoagulant state, with beneficial effects of HU treatment on this pattern. 
Finally, we demonstrated that anaemia and leucocytosis in SCD are both linked to 
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hypercoagulability. As the pathogenesis of vaso-occlusion in SCD is multifactorial, the 
exact contribution of hypercoagulability remains to be determined. It is uncertain 
whether the haemostatic changes observed are causative of disease specific 
complications or are simple epiphenomena. As a result, further studies are required 
to extend and confirm the observed hypercoagulable state in patients with SCD and 
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Summary, discussion and future perspectives
sUmmaRy
Laboratory evaluation of haemostasis has been performed using standard clotting 
assays for several decades. The cell-based model of coagulation has led to renewed 
interest in Thromboelastography (TEG), as this technique has the potential for 
allowing a new look at the process of haemostasis, which is of interest for both 
clinicians and researchers in the field of haemostasis (1-3). TEG is a global test of 
haemostasis that visualizes the viscoelastic changes that occur during coagulation 
in vitro. The technique provides a graphic representation of the quality of the clot 
and the dynamics of its formation and subsequent lysis. TEG has the advantage over 
classical coagulation tests that it is performed bedside and in whole blood, offering 
a rapid overview of the sum of the cumulative effects of platelets and plasma factors 
as well as interacting cellular elements. In contrast, classical coagulation tests 
are performed in plasma under conditioned circumstances and give fragmented 
information on the initiation of the coagulation cascade, and are especially useful in 
analyzing isolated defects in this cascade. TEG was initially used to guide transfusion 
in the setting of hepatic-, cardiovascular-, and trauma surgery where haemostatic 
disturbances are complex and multifactorial (4-7). Moreover, when incorporated into 
a transfusion algorithm, TEG might add to the management of massive blood loss 
(8,9). Nowadays, TEG is used by a growing number of clinicians and its use has been 
expanded to all other areas of haemostasis- and thrombosis-testing. 
The scope of this thesis has been to improve the understanding of TEG technology for 
clinicians working in the field of haemostasis, making them aware of the possibilities, 
but also of the limitations of TEG in coagulation monitoring and haemostasis research.
In Chapter 2 an overview was given on the role of TEG and other point-of-care (POC) 
tests of haemostasis in both the prediction and treatment of massive blood loss. 
For this purpose the current (cell-based) model of haemostasis was lined out with 
special focus on the coagulopathy seen in massive blood loss. Further, we discussed 
the characteristics of the “ideal” POC test of haemostasis. After describing classical 
coagulation tests we focussed on the different POC analysers and methods available 
and gave insight into which coagulation parameter(s) can be measured and whether 





































In Chapter 3 we described the effects of age, gender and the use of oral contraceptives 
on coagulation. TEG parameters were measured in both native and citrated whole 
blood from 120 healthy adults (60 men, 60 women) at various ages, and in an additional 
29 healthy women using oral contraceptives. We observed hypercoagulabiltiy in 
females compared to males and in women using oral contraceptives compared to 
age-matched non-users. Moreover, we observed hypercoagulability with aging. 
Using the method of Bland Altman, we demonstrated no correlation between TEG 
measurements in native and recalcified citrated blood. We concluded that aging, 
female gender, use of oral contraceptives and low-normal haematocrit levels have 
significant procoagulant effects. TEG measurements in native and recalcified citrated 
blood are not interchangeable as our data showed a lack of correlation between the 
TEG measurements in both types of blood samples, due to the very large limits of 
agreement.
In Chapter 4 we analyzed the influence of platelet count on coagulation. We 
performed TEG analyses serially in patients with well documented transient 
thrombocytopenia. A total of 189 TEG analyses were performed in 16 patients with 
a hematological malignancy, all in remission, receiving consolidation courses of 
chemotherapy. TEG outcome using native and citrated blood samples at a median of 
11 times (range 1-17) in the same patients during the decrease of platelet count in 
response to chemotherapy were compared to outcome in 120 healthy adults from 
various age categories. We found an excellent correlation (r = 0.7; p<0.001) between 
TEG clot strength (maximum amplitude) and platelet count. Moreover, platelet count 
was correlated with respectively the initial rate of clot formation (reaction time and 
clotting time), the rate of clot growth (alpha angle), and also with maximum thrombus 
generation, time to maximum thrombus generation and total thrombus generation. 
We concluded that platelet count not only affects the strength of clot formation, as 
was expected, but also all other phases of plasmatic coagulation. Citration of the 
blood sample, aiming at easy storage of the material, masked some of the important 





































In Chapter 5 we described the haemostatic function of both transfused platelets, in 
relation to native circulating platelets. Further we reported on the effect of storage 
time of platelet concentrates on their haemostatic potential. During the decrease 
in platelet count after chemotherapy, TEG parameters were measured serially until 
the transfusion trigger was reached in 92 patients. TEG parameters for different 
ranges of native circulating platelets could be assessed, which were compared to 
ranges obtained in the thrombocytopenic period in which the patient received 
platelet transfusions. Finally we compared the haemostatic potential of fresh platelet 
concentrates (1-3 days) with platelet concentrates with longer storage time (4-5 
days). We found no differences in haemostatic potential between native platelets 
and transfused stored platelets (all p values ≥0.1). The transfusion of fresh platelets 
demonstrated better haemostatic effects than longer stored platelets. Both the time 
until a fixed level of clot firmness was reached (K-time) as well as the rate of clot 
growth (alpha angle) were superior for fresh platelet concentrates. We concluded 
that TEG could monitor the haemostatic effects of platelet transfusion, with 
comparable haemostatic properties of native circulating platelets and transfused 
stored platelets. Further, our data suggested that limited storage time is associated 
with a better haemostatic capacity. 
In Chapter 6 we conducted a study with TEG on the role of red blood cells (RBCs) 
in haemostasis. In 29 patients with chemotherapy induced anaemia we studied the 
effect of progressive anaemia on the coagulation profile. In 24 patients with chronic 
anaemia we studied the effect of transfusion of RBCs on coagulation. Finally, we 
evaluated in 18 patients whether storage time of RBCs had additional effects on 
haemostasis. We observed a significant negative correlation between haemoglobin 
and TEG variables related to both cloth strength and elasticity (p<0.05). Moreover, 
anaemia was associated with a delay in the initiation of the coagulation cascade. 
Correction of anaemia by RBC transfusion resulted in significant shortening of this 
initiation phase with now the opposite effect on clot strength and elasticity. The 
negative effects on clot quality were significantly worse when fresh RBCs were 
transfused compared to longer stored RBCs. Furthermore, in contrast to the longer 
stored RBCs, fresh RBCs did not enhance initial fibrin formation. We concluded that 
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anaemia is associated with a delay in the initiation of the coagulation cascade with 
a finally formed clot with superior strength and visco-elastic properties. Transfusion 
of RBCs is associated with impaired clot quality, with even worse effects on the initial 
fibrin built up and clot quality by fresh RBCs.
In Chapter 7 we described the use of TEG in analysing hypercoagulability in patients 
with sickle cell disease (SCD), both in steady state and in painful crisis. Further, we 
described the effects of Hydroxyurea (HU) and the role of red and white blood cells on 
haemostasis in SCD. In 18 patients with SCD (11 on HU), coagulation parameters could 
be measured in steady state and during 34 painful crises. Coagulation parameters 
in SCD patients were compared to controls and steady state was compared to 
crisis, in relation to HU use. We observed statistically significant procoagulant TEG 
parameters in the SCD population not using HU compared to the control group both 
in steady state and in crisis. Apart from the ultimate clot strength, HU significantly 
reduced hypercoagulability compared to both controls and HU non-users. Further, 
both red and white blood cells were respectibely negatively and positively correlated 
to hypercoagulability. We concluded that in patients with SCD, TEG might be a useful 
tool to both identify and monitor hypercoagulability as well as to detect the effects 
of treatment with HU.
DIsCUssIon anD fUTURe PeRsPeCTIVes
In recent years a growing number of articles and studies on TEG have been 
published, covering different areas of clinical medicine. Despite these publications, 
TEG has been considered a research tool for a long time, and the technique has been 
criticized because of the lack of studies demonstrating its reliability. Indeed, the 
methodology has drawbacks concerning validation and standardisation. The latter 
results into significant intra- and inter-laboratory variability, making comparison 
between results difficult (10-12). Further, studies comparing TEG parameters with 
standard coagulation tests demonstrate poor correlation and there are no clinical 
trials that link TEG variables to clinical outcome. Moreover, randomized studies 





































in patients with massive blood loss are missing. Therefore, implementation of 
such an algorithm in the management of massive blood loss seems preliminary as 
discussed in Chapter 2. A Cochrane review published in 2011 also concluded that 
there is an absence of evidence that the use of TEG or ROTEM improves morbidity 
or mortality in patients with severe bleeding. Application of a TEG or ROTEM guided 
transfusion strategy seemed to reduce the amount of bleeding, but failed to show 
any statistically significant effect on other predefined outcomes as the incidence of 
surgical reoperation due to bleeding, mean length of stay in the intensive care unit 
and number of days in the hospital (13).
In an effort to improve reproducibility and to standardize TEG, an international group 
of investigators joined hands in the year 2010 to form the TEG-ROTEM Working 
Group (14). In their first study a significant inter-laboratory variance with coefficients 
of variation greater than 10% was demonstrated (15). Their study has been the first 
effort to standardize TEG methodology. It shows that still significant work remains 
to be done to improve reliability and reproducibility. In line with the Working 
Group’s call for additional research on validation of TEG, our study group assessed 
own reference values in a large random study population as presented in Chapter 
3. So far we are the first to study a population with a well-balanced age and gender 
distribution and describe both classical and dynamic TEG variables and compare 
these with classical coagulation tests, both in native and in citrated whole blood. 
Although impractical, our study underlines the manufacturer’s recommendation 
that each institution should determine its own normal values before adopting TEG. 
Moreover, it is important to emphasize the fact that TEG measurements in native 
and citrated blood are not interchangeable. Further we found clear procoagulant 
effects of age, gender and use of oral contraceptives on haemostasis, underlining the 
sensitivity of TEG over classical coagulation tests in detecting these differences in the 
haemostatic profile. Although the observed procoagulant effects of aging and female 
gender were subtle and probably physiological, clinicians and researchers working 
with TEG should be aware of these effects when interpretating test results.
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In the operating theatre TEG is increasingly used to guide transfusion- and 
haemostatic- therapy as the technique offers the practical advantage of real-time 
coagulation monitoring with subsequent treatment, based on TEG profile and TEG 
parameters. Low platelet counts (<50 x 109/L) are considered a major risk factor for 
bleeding complications (16). Although TEG parameter Maximum Amplitude (MA) 
is classically (mainly) influenced by platelet count, we found this parameter to be 
insensitive in detecting low platelet counts, as we describe in Chapter 4 (17,18). 
Importantly, when platelet count dropped below 50 x 109/L, TEG performed with 
native whole blood showed a flat TEG curve in over more than 40% of the analyses. 
Further we observed that thrombocytopenia affected all other TEG parameters, 
which makes TEG based haemostatic therapy hazardous in these clinical situations, 
at least when non activated blood samples are used. Moreover, for proper use and 
interpretation of the TEG assay, it is important that also the effects of other isolated 
coagulation defects as well as the effects of haemostatic agents are evaluated and 
validated, before a TEG guided transfusion algorithm can be implemented to manage 
hemorrhage. 
Platelet transfusion is used therapeutically in patients with quantitative or qualitative 
platelet disorders who are actively bleeding, or as prophylaxis in patients who are at 
serious risk of bleeding (19). Optimally, transfused platelets should have the same 
haemostatic capacity as native circulating platelets. Although in vitro tests and markers 
are performed on the platelet product, these tests do not provide information on the 
haemostatic in vivo potential. In Chapter 5 we describe how TEG can monitor the 
haemostatic effects of platelet transfusion, with comparable haemostatic properties 
of native circulating and transfused stored platelets. Further, our data suggest that 
limited storage time is associated with a better haemostatic capacity, at least during 
the initial 24 hours after transfusion. The latter might have clinical implications in 
terms of transfusing only fresh platelet products to patients with active bleeding, 
whereas stored platelet products can be reserved when platelets are transfused for 
prophylaxis. However, a change in platelet transfusion policy is preliminary, as we 
did not measure the (clinical) effects of platelet transfusion on bleeding episodes. 
Future studies relating haemostatic capacity of fresh and stored platelet products 





































Although the primary goal of RBC transfusion is to improve oxygen delivery, RBCs also 
have effects on haemostasis as described in Chapter 6 and 7. We found anaemia to be 
associated with a delay in clot initiation with a finally formed clot of superior quality. 
Interestingly, transfusion of RBCs was accompanied by exactly the opposite effects 
on haemostasis, with faster clot initiation at the cost of clot quality. Remarkably, 
RBCs with a storage time of only 2 days did not demonstrate this procoagulant effect 
on clot initiation; clot quality deteriorated, however. Both observed phenomena can 
probably be explained. First, RBCs positively influence the initiation of haemostasis, 
as under flow conditions they move toward the centre of the vessel, causing a near 
wall excess of platelets with subsequent adhesion, activation and aggregation of 
these platelets. Second, the RBC-inhibiting effect on TEG clot strength is probably 
caused by the formation of a looser clot structure with increasing amounts of RBC 
built in the fibrinogen network. Recently, our results were confirmed by an in vitro 
study where increasing amounts of RBC also reduced clot strength (20). We consider 
our observation of importance for workers in the field of haemostasis using TEG, as 
they should be aware of the effects of haematocrit on haemostasis when analyzing 
TEG parameters. Further, we can only speculate whether the haemostatic effects 
of RBCs are somehow related to the worse clinical outcome as seen in critically ill 
patients, in relation to the number of received RBC transfusions (21). The importance 
of RBC in haemostasis is also highlighted in Chapter 8, where we used TEG to study 
haemostasis in patients with sickle cell disease (SCD). Although the procoagulant 
state observed in these patients is considered to be multifactorial, there is no single 
test to quantify or qualify this condition. With TEG we could visualize and measure 
this procoagulant state, which was even more pronounced during painful sickling 
crisis. Moreover, we could also detect the beneficial effects of treatment with 
Hydroxyurea on this procoagulant state. It remains however uncertain whether the 
haemostatic changes observed are causative of disease specific complications or are 
simple epiphenomena. As a consequence, further studies are required to relate TEG 
parameters to clinical outcome, in relation to HU use.
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We consider TEG a promising tool for the evaluation of haemostasis, both in the clinical 
and experimental field, because the technique allows a unique, more physiological 
view at haemostasis. In contrast to classical coagulation tests, and in spite of it’s 
global character, the technique can detect age, gender and hormonal effects on the 
coagulation profile. Furthermore, TEG seems capable in demonstrating the effects of 
platelets and red blood cells on haemostasis and has potential as an in vivo quality 
test of blood products. Also, TEG might play a future role in monitoring and treating 
patients with SCD. However, despite it’s enormous opportunities, the TEG technique 
still has several limitations. Although in recent years much progress has been made 
to improve its reliability and reproducibility as well as to standardize and validate the 
different test modifications and applications, the technique still cannot be utilized 
to its full capacity, mainly because of inconsistencies in study results. Importantly, 
benefits to the patient need to be well documented to enable a more widespread use 
of TEG haemostasis testing in the operating theatre. Moreover, we want to emphasise 
the importance of obtaining own reference ranges for comparison. Further, as far 
as quality assurance is concerned, it is no less important than for conventional 
laboratory-based coagulation tests to deploy both internal quality control and 
external quality assessment. We hope that much more investment is directed to TEG 
studies in both experimental and clinical fields to improve applications and promote 
use. Targeted use of TEG, interpretation of the curves based on the clinical situation 
and combined with information from classical coagulation tests, may be beneficial 
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Samenvatting, discussie en toekomstperspectieven
neDeRlanDse samenVaTTInG
Bij de analyse van de stollingsstatus van een patiënt wordt sedert decennia gebruik 
gemaakt van klassieke stollingstesten. Het huidige cellulaire model van stolling, met 
meer aandacht voor de rol van rode en witte bloedcellen alsmede bloedplaatjes, 
heeft aanleiding gegeven tot hernieuwde interesse in de Tromboelastografie (TEG). 
Met de TEG techniek wordt op een unieke en meer fysiologische manier naar stolling 
gekeken, wat interessant is voor zowel clinici als onderzoekers actief op het gebied 
van hemostase. TEG is een globale hemostasetest die in vitro de visco-elastische 
veranderingen van de stolselvorming visualiseert. De techniek levert een grafische 
weergave van niet alleen de vorming en afbraak van het stolsel, maar ook van de 
kwaliteit van het stolsel. Het voordeel van TEG is dat het onderzoek direct aan het bed 
van de patiënt in volbloed kan worden verricht. De test geeft zo een snel overzicht 
van de cumulatieve hemostatische effecten van bloedplaatjes, plasmafactoren en 
cellulaire bloedelementen. Klassieke stollingstesten daarentegen worden onder 
geconditioneerde omstandigheden in plasma uitgevoerd en geven gefragmenteerde 
informatie over met name de initiatie van de stollingscascade. Klassieke stollingstesten 
zijn derhalve met name informatief bij de analyse van geïsoleerde stollingsdefecten. 
TEG vindt historisch zijn toepassing in leverchirurgie, in cardiovasculaire chirurgie 
en bij traumata, waarbij de optredende stollingsstoornissen vaak complex en 
multifactorieel van aard zijn. Daarnaast kan TEG van nut zijn bij de behandeling van 
patiënten met massaal bloedverlies wanneer deze test wordt geïncorporeerd in een 
transfusiealgoritme. Tegenwoordig is TEG een test die snel aan populariteit wint bij 
uiteenlopende disciplines en die wordt ingezet in uiteenlopende deelgebieden van 
stollings- en tromboseonderzoek.
Het belangrijkste doel van dit proefschrift was om het kennisniveau van clinici die 
gebruik maken van de TEG te verbeteren, waarbij het van belang is dat de gebruiker 
niet alleen op de hoogte is van de mogelijkheden, maar ook van de potentiële 





































In Hoofdstuk 2 is een overzicht gegeven van de rol die TEG en andere zogenaamde 
“point-of-care” (POC) hemostasetesten kunnen spelen in het voorspellen en 
behandelen van massaal (operatief) bloedverlies. Allereerst werd om deze reden het 
huidige cellulaire hemostase model uiteengezet, met extra aandacht voor de specifieke 
stollingsstoornissen zoals deze optreden tijdens massaal bloedverlies. Daarnaast zijn 
de karakteristieken beschreven waaraan de “ideale” POC hemostasetest zou moeten 
voldoen. Nadat inzicht is gegeven in de achtergrond van de klassieke stollingstesten, 
hebben wij ons gericht op de diverse POC technieken en testen. Tevens hebben wij 
onderzocht welke stollingsparameters hiermee specifiek kunnen worden bepaald en 
of de test potentiële klinische waarde heeft bij massaal bloedverlies.
 In hoofdstuk 3 zijn de effecten van leeftijd, geslacht en gebruik van orale anticonceptiva 
(OAC) op de stolling beschreven. TEG parameters werden bepaald in volbloed en in 
citraat-ontstold volbloed in 120 volwassenen (60 vrouwen, 60 mannen) met variabele 
leeftijdsopbouw en in een extra groep van 29 jonge vrouwen die OAC gebruikten. 
Een toename in neiging om te stollen werd aangetroffen bij vrouwen ten opzichte 
van mannen, bij OAC gebruiksters ten opzichte van jonge vrouwen die geen OAC 
gebruikten en bij vorderende leeftijd. Daarnaast vonden we geen correlatie tussen 
TEG parameters bepaald in volbloed en TEG parameters bepaald in citraat-ontstold 
bloed volgens de methode van Bland Altman. We concludeerden dat leeftijd, 
vrouwelijk geslacht, OAC gebruik en laag normale hematocrietwaarden aanleiding 
geven tot een significante toename in de neiging om te gaan stollen. Daarnaast 
kunnen TEG parameters bepaald in volbloed niet uitgewisseld worden met die van 
citraat-ontstold volbloed aangezien er onvoldoende mate van overeenkomst is 
tussen beide testmethoden.
In hoofdstuk 4 analyseerden we het effect dat het bloedplaatjesaantal heeft op de 
stolling. Hiervoor verrichtten we een serie TEG metingen bij patiënten met goed 
gedocumenteerde passagère trombocytopenie. In totaal werden 189 TEG metingen 
verricht in 16 patiënten, allen bekend met een hematologische maligniteit in remissie, 
die behandeld werden met consoliderende chemotherapiekuren. Gemiddeld 





































verricht (range 1-17) tijdens het dalen van het bloedplaatjesaantal. De uitkomsten 
werden vergeleken met die van 120 gezonde proefpersonen met variabele leeftijd. 
We vonden een uitstekende correlatie (r = 0.7, p < 0.001) tussen de sterkte van 
het stolsel (maximale amplitude) en het bloedplaatjesgetal. Daarnaast was het 
bloedplaatjesgetal gecorreleerd met de initiële snelheid van stolselvorming (R-tijd en 
K-tijd), de snelheid van de groei van het stolsel (alphahoek) alsook met de nieuwere 
TEG parameters (MTG, TMG, TTG). We concludeerden dat het bloedplaatjesaantal 
niet alleen effect heeft op de elastische trekkracht van het gevormde stolsel, maar 
ook op alle andere fases van de plasmatische stolling. Ontstollen van volbloed 
middels citraat maskeerde overigens een aantal belangrijke biologische parameters 
van stolling.
In hoofdstuk 5 is de hemostatische functie van getransfundeerde bloedplaatjes 
vergeleken met die van autologe (natieve) circulerende bloedplaatjes. Tevens werd 
het effect van de opslagduur van deze bloedplaatjes op hun hemostatische functie 
bestudeerd, waarbij verse bloedplaatjes (opslagduur 1-3 dagen) werden vergeleken 
met langer opgeslagen bloedplaatjes (opslagduur 4-5 dagen). In 92 patiënten, 
behandeld met chemotherapie, zijn tijdens de daling van het bloedplaatjesaantal op 
meerdere momenten TEG analyses uitgevoerd totdat de patiënt afhankelijk werd van 
een bloedplaatjestransfusie. TEG parameters voor verschillende ranges van natieve 
bloedplaatjesaantallen werden vergeleken met diezelfde ranges verkregen tijdens een 
bloedplaatjestransfusie. Er werd geen verschil aangetoond tussen de hemostatische 
functie van autologe en getransfundeerde bloedplaatjes (alle p waarden ≥ 0.1). De 
hemostatische effecten van verse bloedplaatjes waren overigens beter dan die van 
opgeslagen bloedplaatjes voor wat betreft de tijd die nodig was om een kritische 
hoeveelheid stolsel te produceren (K-tijd) alsook de snelheid waarmee het stolsel 
werd gevormd (alphahoek). We concludeerden in deze studie dat TEG in staat 
was om de hemostatische effecten van een bloedplaatjestransfusie te monitoren, 
waarbij de functie van getransfundeerde bloedplaatjes vergelijkbaar was met die van 
natieve bloedplaatjes. Daarnaast suggereerden onze data dat kortere opslagduur van 
bloedplaatjes geassocieerd was met een betere hemostatische capaciteit. 9




































In hoofdstuk 6 is de rol van rode bloedcellen (RBC) in de hemostase bestudeerd 
middels TEG. Allereerst werd in 29 met chemotherapie behandelde anemische 
patiënten het effect van een dalend hemoglobine getal op de stolling beschreven. 
Vervolgens werd in 24 patiënten met chronische anemie het effect van een transfusie 
met RBC op de stolling beschreven. In nog eens 18 patiënten werd bestudeerd of 
de duur van opslag van rode bloedcelconcentraten van additionele invloed was op 
deze hemostatische effecten. Wij vonden een significant negatieve correlatie tussen 
hemoglobine en de TEG variabelen corresponderend met de elastische trekkracht 
van het gevormde stolsel (p < 0.05). Daarnaast was anemie geassocieerd met het 
trager op gang komen van de stollingscascade. Het transfunderen met RBC in geval 
van anemie daarentegen leverde exact de tegenovergestelde hemostatische effecten 
op met nu een verslechtering van de uiteindelijke elastische trekkracht van het stolsel 
waarbij de stollingscascade wel sneller op gang kwam. De genoemde negatieve 
effecten op de elastische kwaliteit van het stolsel werd met name gezien wanneer 
verse rode bloedcelconcentraten werden gegeven. Verse rode bloedcelconcentraten 
gaven overigens geen versnelling van het begin van de stollingscascade. De conclusie 
van deze studie was dat anemie enerzijds geassocieerd is met een vertraging van de 
aanvang van de stollingscascade en anderzijds met een verbetering van de elastische 
kwaliteit van het gevormde stolsel. Transfusie van met name verse RBC is geassocieerd 
met verslechtering van de elastische kwaliteit van het gevormde stolsel.
In hoofdstuk 7 is de rol van TEG beschreven bij het analyseren van de verhoogde 
stollingsstatus bij patiënten met sikkelcelziekte, zowel tijdens pijnlijke vaso-
occlusieve crises als ook tijdens klinisch rustige perioden. Daarnaast zijn de effecten 
van behandeling met Hydroxyureum (HU) alsook de rol van rode en witte bloedcellen 
op hemostase bij deze aandoening bestudeerd. Bij 18 patiënten met sikkelcelziekte 
(waarvan 11 HU gebruikten) werden stollingsparameters in rust bepaald en tijdens 
in totaal 34 pijnlijke crises. Stollingsparameters van patiënten met sikkelcelziekte 
werden vergeleken met die van gezonde controlepersonen en de stollingsstatus in 
rust werd vergeleken met die tijdens pijnlijke crises in relatie tot gebruik van HU. Wij 
observeerden bij patiënten met sikkelcelziekte zonder HU gebruik een significante 





































als in rust. Met uitzondering van de uiteindelijke trekkracht van het gevormde stolsel, 
verminderde HU gebruik deze toegenomen stollingsstatus significant in vergelijking 
met zowel patiënten die geen HU gebruikten als met controlepersonen. Rode en 
witte bloedcellen waren tenslotte respectievelijk negatief en positief gecorreleerd 
met een toegenomen stollingsstatus. De conclusie was dat TEG een potentieel 
interessante techniek is om de stollingsstatus bij patiënten met sikkelcelziekte te 
analyseren en te vervolgen, waarbij ook de effecten van behandeling met HU kunnen 
worden gedetecteerd.
DIsCUssIe en ToeKomsTPeRsPeCTIeVen
In de afgelopen jaren zijn een groeiend aantal artikelen en studies over TEG 
gepubliceerd die vrijwel alle deelgebieden van de geneeskunde omvatten. 
Ondanks deze publicaties werd TEG nog lange tijd als experimenteel beschouwd 
en bekritiseerd vanwege een gebrek aan studies die de betrouwbaarheid van deze 
techniek aantonen. Een belangrijk nadeel is de beperkte validatie en standaardisatie 
van de TEG methodiek, resulterend in aanzienlijke variatie in uitkomsten, zowel 
tussen laboratoria alsook binnen één laboratorium, wat onderlinge vergelijking van 
uitkomsten problematisch maakt. Bovendien laten vergelijkende studies slechts 
zeer beperkte correlaties zien tussen TEG parameters en klassieke stollingstesten. 
Tenslotte zijn er vrijwel geen studies verricht waarbij TEG werd gerelateerd aan 
de klinische uitkomst. Belangrijk is dat goede gerandomiseerde studies ontbreken 
die een op TEG gebaseerd transfusiealgoritme vergelijken met een gefixeerd en 
op klassieke stollingstesten gebaseerd transfusiealgoritme in geval van massaal 
bloedverlies. Om deze redenen lijkt het vooralsnog prematuur om TEG standaard op 
te nemen in het behandelalgoritme van massaal bloedverlies, zoals bediscussieerd 
is in Hoofdstuk 2. Een in 2011 verschenen Cochrane review concludeerde eveneens 
dat er nog onvoldoende bewijsvoering bestaat dat TEG of ROTEM de morbiditeit 
en mortaliteit verbetert wanneer deze hemostasetest wordt geïncorporeerd in het 
behandelalgoritme van massaal bloedverlies. Alhoewel een dergelijke toepassing 
van TEG de hoeveelheid bloedverlies mogelijk wel beperkt, leidt deze echter niet tot 
afname van andere pregedefinieerde uitkomsten zoals de incidentie van heroperaties 
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ten gevolge van bloeding, de gemiddelde opnameduur op de intensive care en het 
aantal dagen klinische opname.
In een poging de reproduceerbaarheid en standaardisatie van de TEG techniek te 
verbeteren heeft een internationale groep onderzoekers de handen ineengeslagen 
en in 2010 de “TEG-ROTEM Working Group” opgericht. In hun eerste studie werd 
een significante variatie tussen laboratoria gevonden, met variatiecoëfficiënten 
boven de 10%. Deze studie was overigens de eerste waarbij een serieuze poging 
werd gedaan om de TEG methodiek te standaardiseren. Het is duidelijk dat er nog 
aanzienlijke inspanningen geleverd moeten gaan worden om de betrouwbaarheid en 
reproduceerbaarheid van de techniek verder te verbeteren. In overeenstemming met 
het verzoek van de Working Group om aanvullend validatie onderzoek te verrichten 
naar TEG, heeft onze onderzoeksgroep eigen referentiewaarden bepaald in een grote 
random populatie zoals beschreven in Hoofdstuk 3. Tot op heden is dit het eerste 
onderzoek waarbij in gezonde vrijwilligers met een evenredige verdeling in leeftijd 
en geslacht zowel klassieke als “nieuwe” TEG parameters zijn bepaald en vergeleken 
met klassieke stollingstesten, zowel in volbloed als in citraat-ontstold volbloed. 
Alhoewel onpraktisch ondersteunt onze studie wel de aanbeveling van de fabrikant 
dat gebruikers van TEG allereerst eigen referentiewaarden dienen te bepalen 
voordat zij TEG klinisch gaan toepassen. Daarnaast is het van belang om nogmaals 
te benadrukken dat TEG metingen verricht in volbloed niet uitwisselbaar zijn met 
die verricht in citraat-ontstold bloed. Verder hebben we aangetoond dat leeftijd, 
geslacht en gebruik van orale anticonceptiva variabelen zijn die de stollingsstatus 
duidelijk verhogen. Dit onderstreept nogmaals dat TEG sensitiever is dan de klassieke 
stollingstesten in het detecteren van verschillen in het hemostatische profiel van 
patiënten. Alhoewel de “pro-coagulante” effecten van leeftijd en vrouwelijk geslacht 
subtiel en mogelijk zelfs fysiologisch waren, lijkt het zinvol dat onderzoekers en clinici 
die gebruik maken van TEG zich bewust zijn van deze effecten bij het interpreteren 
van testuitslagen.
In operatiekamers wordt TEG in toenemende mate ingezet bij de interpretatie en de 





































techniek is immers dat vrijwel direct aan het bed van de patiënt een snelle en globale 
indruk kan worden verkregen van diens stollingsstatus en dat direct een hemostatische 
behandeling kan worden ingezet op basis van het waargenomen TEG profiel en de 
TEG parameters. Een tekort aan bloedplaatjes (< 50 x 109/L) geeft een verhoogd 
risico op bloedingcomplicaties. Alhoewel TEG parameter Maximale Amplitude (MA) 
voornamelijk een resultante is van functie en aantallen bloedplaatjes, vonden wij dat 
deze parameter toch weinig sensitief was indien bij patiënten sprake was van sterk 
verlaagde bloedplaatjesaantallen, zoals beschreven in Hoofdstuk 4. Het meest van 
belang hierbij is dat in het geval van diepe trombopenie (< 50 x 109/L) TEG verricht in 
volbloed in meer dan 40% van de analyses een volkomen vlakke (inconclusieve) curve 
opleverde. Tevens was de trombopenie niet alleen van invloed op de MA parameter 
maar op alle andere TEG parameters. Het is om deze reden dan ook riskant om bij 
diepe trombopenie het TEG profiel en de TEG parameters (bepaald in volbloed) te 
gebruiken als leidraad voor hemostatische therapie. Het is daarom noodzakelijk dat 
voor een correct gebruik en interpretatie van TEG allereerst het effect van andere 
geïsoleerde stollingsdefecten als ook die van hemostatica worden geëvalueerd en 
gevalideerd, voordat een op TEG gebaseerd transfusiealgoritme in de analyse en 
behandeling van bloedverlies kan worden geïncorporeerd. 
Transfusie van bloedplaatjes wordt volgens afspraak verricht indien er sprake is van 
een bloedingsneiging in het kader van een kwalitatieve of kwantitatieve aandoening 
van de bloedplaatjes of profylactisch indien het risico op bloedingen fors verhoogd 
is. Optimaal hebben getransfundeerde bloedplaatjes dezelfde hemostatische 
capaciteit als de natieve circulerende bloedplaatjes. Alhoewel bloedplaatjes 
producten in vitro worden getest op kwaliteit, geven deze testen geen informatie 
over het in vivo hemostatisch potentieel van deze bloedplaatjes. In Hoofdstuk 5 
beschrijven we het gebruik van TEG bij het evalueren van het hemostatische effect 
van een bloedplaatjestransfusie. Middels TEG konden wij geen verschil aantonen 
in hemostatische eigenschappen tussen natieve circulerende en getransfundeerde 
opgeslagen bloedplaatjes. Daarnaast suggereerden onze data dat beperkte opslagduur 
van bloedplaatjesproducten geassocieerd is met een betere hemostatische capaciteit 
gedurende tenminste de eerste 24 uur na transfusie. Dit laatste kan klinisch relevant 
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zijn indien sprake is van een acute bloeding waarbij transfusie van verse bloedplaatjes 
mogelijk de voorkeur verdient. Bloedplaatjes met langere opslagduur daarentegen 
kunnen gereserveerd worden voor die gevallen waarin de transfusie profylactisch 
van aard is. Al met al lijkt deze aanbeveling nog prematuur omdat in onze studie 
niet het effect op harde eindpunten zoals bloedingsepisoden is meegenomen. Om 
deze reden zijn toekomstige studies dan ook onontbeerlijk waarbij de middels TEG 
gemeten hemostatische capaciteit van verse en opgeslagen bloedplaatjes wordt 
gerelateerd aan het aantal bloedingscomplicaties dat optreedt na transfusie.
Alhoewel het primaire doel van een transfusie met rode bloedcellen (RBC) het 
verbeteren van de zuurstoftoevoer naar de weefsels is, hebben RBC ook effecten op 
de hemostase zoals beschreven is in Hoofdstuk 6 en 7. Zo toonden wij aan dat anemie 
geassocieerd is met een vertraging in de initiatie van de stolling waarbij het uiteindelijk 
gevormde stolsel wel van een superieure kwaliteit is. Interessant is dat transfusie 
met RBC exact het tegenovergestelde effect op hemostase sorteerde, met snellere 
initiatie van de stolling ten koste van de kwaliteit van het stolsel. Opmerkelijk was dat 
transfusie van verse RBC met een opslagduur van 2 dagen de initiatie van de stolling 
niet katalyseerde, terwijl wel de kwaliteit van het stolsel nadelig werd beïnvloed. 
Het lijkt dat beide geobserveerde fenomenen toch verklaard kunnen worden. 
Allereerst is bekend dat RBC de initiatie van stolling positief beïnvloeden doordat 
in de bloedstroom deze cellen naar centraal worden gemanoeuvreerd waarbij de 
kleinere bloedplaatjes hogere concentraties bereiken langs de vaatwand. Ter hoogte 
van het vaatendotheel vindt vervolgens adhesie, activatie en aggregatie plaats in 
het kader van de primaire hemostase. Het negatieve effect van RBC op de kwaliteit 
van het stolsel wordt mogelijk veroorzaakt doordat bij hogere concentratie van RBC 
deze cellen meer worden ingebouwd in het fibrinenetwerk wat aanleiding geeft tot 
een minder hechte structuur van het gevormde stolsel. Onze studie-uitkomsten 
werden recent bevestigd in een in vitro studie waarbij hogere concentraties van RBC 
eveneens gepaard gingen met inferieure kwaliteit van het stolsel. Onze bevindingen 
zijn relevant voor onderzoekers en clinici actief op het terrein van de hemostase 
daar zij zich bewust dienen te zijn van de effecten van hematocriet op hemostase 





































speculeren over een eventuele relatie tussen de hemostatische effecten van RBC en 
de inferieure klinische uitkomst in kritisch zieke patiënten in relatie tot het aantal 
bloedtransfusies dat deze patiënten hebben ontvangen. Het belang van RBC in 
hemostase wordt in Hoofdstuk 8 nogmaals belicht, waar we TEG gebruikten om 
hemostase in patiënten met sikkelcelziekte te bestuderen. Alhoewel de verhoogde 
stollingsstatus bij deze patiënten als multifactorieel wordt beschouwd, bestaat er 
geen unieke test om deze conditie te kwantificeren of te kwalificeren. Met behulp 
van TEG waren wij in staat om deze verhoogde stollingsstatus te visualiseren en te 
kwantificeren, waarbij ten tijde van een pijnlijke sikkelcrisis deze stollingstatus nog 
verder was toegenomen. Daarnaast waren we in staat om middels TEG de positieve 
effecten van behandeling met HU op deze stollingstatus aan te tonen. Het blijft 
overigens nog onzeker of de geobserveerde hemostatische veranderingen causaal 
zijn aan ziektespecifieke complicaties of dat deze veranderingen eenvoudigweg 
epifenomenen zijn. Van belang is dat toekomstige studies de relatie tussen TEG 
parameters, klinische uitkomst en gebruik van HU verder bestuderen.
Wij beschouwen TEG als een veelbelovende techniek voor onderzoek van hemostase, 
zowel in de klinische als in de experimentele setting, omdat door middel van deze 
techniek op een unieke en meer fysiologische manier naar stolling kan worden 
gekeken. In tegenstelling tot klassieke stollingstesten en ondanks het globale karakter 
van de test is TEG goed in staat om de effecten van leeftijd, geslacht en OAC op 
het stollingsprofiel weer te geven. Verder is TEG in staat gebleken om de effecten 
van zowel bloedplaatjes als RBC op hemostase aan te tonen en heeft potentieel 
als een in vivo kwaliteitstest van bloedproducten. Bovendien bestaan er voor TEG 
toekomstige mogelijkheden op het terrein van analyse en behandeling van patiënten 
met sikkelcelziekte. Echter ondanks de aanzienlijke mogelijkheden heeft de TEG 
techniek nog altijd een aantal beperkingen. In de afgelopen jaren is forse progressie 
geboekt wat betreft de reproduceerbaarheid, betrouwbaarheid, standaardisatie en 
validatie van de verschillende modificaties en toepassingen van TEG. Desalniettemin 
kan de TEG techniek nog niet ten volle uit worden benut en toegepast aangezien 
verrichte studies nog altijd inconsistente uitkomsten opleveren. Het is van groot 
belang dat met name de klinische voordelen die te behalen zijn met TEG goed 
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worden gedocumenteerd alvorens de TEG techniek op grote schaal zijn toepassing 
kan vinden op onder andere de operatiekamer. Verder willen we nogmaals het belang 
van het verkrijgen van eigen referentiewaarden benadrukken om deze te gebruiken 
als interne vergelijking. Daarnaast is het vanuit het oogpunt van kwaliteitsbewaking 
niet minder belangrijk voor TEG dan voor klassieke stollingstesten die in het centrale 
laboratorium worden bepaald om zowel interne kwaliteitscontrole als externe 
kwaliteitsbeoordeling te ontwikkelen. Wij hopen dat in de nabije toekomst nog meer 
geïnvesteerd gaat worden in zowel klinische als experimentele studies met TEG om 
de diverse toepassingen verder te verbeteren en te stimuleren. Doelgerichte inzet 
van de TEG techniek, met interpretatie van de TEG curve en haar parameters in de 
klinische context en gecombineerd met informatie uit klassieke stollingstesten, heeft 

















































































































Ik ben gestart met mijn promotieonderzoek als fellow op de afdeling hematologie 
van het UMCG. Het analyseren en opschrijven van de data heeft uiteindelijk 
plaatsgevonden in de afgelopen jaren naast mijn werkzaamheden als internist-
hematoloog in Ziekenhuis Bethesda te Hoogeveen. Gedurende zowel mijn 
academische als perifere jaren ben ik een groot aantal personen zeer erkentelijk 
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heeft bijgedragen heel hartelijk danken. Daarbij wil ik een aantal personen in het 
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ik je dankbaar voor het feit dat je mij hebt opgeleid in het mooiste deelgebied dat 
er bestaat binnen de interne geneeskunde, de hematologie. Met plezier en trots kijk 
ik terug op de fijne jaren die ik op de afdeling Hematologie van het UMCG mocht 
doorbrengen. Jouw gedrevenheid en enthousiasme om mij - en andere fellows - de 
fijne kneepjes van het vak bij te brengen heeft nog altijd mijn grote bewondering. Met 
name je enorme kennis betreffende de morfologie en immunofenotypering van alle 
denkbare lymfomen en leukemieën hebben op mij een onuitwisbare indruk gemaakt. 
Ook je voortvarendheid en doortastendheid waarmee je het promotieonderzoek 
begeleidde zijn voor mij van grote waarde geweest. Ondanks je werkdruk zag je altijd 
kans om binnen een mum van tijd artikelen, voorzien van waardevol commentaar, te 
retourneren. Nogmaals mij grote dank hiervoor.
Geachte dr. J.T.M. de Wolf, beste copromotor, beste Joost. Ik ken geen hematoloog 
die naast zo’n brede hematologische kennis ook nog eens zoveel diepgang per 
deelgebied kan aanbrengen. Jij hebt me destijds enthousiast gemaakt voor het 
verrichten van wetenschappelijk onderzoek met de thromboelastografie, wat 
uiteindelijk heeft geresulteerd in dit proefschrift. Ik heb je niet alleen leren kennen 





































ook als positieve en enthousiaste persoonlijkheid. Jaloers ben ik op je indrukwekkend 
idee- en hypothesegenererend vermogen. Wetenschappelijke discussies met jou 
waren leerzaam en inspirerend en vonden altijd plaats in een zeer prettige open 
sfeer, waar ook ruimte was voor humor en “social” talk. Je hebt me gevormd als 
wetenschapper en daar ben ik je erg erkentelijk voor.
Beste drs. Bosman, beste Lotte. Ik ben je nog altijd dankbaar voor het feit dat je 
destijds je wetenschappelijke stage op de afdeling Hematologie van het UMCG hebt 
gedaan. Mede dankzij jouw ijver en doorzettingsvermogen is het ons gelukt om 
al die honderden bloedmonsters bij patiënten en controlepersonen af te nemen. 
Ook het verrichten van TEG analyses (vaak buiten kantooruren) was bij jou altijd in 
vertrouwde handen. Ik kon me geen betere assistent wensen!
Tevens ben ik dr. N.J.G.M Veeger erkentelijk voor zijn waardevolle bijdrage in de 
statistische onderbouwing van de studie-uitkomsten.
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danken voor de uiteindelijke beoordeling van het proefschrift.
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bedanken voor hun aandeel in mijn opleiding tot hematoloog. De samenwerking met 
jullie was uitermate prettig en leerzaam. Ook heden nog maak ik dankbaar gebruik 
van de waardevolle adviezen inzake hematologische casuïstiek gegeven door prof. 
dr. E. Vellenga, IKN consulent voor Ziekenhuis Bethesda. Onmisbaar en uitermate 
leerzaam!
Natuurlijk ben ik ook mijn collega’s van de vakgroep interne geneeskunde van 
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voor de ervaren collegialiteit en amicaliteit. Zonder deze open en warme sfeer, 





































onderzoek, had mijn promotieonderzoek nooit kunnen gedijen. Met name wil ik 
hierbij mijn collega dr. F.C. Huvers nog noemen, die “achter de schermen” fungeerde 
als katalysator. Beste Frank, het zijn jouw enthousiasmerende woorden geweest die 
er mede voor gezorgd hebben dat ik goed gemotiveerd mijn onderzoek heb kunnen 
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warmte en liefde waarmee ik door hen wordt omringd en die o zo belangrijk zijn 
om te floreren. Uit het diepst van mijn hart wil ik mijn beide ouders bedanken. 
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onvoorwaardelijke steun en liefde had ik nooit de rust en ruimte kunnen vinden om 
het promotieonderzoek af te ronden. Daarnaast wist je altijd de balans te bewaken 
tussen privé en werk zodat we kunnen terugkijken op al heel wat geïncasseerde 
“quality time” met ons gezin. Onze lieve dochters Jasmijn, Merel en Amber maken 
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